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Abstract 
Application of recombinant viral vectors has become one of the most explored strategies for cancer 
gene therapy. This is due to the unique ability of viruses, given the right conditions, to very 
specifically target, infect and kill cancer cells. Among therapeutic viruses, due to high-level 
transgenic expression and induction of p53-independent apoptosis in infected cells, alphaviral 
vectors are thought to harbor high potential.  
The aim of this research was to optimize the efficient gene delivery strategy by investigating 
different mouse tumor models in conjunction with recombinant alphavirus vectors. Special attention 
was given to the application of recombinant particles and viral RNA and to the characterization of 
alphavirus oncotropism in different tumor models in vitro and in vivo. In parallel, we have detected 
intracellular mechanisms that could affect vector transduction and replication in cancer cells. 
We have compared the biodistribution of recombinant SFV particles (recSFV) and naked viral RNA 
replicon (recRNA) in tumor-free, as well as 4T1 mammary tumor and B16 melanoma tumor-
bearing mice, as a consequence of different vector administration strategies. In both tumor models, 
we could show for the first time the predominant tumor targeting-capabilities of recSFV at a 
reduced viral dose upon systemic virus inoculation.  
The high potential of SFV recRNA as a biosafe approach for the development of therapeutic 
treatment was demonstrated. Intravenous inoculation of recRNA provided primary brain targeting, 
whereas intratumoral inoculation triggered high and localized transgene expression levels in tumors. 
To prolong transgene expression, we have tested several re-inoculation strategies of virus-based and 
RNA-based vectors. To enhance vector therapeutic potential, recSFV was applied in combination 
with different dosages of chemotherapeutic drug 5-fluorouracil to mammary tumor-bearing mice. 
This adjunct treatment facilitated intratumoral spread of recSFV and increased transgene synthesis 
resulting in significant reduction of tumor volume. This synergetic therapeutic effect was achieved 
due to enhanced vector permeability and inhibition of interferon (IFN) response. 
Investigating alphavirus infectivity, we found that alphaviruses efficiently infected B16 mouse 
melanoma tumors in vivo via predominant tumor targeting. In contrast their transduction efficiency 
in B16 cells cultivated in vitro was blocked. Therefore, we hypothesize that the tumor 
microenvironment alters gene expression in B16 cells, leading to up-regulation of virus-binding 
receptors or factors associated with virus entry and replication. Subsequent proteome analysis 
comparing B16 mouse melanoma cells cultured in vitro versus B16 cells isolated from tumors, 
unrevealed 277 differently regulated proteins. Annotating these proteins with their biological and 
molecular functions, we could identify a complex of genes associated with antiviral responses and 
cytoskeleton organization, respectively that could determine alphavirus activity. Importantly, we 
observed a decrease in expression of interferon alpha (IFN-alpha) in tumor-isolated cells that 
resulted in the suppression of several IFN-regulated genes and pathways. We therefore speculate 
that these specific mechanisms may critically abrogate host cells’ antiviral defense in tumors. 
Additionally, differences in the expression of genes that regulate cytoskeletal organization caused 
significant alterations in cell membrane elasticity. As a consequence, for the first time, the physical 
state of cell membranes could be associated with conditions favorable to alphavirus infection and 
replication. 
Taken together, our findings extend our knowledge about alphaviruses and their therapeutic 
properties with respect to tumor targeting and organ-directed gene delivery. The studies also 
provide a foundation regarding their application in future, more clinically oriented, studies. 
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Abbreviations 
Gene abbreviations 
Actc1 Actin 
Adh7 Alcohol dehydrogenase class 4 mu/sigma chain 
Aif1l Allograft inflammatory factor 1-like 
Aspm Abnormal spindle-like microcephaly-associated protein homolog 
Bcl-2 Apoptosis regulator Bcl-2 
Cald1 Non-muscle caldesmon 
Capg Macrophage-capping protein 
Cdk2 cyclin dependent kinase 2 
Cd97 CD97 antigen 
Cfl1 Cofilin-1 
Crem Four and a half LIM domains protein 5 
Cryab Alpha-crystallin B chain 
Csf1 Macrophage colony-stimulating factor 1 
Csnk2b Casein kinase II subunit beta 
Ctla-4  Cytotoxic T-lymphocyte protein 4 
DC-SIGN dendritic cell-specific HIV-1-binding protein 
Dst Dystonin 
Ds-Red Discosoma sp. red fluorescent protein 
Dync1h1 Cytoplasmic dynein 1 heavy chain 1 
Dynll2 Dynein light chain 2 
Dynlt1 Dynein light chain Tctex-type 1 
EGFP Enhanced Green Fluorescent Protein 
Etv6 Transcription factor ETV6 
Flnc Filamin-C 
Gfap Glial fibrillary acidic protein 
GITR Glucocorticoid-Induced TNFR family Relatedgene 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
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Gpx1 Glutathione peroxidase 1 
Gsto1 Glutathione S-transferase omega-1 
Gstz1 Maleylacetoacetateisomerase 
Her2/neu Human epidermal growth factor receptor-2 
Hist1h1a Histone H1.1 
Hist1h1t Histone H1t 
Hspb1 Heat shock protein beta-1 
Hsp90aa1 Heat shock protein HSP 90-alpha 
Ifi35 Interferon-induced 35 kDa protein homolog 
Il-4 Interleukin 4 
Il-12 Interleukin 12 
Il-15  Interleukin 15 
Il-18 Interleukin 18 
 IFN-alpha Interferon alpha 
IFN-beta Interferon beta 
Kif1a Kinesin-like protein Kif1a 
LacZ β-galactosidase, 
Lamp-1 lysosome-associated membrane protein 1  
Lmna Prelamin-A/C 
L-SIGN C-type lectin 
Luc Firefly luciferase 
MAGE Melanoma-associated antigen 
Map7 Ensconsin 
MART-1/Melan-A Melanocytic proteinMelan 
Mlph Melanophilin 
MUC18 Cell surface glycoprotein MUC18 
Myo5a Unconventional myosin-Va 
Myo18a Unconventional myosin-XVIIIa 
Nfe2l2 Nuclear factor erythroid 2-related factor 2 
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Opa1 Dynamin-like 120 kDa protein 
Pdcd4 Programmed cell death protein 4 
Pmel17/gp100 Melanocyte protein pmel 
Psca Prostate stem cell antigen  
Psma Prostate-specific membrane antigen 
Pycard Apoptosis-associated speck-like protein containing a CARD 
Rps21 40S ribosomal protein S21 
Scrib Protein scribble homolog 
Sgtb Small glutamine-rich tetratricopeptide repeat-containing protein 
beta 
Ss18 Protein SSXT 
Stat1 Signal transducer and activator of transcription 1 
Steap Metalloreductase 
S100a11 Protein S100-A11 
S100b Protein S100-B 
Timm10b Mitochondrial import inner membrane translocase subunit Tim10 B 
Tmod1 Tropomodulin-1 
Trp-1 Tyrosinase-related protein-1 
Trp-2 Tyrosinase-related protein-2 
Tubb6 Tubulin beta-6 chain 
Txnl1 Thioredoxin-like protein 1 
VEGFR2 Vascular endothelial growth factor receptor 2 
 
Other abbreviations 
AAV Adeno-associated virus 
AFM Atomic force microscopy  
APCs Antigen-presenting cells 
CAN Acetonitrile  
cDNA Complementary DNA 
CEA Carcinoembryonic antigen  
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CRT Calreticulin 
CTL  Cytotoxic T lymphocytes 
DCs Dendritic cells 
DMSO Dimethyl sulfoxide 
dsDNA Double stranded DNA 
DTT  Dithiothreitol 
EMA European Medicine’s Agency 
EPR Enhanced permeability and retention 
ER Endoplasmic reticulum  
 FACS  Fluorescence-activated cell sorting 
FBS Fetal bovine serum 
FDA Food and Drug Administration (USA)  
FDR False discovery rate 
GO Gene Ontology 
Gln Glutamine 
Glu Glutamic acid 
HCC Hepatocellular carcinoma 
HDACi Histone deacetylase inhibitors 
HIV Human immunodeficiencyvirus 
HPV Human papilloma virus  
HSV Herpes virus 
H&E Hematoxylin and eosin staining  
i.p. Intraperitoneal injection 
i.t. Intratumoral injection 
i.u. Infection units 
i.v. Intravenous injection 
LC-MS  Liquid chromatography-mass spectrometry  
Lys-C Lysylendopeptidase 
mAbs Monoclonal antibodies 
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MDSCs Myeloid-derived suppressor cells 
MHC Major histocompatibility complex  
MLN Mediastinal lymph nodes 
MOI Multiplicity of infection 
mRNA Messenger RNA 
MTT MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium 
bromide, a tetrazole) 
PANTHER Protein ANalysisTHrough Evolutionary Relationships 
PBS Phosphate-buffered saline 
PI Propidium iodide  
PKR Protein kinase R 
p53 Cellular tumor antigen p53 
RC Replication competent  
RD Replication deficient  
recSFV Recombinant Semliki Forest virus 
recSIN Recombinant Sindbis virus 
RLUs Relative light units  
rRNA Ribosomal RNA 
RT-PCR Reverse transcription polymerase chain reaction 
s.c. Subcutaneous injection 
siRNA Small interfering RNA 
ssDNA Single-stranded DNA 
TAA Tumor-associated antigens  
TFA Trifluoroacetic acid  
tRNA Transfer RNA 
VEE Venezuelan Equine Encephalitis virus  
VLP Virus-like particles 
v.p. Viral particles 
β-hCG Human chorionic gonadotropin 
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5-FU  5-fluorouracil 
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Introduction 
Oncolytic alphaviral systems were successfully used in various mouse tumor models. In clinics 
however, alphavirus-based cancer virotherapy is not yet considered a mature field. The major 
limitations for broad application of alphavirus are the lack of detail characterization of these viruses 
and understanding optimal treatment strategy. There is insufficient information about virus 
infectivity of different tumor models, distribution, transgene expression time, effect of vector re-
administration and interrelationships between alphavirus infectivity and tumor microenvironment. 
Moreover, alphavirus-activity in combination with chemotherapeutic drugs is poorly explored.  
 Aim of the study 
Our research focuses on characterization of alphavirus oncotropism and its oncolytic properties in 
cancer models in vitro and in vivo. The major aim of the study was the development of an optimal 
strategy for efficient alphaviral vector delivery and transgene expression in mouse tumors. To 
achieve a synergic therapeutic effect, application of recombinant alphavirus vectors in combination 
with classical chemotherapeutic drugs was tested. Special attention was given to the investigation 
of favorable intracellular conditions that promote alphavirus transduction and replication. 
Objectives 
This study has five major objectives which are also outlined in Figure 1 
Objective 1: Generation of recombinant SFV and SIN viruses, their characterization as gene 
transfer vectors and evaluation of their utility in comparison with one and other in context with 
different cancer cell lines. On this basis, by analyzing susceptibility to viral infection, cytotoxicity 
and inhibition of cell proliferation, identify the most effective therapeutic vector for specific tumor 
cell lines  
Objective 2: Investigation of recSFV virus-based and RNA-based vector biodistribution and 
infection ability in 4T1 mouse mammary tumor model. 
Task 1: to investigate, by applying several vector inoculation modes, recSFV biodistribution and 
transgene expression level in tumor-free and 4T1 tumor-bearing mouse models.  
Task 2: to investigate naked recSFV RNA biodistribution and transgene expression level in tumor-
free and 4T1 tumor-bearing mice. 
Task 3: to optimize recSFV and recSFV RNA vectors re-administration strategies in order to 
prolong transgene expression in tumor-free and 4T1 tumor-bearing mouse models. 
14 
 
Objective 3: Development of an optimal cancer treatment strategy using recombinant recSFV virus 
vector and chemotherapeutic drug 5-FU in 4T1 mouse mammary tumor models. 
Task 1: to examine potential synergistic effects of recSFV and 5-FU on 4T1 cells in vitro. 
Task 2: to explore whether combining recSFV vector and 5-FU treatment in 4T1 tumor-bearing 
mice would potentiate tumor clearance. 
Task 3: to elucidate factors which underlie potential synergistic therapeutic effects of recSFV and 5-
FU drug administration in 4T1 tumors in vivo. 
Objective 4: Investigation of recSFV vectors’ infection ability and biodistribution in a B16-F10 
mouse melanoma tumor model. 
Task 1: to assess recSFV biodistribution and transgene expression level in B16-F10 tumor-bearing 
mouse models in dependence with several vector inoculation modes.  
Task 2: to compare recSFV infectivity of B16 melanoma cells at different conditions (in vitro and 
ex vivo) 
Objective 5: By profiling B16 melanoma cells susceptible or non-susceptible for alphavirus 
infection, identify candidate genes that are associated with establishing favorable conditions for 
recSFV infection and replication. 
Task 1: to compare protein profiles form B16 cells cultivated in vitro versus B16 cells isolated from 
tumor (ex vivo). 
Task 2: to analyze in-depth these proteins to understand biological mechanisms that govern 
alphavirus infectivity  
Task 3: to compare the physical features of cell membranes from B16 cultured in vitro and tumor 
isolated B16 cells (ex vivo) using atomic force microscopy (AFM). 
 
4T1 mouse mammary
carcinoma cells 
B16 mouse 
melanoma cells 
4T1 tumor models B16 tumor models
B16 cells
in vitro B16 cellsex vivo
4T1 tumor models
5-FUrecSFV
Recombinant alphavirus vector 
production and investigation of vector 
infectivity in vitro
Investigation of vector infectivity 
and biodistribution in vivo
Combined therapy:
alphavirus+chemotherapy
Comparative protien proﬁling of
 in vitro and ex vivo B16 cells
Investigation of vector infectivity 
and biodistribution in vivo
Objective 1
Objective 2
Objective 3
Objective 4
Objective 5
16
Figure 1: Schematic representation of the objectives. Objective 1 includes alphavirus infection of different cancer 
cell lines in vitro, where 2 cell lines, namely 4T1 and B16 cells, were selected for further experiments. Objective 2 and 
3 involve in vitro and in vivo experiments using 4T1 cells. Objective 4 and 5 contain in vitro, in vivo and ex vivo 
experiments using the B16-F10 cell line.
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Review of the literature 
1.1 Cancer gene therapy and viral vectors; introduction 
Gene therapy is a relatively new paradigm in medicine with enormous therapeutic potential. 
Actually, almost 2000 clinical trials using gene therapy were approved worldwide in period from 
1989 to 2016 (Gene Therapy Clinical Trials Worldwide). Initially, therapeutic transgenes were 
delivered via non-specific vectors that induced toxicity to the cancer cells but to normal cells as 
well. Thus, viruses represent an attractive vehicle for cancer gene therapy due to their capacity to 
effectively deliver genes to their specific targets. The idea of using viral replication triggering 
subsequent cell destruction for treatment of malignant diseases emerged for the first time more than 
a century ago. A report by Dock in 1904 documented dramatic remission of leukemia in a patient 
who suffered from influenza infection (Dock, 1904). In nowadays, viruses are being investigated in 
three main gene therapy treatment approaches: immunotherapy, gene transfer and oncolytic 
virotherapy. In virus-based cancer immunotherapy genetically modified cells and viral particles 
stimulate the immune system to destroy cancer cells. For gene transfer, that is a more recent 
treatment modality, transgenes are directly delivered into cancerous cells. In comparison, oncolytic 
virotherapy uses viral particles that replicate within the cancer cell subsequently causing cell death.  
Recent reviews have summarized therapeutic achievements of viral vector-based cancer treatment 
in completed and ongoing clinical trials (Donnelly et al., 2012, Fukuhara H et al., 2016; Gong et al., 
2016; Russell et al., 2012) as follows: as in preclinical studies, they support the key concepts of 
efficient therapy: i) successful viral vectors should have predominant tumor tropism to be able to 
target metastatic cancer after systemic vector infusion, ii) physical barriers that limit vector 
distribution within the tumors can be overcome by additional chemical adjuvants, and iii) immune 
cells and tumor microenvironment can either be synergic and inhibiting factors for virus vector 
activity. 
Despite several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), 
and herpes simplex virus, have been modified to enhance their efficacy in gene therapy 
applications; all these vector systems have unique advantages and limitations. For instance, 
retroviral vectors can permanently integrate into the host’s genome, but require mitotic cell division 
for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and 
non-dividing cell types, but immune elimination of infected cells often limits gene expression in 
vivo. AAV also infects many non-dividing and dividing cell types, but has a limited DNA capacity. 
Herpes simplex virus can deliver large amounts of exogenous DNA; however, cytotoxicity and 
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maintenance of transgene expression remain as obstacles. Since 1950’s, safety and efficacy of 
several viral vectors including adenovirus, retrovirus, AAV virus (Chira et al., 2015) as well as 
Semliki Forest virus, Newcastle virus, Sendai virus, rabies virus, measles virus, mumps virus, 
influenza virus and others have been reported in several anecdotal and formal clinical trials 
(Chiocca et al., 2002). Nevertheless, only in 2015 the U.S. Food and Drug Administration (FDA) 
and the European Medicine’s Agency (EMA) approved the first virus-based advanced therapy 
“OncoVEXGM-CSF” for melanoma treatment. OncoVEXGM-CSF is a genetically modified herpes 
simplex virus type 1 designed to replicate within tumors and produce an immunostimulatory protein 
called granulocyte-macrophage colony-stimulating factor (GM-CSF). The latter molecule induces 
cell death and promotes an anti-tumor immune response (Pol et al., 2015). Additionally, according 
to BioCentury, many clinical trials with several viral vectors are currently ongoing. Among these 
two viral vectors are tested in phase III trials, nine in phase II and at least eight in phase I. Probably 
these numbers will increase further (Cuickner-Meisne, 2016), what supports the positive dynamics 
of virotherapy in cancer. Taken together this clearly emphasizes the necessity of additional 
preclinical studies aiming at exploiting viruses for designing novel strategies for cancer treatment. 
1.2 Alphavirus 
1.2.1 Alphavirus structure and replication 
Alphaviruses are enveloped viruses that belong to the Togaviridae family which are predominantly 
transmitted to vertebrates by mosquitoes.The classical vectors for the expression of heterologous 
genes were developed based on Semliki Forest virus (SFV) (Liljestrom and Garoff, 1991), Sindbis 
virus (SIN) (Xiong et al., 1989) and Venezuelan equine encephalitis virus replicons (VEE) (Davis 
et al., 1989). Alphaviruses contain approximately 11.5 kb long capped and polyadenylated positive-
strand RNA genome that is functionally divided in two parts (two open reading frames ORF) 
coding the nonstructural and structural proteins correspondingly (Figure 2A).Upon delivery into 
the cytoplasm, from the first ORF the genomic RNA is processed into four viral nonstructural 
proteins nsP1-4 making the replication complex. The role of each nsP protein is different. Briefly, 
nsP1 protein initiates the negative strand RNA synthesis and capping of virus RNAs. NsP2 is the 
protease responsible for processing of the viral replication proteins (Strauss and Strauss, 1994). No 
enzymatic function was shown for the nsP3, however, it is essential for the synthesis of negative 
strand and SG RNAs (LaStarza et al., 1994). NsP4 acts as catalytic subunit of the RNA polymerase 
in the alphavirus replication complex (Strauss and Strauss, 1994). Together, this complex mediates 
replication of the plus strand (42S) genome into full-length minus strands that is later transcribed 
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into new 42S genomic RNA and 26S subgenomic (SG) RNA. The SG RNA internally initiated at 
the 26S promoter on the 42S minus RNA strands (Figure 2B). The second ORF codes for the 
structural proteins which also are synthesized as a large polyprotein to produce capsid protein (C) 
and the three envelope proteins (p62, which is the precursor of E2, 6K, and E1) (Hahn and Strauss 
1990; Schlesinger and Schlesinger, 2001). After synthesis, the C proteins complex with genomic 
RNA into nucleocapsid structures in the cell cytoplasm. Only the genomic RNA could be packaged 
because of the encapsidation signal that is located within the nsP1 gene for SIN and in the nsP2 
gene for SFV (Frolova et al., 1997). Cleavage of the intermediates of the other structural proteins is 
required for the encapsidation and budding of infectious viral particles (Garoff et al., 2004). 
Figure 2: Genome structure (A) and replication cycle (B) of alphaviruses. RER – rough endoplasmic reticulum; 
TGN – trans Golgi network; NC – nucleocapsid. 
In most cases replication of alphavirus RNA drives cell death in infected cells. Alphaviruses may 
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have developed multiple strategies to induce programmed cell death via the mitochondria. One of 
the main players in apoptosis induction by alphavirus infection is the host protein kinase R (PKR) 
(Balachandran et al., 2000; Gorchakov et al., 2004; Venticinque et al., 2010). PKR activation results 
in significant changes to the cell, which manifest as both cellular stress and translational inhibition 
through eIF2a phosphorylation (Williams, 2001; Williams, 1999). Another death mechanism is 
triggered by activation of proapoptoticbcl-2 family members Bax and Bak leading to the release of 
cytochrome c and other apoptotic factors (caspase 9, caspase 3 and caspase 7) (Urban et al., 2008; 
Scallan et al., 1997). 
A key step in virus infection and replication is the entry of the viral particle into the host cell. 
Unfortunately, little is known about the viral determinants and cell surface receptors that modulate 
entry and replication. Various studies have reported that alphaviruses enter the cell via receptor-
mediated endocytosis, involving multiple proteins implicated in virus absorption/transduction, such 
as heparan sulfate, laminin receptor, the major histocompatibility complex (MHC), DC-SIGN, L-
SIGN, heat shock 70 protein, and α1β1 integrin, among others (Smit et al., 2002; Wang et all., 
1992; Helenius et al., 1978; Klimstra et al., 2003; Ryan et al., 1992; La Linn et al., 2005). However, 
it is most likely that alphaviruses may utilize multiple surface proteins as receptors or alternative 
entry pathways in different cells. 
1.2.2. Recombinant alphavirus vectors 
Semliki Forest virus (SFV) and Sindbis virus (SIN) are the best-studied alphaviruses which have 
been used for the development of different gene expression systems. Three types of vectors have 
been engineered, namely: replication-deficient vectors, replication-competent vectors and layered 
DNA vectors (Figure 3).  
Replication-deficient vectors or one-step infection RNA vectors. 
For this application, vectors were generated in such a way where the alphavirus nonstructural and 
structural genes have been split on separate plasmid vectors. The expression vector plasmid contain 
only the nonstructural coding region, which is required for the production of the nsP1–4 replicase 
complex, 26S subgenomic promoter, and a multiple cloning site with several unique restriction sites 
for the foreign gene insertion under the control of SP6 RNA promoter for in vitro transcription of 
RNA. In the same manner, the structural genes are transcribed from helper vectors. For the 
production of the infectious particles, in vitro-transcribed recombinant and helper RNAs are 
cotransfected into packaging mammalian cells (usually BHK-21 cells) by either electroporation or 
applying transfection/lipofection reagents, leading to generation of replication-deficient particles. 
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The helper construct provides the structural proteins to assemble new virus particles, while the 
recombinant construct provides the nonstructural proteins for RNA replication of both recombinant 
and helper RNAs. The system is self-limiting because helper-RNAs are not encapsidated into new 
generated viral particles due to absence of encapsulation signal. The produced recombinant virus 
contains only recombinant RNA genome without structural genes encoded, thereby is able to infect 
animal cells and express the transgenes providing a one-step infection without propagation of new 
virus particles.  
However, the production of replication-deficient alphavirus vectors has been complicated by the 
emergence of propagation-competent vector during the vector production. There have been several 
attempts to eradicate this problem, including construction of split helper systems for Sindbis, SFV 
and VEE vector production (Frolov et al., 1997; Pushko et al., 1997; Smerdou and, Liljestrom, 
1999). Frolov et al. constructed chimeric split helper RNA for the production of alphavirus vectors. 
In this approach, the helper RNA was divided into two parts, one coding for capsid and the other 
coding for envelope glycoproteins (Figure 3; helper part). 
Replication-competent RNA vectors 
Replication-competent alphavirus vectors contain full virus genome encoding non-structural genes 
as well as structural genes. These vectors may contain two 26S promoters providing synthesis of 
two SG mRNAs: the first controls expression of the heterologous product, and the second controls 
production of virus structural proteins (Figure 3, see the structure of the replication-competent 
vector). For the expression of gene of interest, these vectors may synthesize the transgene as 
cleavable part of both structural and non-structural polyprotein (Thomas et al., 2003; Tamberg et 
al., 2007). In other cases, the insert is located in non-structural polyprotein genes and produced as a 
fusion protein (Atasheva et al., 2007). In contrast to one step infection vectors, replication-
competent vectors have self-replicating RNA genome. They are able to produce infectious virus 
particles in host cell after infection and to spread from cell to cell. Despite replication-competent 
vectors could provide enhanced distribution and expression in infected tissue, they have been less 
frequently used for in vitro and in vivo application than replication-deficient vectors. 
DNA-based vectors 
DNA-based alphavirus vectors have been generated by replacement the SP6 RNA polymerase 
promoter with DNA promoter (e.g., CMV IE, RSV LTR) that makes it possible to express the 
transgenes directly from alphavirus plasmid DNA (Figure 3, see alphavirus DNA vector). The 
introduction of this DNA-based vector into host cells provides transient expression of the transgene, 
however, the efficacy of gene delivery in this case fully relies on the efficacy of transfection 
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technique. To produce recombinant viral particles, the DNA-based expression vector could be 
cotransfected with DNA-based helper vector, however, using RNA-based vectors the number of the 
obtained virus particles could be 102-103 higher (Diciommo and Bremner, 1998).  
Figure 3: Schematic representation of recombinant alphavirus-based constructs. The major vector types are 
demonstrated: replication-deficient RNA vectors, replication competent RNA vectors, alphavirus helpers and DNA 
layered vectors. The examples of each type of vector are shown for Semliki Forest (SFV) and Sindbis (SIN) viruses. 
MCS – multiple cloning site; ARC – antibiotic resistance cassette.  
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1.2.3. Alphavirus vectors as gene delivery tools in cancer therapy 
The application range of the virus-based expression systems in gene therapy depends on several 
properties of the vectors, including packaging capacity, replication sufficiency, host range, tissue 
specific targeting, duration of transgene expression, and complexity and efficacy of the vector 
production. Alphavirus vectors have a lot of natural features that make them attractive for 
application in cancer gene therapy. The major advantages of the alphaviruses include (i) an ability 
to infect a broad host range of mammalian cells, (ii) induction of strong induction of p53-
independent apoptosis and (iii) an ability to efficiently overcome immunological tolerance by the 
activation of innate antiviral pathways (Lundstrom, 2009; Quetglas et al., 2010; Osada et al., 2012). 
Replication of alphavirus-based systems is extremely efficient producing around 105 new virions 
per host cell (Berglund et al., 1993; Schlesinger, 1995). Vectors have an inserted gene size capacity 
of at least 5 kb and the efficacy of transgene production under favorable intracellular conditions 
reaches approximately 20% of the total cell protein (Pushko et al., 1997). Low specific immune 
response against the vector itself and the absence of vector pre-immunity allow application of 
alphaviruses in broad spectrum of gene therapy strategies.  
The history of using the alphaviruses for cancer treatment started in 1975, when Griffith et al. has 
shown that pre-immunization with extract of fibrosarcoma cells infected with SFV has induced 
antitumoral protection against malignant tumor in treated mice (Griffith et al., 1975). In nowadays, 
cancer virotherapy is based not only on stimulation of anti-tumor immune response, but also on the 
ability of the viruses to preferentially infect and kill cancer cells. The possibility to apply systemic 
administration modes of alphaviruses for predominant infection of cancer cells would open a new 
door to widespread application of the vectors. Systemic administration may be the most effective 
method to reach various metastatic sites and is much more amenable than a surgical procedure from 
a translational perspective. Thus far, only SIN has been considered to be capable of targeting 
tumors upon systemic injection of the vector in mouse models (Meruelo, 2004; Tseng et al., 2004; 
Unno et al., 2005; Tseng et al 2010; Suzme et al 2012). In contrast, specific tumor targeting by SFV 
vectors has not been confirmed in vivo until 2012 and vectors were administrated by direct 
intratumoral route in most studies (Murphy et al., 2000; Rodriguez-Madoz et al., 2007; Maatta et 
al., 2007; Quetglas et al., 2012b). Only recently, we have demonstrated that SFV has a predominant 
tumor tropism upon systemic injection with a reduced viral dose, proving that tumor-targeted 
delivery by the vector could be possible under certain conditions (Vasilevska et al., 2012, Paper I). 
Alphaviruses have been tested as therapeutic approaches in different ways to establish the best 
strategy for efficient cancer therapy. Positive therapeutic effect has been achieved in several mouse 
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tumor models after alphavirus inoculation due to natural oncolytic properties of the vector. Rapid 
induction of apoptosis in the infected tumor cells affected the tumor growth, however, this strategy 
did not result in complete tumor regression (Asselin-Paturel et al., 1999; Chikkanna-Gowda et al., 
2005; Smyth et al., 2005). In contrast, treatment based on high level expression of 
immunomodulator genes, such as cytokines or growth factors by the vectors resulted in significant 
inhibition of tumor development or complete regression in animal models (Asselin-Paturel et al., 
1999; Rodriguez-Madoz et al., 2005; Chikkanna-Gowda et al., 2005; Lyons et al., 2007). Despite 
recombinant virus particles are the most frequently applied vectors in cancer gene therapy, viral 
RNA (naked or encapsulated into transfection vesicles) also can be used as an alternative gene 
delivery vector. In vitro transcribed alphaviral RNA is capable to replicate itself providing equal 
efficiency of transgene expression and induction of cell apoptosis. However, in comparison with 
enveloped viral particles, administration of self-replicating RNA does not induce antivector 
immunity and is safe for in vivo application (Vignuzzi et al., 2001; Cheng et al., 2001a). So far, 
inoculation of SFV RNA was applied only as a technique to stimulate or enhance the immune 
system’s responses against cancer. Ying et al., have demonstrated that intramuscular pre-
vaccination with small dose of naked SFV RNA (1 µg) was enough to trigger complete protection 
from tumor development extending the survival of treated mice (Ying et al., 1999). 
1.3 Efficacy of therapeutic and prophylactic anti-cancer vaccines based on 
alphaviral vectors 
Several treatment strategies using replication-deficient and replication-competent alphaviruses such 
as SFV, SIN and VEE were found effective in different cancer models due to targeted immunogene 
delivery and oncolytic properties of the vectors. It was shown, that therapeutic efficacy of 
alphavirus-based vaccines depends on vaccination settings (or administration mode): prophylactic 
vaccine (immunization was applied prior cancer cells challenge) or therapeutic vaccine 
(immunization was applied in tumor-established models). Here the brief overview of alphavirus 
application in melanoma and breast cancer treatment is provided. The therapeutic results of 
alphavirus-based vaccines in other cancer types are shown in supplementary Review paper 1. 
1.3.1 Melanoma 
Melanoma is one of the most aggressive forms of skin cancer. According to Cancer Research 
statistics, mortality rates induced by malignant melanoma have increased by 156% since the early 
1970s (CancerStatistics.org). Melanoma tumors arise from melanocytes and contain specific tumor-
associated antigens (TAA), which can be categorized as differentiation antigens such as 
26 
Pmel17/gp100, p75/tyrosinase-related protein TRP-1, MART-1/Melan-A and the retained intron in 
tyrosinase-related protein (TRP-2-INT2), as well as tumor-associated antigens, like MAGE, or a 
melanoma cell adhesion molecule (MUC18) (Pleshkan et al., 2011). These antigens have been used 
as main targets for alphavirus-based prophylactic and therapeutic immunotherapy of melanoma. 
The tyrosinaseis an enzyme that plays a key role in melanogenesis (Kumar et al., 2011). Successful 
stimulation of immune response against melanoma by alphavirus-based vaccines expressing either 
mouse or human tyrosinase-related protein 1 (TRP-1) has been demonstrated in several studies. For 
the first time, in 2003, Wolfgang W. Leitner et al., have evidenced that prophylactic intramuscular 
pre-immunization with Sindbis DNA-based pSin-mTRP-1 and pSin-hTRP-1 tumor vaccines was 
capable to break immunological tolerance and activate anti-cancer immune system in B16 mouse 
melanoma models (Leitner et al., 2003). Two years later, these results were re-proved by Stacie M. 
Goldberg et al., who demonstrated that prophylactic inoculation of VEE virus-like particles 
encoding mouse or human TRP-1 has stimulated high immune responses and caused a significant 
delay of tumor development in immunocompetent melanoma tumor-bearing mice (Goldberg et al., 
2005). 
In 2010, Avogadri et al., has examined the potential of therapeutic application of VEE-TRP-2 VLP 
vaccines in controlling of melanoma tumor growth. In their study, administration of VEE-TRP-2 
VLP started as late as 5 days after tumor inoculation has triggered time-dependent anti-tumor 
protection (Avogadri et al., 2010). Interestingly, the applied therapeutic treatment was significantly 
more efficient in contrast to immunization with combination of VEE-gp100 and VEE-tyrosinase 
vectors. Moreover, vaccination with all three VEE vectors resulted in similar therapeutic efficacy as 
VEE-TRP-2 alone. Continuing the set up of the more potent treatment based on VEE-TRP-2 vector, 
4 years later, the same group demonstrated that efficacy of VEE-TRP-2 vaccine can be increased in 
combination with either antagonist anti-CTLA-4 or agonist anti-GITR immunomodulatory 
monoclonal antibodies (mAbs). This combined strategy induced complete B16 tumor regression in 
90% and 50% of mice respectively and augmented ~4- and 2-fold the TRP2-specific CD8+ T-cell 
response and circulating Abs, compared to the vaccine alone (Avogardi et al., 2014).  
Murine melanoma cell adhesion molecule (MCAM/MUC18) seems to be another attractive target 
for therapy, because it is expressed in late primary and metastatic melanoma and almost is not 
expressed by healthy melanocytes. Although, immunization with Sindbis DNA vector (SINCp) 
expressing MCAM/MUC18 has not revealed any therapeutic effects against parental B16-F10 cells. 
Apparently, the negative data were obtained due to extremely low expression of this antigen in 
B16-F10 cells (Leslie et al., 2007).  
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In another study devoted to alphavirus DNA-based vaccines, the combination of SFV DNA 
expressing 1–4 domains of murine VEGFR2 and IL12 together with additional SFV DNA vaccine 
targeting survivin and β-hCG was proposed as a novel synergic strategy that targeted tumor cells 
and angiogenesis simultaneously. The combined vaccines inhibited the tumor growth and improved 
the survival rate in B16 melanoma mouse models. Furthermore, the treatment elicited efficient 
humoral and cellular immune responses against survivin, β-hCG and VEGFR2 and led to decrease 
of microvessel density in the tumors (Yin et al., 2015). 
Several studies have demonstrated that delivery and expression of cytokine genes in melanoma cells 
can drive dramatic inhibition of tumor development and strong induction of specific anti-tumor 
immunity. In preclinical models of cancer, gene therapy with interleukin 12 has reached 
unprecedented levels of success, especially if it was combined with immunotherapy. In alphavirus 
context, Asselin-Paturel with co-authors in 1999 have demonstrated that single intratumoral 
injection of recombinant SFV-IL-12 VLP induced dramatic tumor necrosis in all treated mice 
allografts leading to 70–90% of tumor growth inhibition. However, the completed tumor regression 
was not achieved in this study (Asselin-Paturel et al., 1999). To improve the outcomes of the 
treatment strategy, in another research, the inoculation of SFV-IL-12 was applied in combination 
with co-stimulation with agonist anti-CD137 monoclonal antibodies, that revealed powerful 
synergic therapeutic effect (Quetglas et al., 2012a). In more details, stimulation of immune system 
with agonist agents acting on CD137 expressed on primed T cells promoted an increase of tumor-
eradicating cytotoxic T-cell responses. Thus, combined treatment with both SFV-IL-12 and CD137 
mAb extremely enhanced the therapeutic efficacy causing50% and 75% of complete tumor 
remissions (Melero et al., 1997). 
In battle with melanoma progression, oncolytic properties of the replication-competent alphavirus 
vectors were also explored. In that context, avirulent SFV strain A7 was used as a therapeutic 
vaccine upon systemic and direct inoculation routesin human melanoma-bearing SCID xenografts 
(Vaha-Koskela et al., 2006). The tested treatment strategy has indicated promising dynamic 
independently on vector injection mode, showing that significant tumor regression could be 
achieved by a single administration of VA7. The neurotropism of SFV did not restrict its ability to 
target tumors, as within 3 weeks VA7 had caused regression of tumors to far below the starting 
volume. Nevertheless, in depth analysis identified integration of small groups of dividing tumor 
cells in strands of connective tissue, indicating the potential tumor remission in the future.  
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1.3.2 Breast cancer 
Breast cancer is the most common cancer in women worldwide and the second most common 
cancer overall. About 30-40% of breast cancers overexpress the growth-promoting protein 
HER2/neu that correlates with tumor aggressiveness and poor prognosis, making it one of the major 
target for immunotherapy (Banin Hirata et al., 2014). Beneficial therapeutic data were achieved 
after intramuscular vaccination with Sindbis VLP DNA-based expression system (ELVIS-neu) 
expressing neu gene 14 days before injection of cancer cells overexpressing neu. A strong 
protection of mice against tumor development was observed. Pre-immunization with ELVIS-neu 
resulted in decrease of lung metastasis’ incidence from mammary fat pad tumors, as well as caused 
a reduction of the number of lung metastases developed from intravenous injection of neu 
overexpressing cells. It should be noted, that intradermal vaccination was also efficient, despite 
required 80 % less plasmid for a similar level of protection (Lachman et al., 2001). In similar 
experiment, Wang et al., has demonstrated that treatment efficacy of pSINCP/neu vector 
application is depended on vaccination type: therapeutic or prophylactic. They showed that the 
vaccine could be effective only if administrated before tumor challenge (Wang et al., 2005).  
The effect of immunotherapy stimulated by pSINCP/neu DNA vaccine and VEE/neu VLP could be 
favored by co-treatment with chemotherapy. Application of chemical anticancer agent doxorubicin 
at concentration 5 mg/kg prior alphavirus-based vaccination significantly delayed tumor 
progression. Interesting, but mice treated only with chemotherapy alone did not show regression of 
tumor growth, despite doxorubicin is established as standard adjuvant in breast cancer therapy. It 
should be emphasized that alphavirus-based vaccines have synergic therapeutic effect only with 
particular chemical agents. In contrast, combination of the paclitaxel drug at concentration 25 
mg/kg and pSINCP/neu vector was ineffective (Eralp et al., 2004).  
Important, but in the case of the breast cancer therapy, the therapeutic alphavirus-based vaccines are 
not effective against established tumor. Only 36% of rat breast tumors were affected by VEE-neu 
VLP vaccination, when it was subcutaneously administrated 2 days after the cancer cells (Laust et 
al., 2007). However, different modulations in treatment strategies can significantly improve 
therapeutic outcomes. For instance, immunization of transgenic human breast tumor-bearing mice 
with dendritic cells infected with VEE VLP expressing the extracellular-transmembrane domains of 
rat neu oncoprotein has revealed an activation of both cellular and humoral immune response 
against neu and caused inhibition of tumor development (Moran et al., 2007). 
Replication-enhanced alphavirus vectors expressing cytokines such us IL-12 have been generated as 
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a cancer therapy agents. Chikkanna-Gowda et al., has applied enhanced Semliki Forest virus vector 
(SFV10-E) that expresses foreign genes (in this case IL-12) at levels up to 10 times higher than the 
original SFV10 vector. Direct intratumoral inoculation of this vector at high titre led to complete 
tumor regression in four out of six mice and decreased the numbers of lung metastases (Chikkanna-
Gowda et al., 2005). The efficacy of the same improved SFV10-E VLP vector was re-proved in 
another study, where therapeutic inoculation of SFV10-E encoding VEGFR-2 and IL4 reduced 
significantly inhibited tumor growth and pulmonary metastatic spread in treated mice (Lyons et al., 
2007). 
Aiming to develop an effective therapy against metastatic breast cancer and to enhance the efficacy 
of alphavirus vectors, the novel treatment strategy based on the combined intratumoral 
administration of SFV-IL-12 and attenuated Salmonella LVR01 followed by surgical removal of 
the treated primary 4T1 tumors was tested. This neoadjuvant combined therapy was markedly 
synergistic compared to each treatment alone resulting in 90% long-term survival (Kramer et al., 
2015). 
1.4 Clinical trials 
Despite a lot of beneficial results of cancer treatment have been shown in preclinical studies, only 
some of therapeutic strategies were translated in clinical trials for human treatment. In alphavirus 
context, the first clinical data were published in 2003 by Ren et al., where first phase I/II clinical 
study using Semliki forest virus vector expressing the human interleukin 12 gene and encapsulated 
in cationic liposomes (LSFV–IL12) was described. To evaluate the biosafety and optimal dosage of 
the vector, LSFV–IL12 was intravenously administrated in cancer patients with stage III or IV 
metastasizing melanoma or renal cell carcinoma every 3 days for 4 weeks in two different 
concentrations. No toxic effect has been determined after the therapy was as well as the 
functionality of the internal organs has not been affected, however, the treatment resulted in 10-fold 
increase of IL-12 concentration in the peripheral blood of the treated patients (Ren et al., 2003).  
Another phase I/II study was based on alphavirus ability to infect dendritic cells with high efficacy. 
Patients with advanced or metastatic cases of lung, colon, breast, appendix or pancreatic cancers 
were pretreated with multiple courses of chemotherapy and then got injected up to four times with 
VEE VLP expressing the carcinoembryonic antigen (CEA). Despite the majority of patients had 
dramatically low rate of clinical response after the therapy, the CEA-specific T cell and antibody 
response was found to be clinically relevant. The regression of liver metastasis has been observed in 
patient with pancreatic cancer. Additionally, two patients with no evidence of disease remained in 
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remission and two patients were able to maintain stable disease (Morse et al., 2010).  
Recently, in 2012, phase I clinical trials have been performed accessing the therapeutic efficacy of 
VEE VLP expressing prostate specific membrane antigen (PSMA) in patients with castration 
resistant metastatic prostate cancer. Patients were vaccinated with different vector dosages by 
maximally 5 subcutaneous administration routes in the deltoid region. However, the therapeutic 
effect was very low. The treatment was generally well-tolerated and did not demonstrate any toxic 
side effects, but only a small number of patients demonstrated a humoral response to PSMA. No 
cellular immune response to PSMA has been observed (Slovin et al., 2013). 
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2 A short description of the methods 
2.1 Cell lines 
BHK-21 cells (baby hamster kidney cells), H2-35 cells (mouse hepatocytes transformed with a 
temperature-sensitive strain of simian virus 40) and the tumor cell lines 4T1 (mouse mammary 
carcinoma), Huh-7 (human hepatocarcinoma), PA1 (human ovarian teratocarcinoma), C-33A 
(human cervical carcinoma), B16-F10 (mouse melanoma) and MCF-7 (human breast 
adenocarcinoma) were obtained from the American Type Culture Collection (ATCC/LGC 
Prochem). 
BHK-21 cells were cultured in BHK - Glasgow MEM (GIBCO/Invitrogen) supplemented with 5% 
fetal bovine serum (FBS), 10% tryptose phosphate broth, 2 mM L-glutamine, 20mM HEPES and 
antibiotics (100 µg ml-1 streptomycin and 100 U ml-1 penicillin). The 4T1 and MCF-7 cell lines 
were cultured in Dulbecco’s Minimal Essential Medium (D-MEM, GIBCO/Invitrogen) 
supplemented with 10% FBS and 2 mM L-glutamine. The Huh-7, PA1 and B16-F10 cell lines were 
cultured in D-MEM-GlutaMax (GIBCO/Invitrogen, UK) supplemented with 10% FBS and 40 µg 
ml-1 gentamicin. H2-35 cells were cultured in D-MEM-GlutaMax (GIBCO/Invitrogen) 
supplemented with 5% FBS without antibiotics. C-33 A cells were cultured in 40% D-MEM 
(GIBCO/Invitrogen) and 45% RPMI 1640 (GIBCO/Invitrogen) supplemented with 15% FBS, 10 
mM HEPES, 2 mM L-glutamine and antibiotics (40 µg ml-1 gentamicin). 
2.2 Generation of the plasmids 
pSFV/EGFP and pSINRep5/EGFP  
The pSFV1 (Liljestrom and Garoff, 1991) and pSinRep5 (Bredenbeek et al., 1993) vectors were 
used in this study. The enhanced green fluorescent protein (EGFP) gene was introduced into both 
vectors under the 26S subgenomic promoter. The EGFP gene was cut out of the pEGFP-C1 
plasmid (Clontech) with NheI and HpaI restriction endonucleases, treated with T4 DNA polymerase 
(Thermo Scientific) to blunt the DNA ends and ligated with the pSFV1 and pSinRep5 vectors, 
which were cleaved with SmaI and PmlI, respectively. Additionally, a pSFV1/DS-Red construct 
carrying the red fluorescent protein gene (DS-Red) (Matz et al., 1999) was generated. 
recSFV/DS-Red 
 The DS-Red gene was amplified by PCR (primers: 5’-ATTAGGATCCACCGGTCGCCACCATG-
3’ and 5’-TATCCCGGGCTACAGGAACAGGTGGTG - 3’) using the pDsRed-Monomer-C1 
plasmid as a template (Clontech). The PCR fragment was cleaved with BamHI and SmaI and 
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ligated into a pSFV1 vector hydrolyzed with the same enzymes. 
recSFV/EnhLuc 
The pSFV1/Enh vector was generated based on the pSFV1 vector by insertion of the 50 region of 
SFV capsid gene sequence (36 codons), acting as a translational enhancer for efficient heterologous 
gene expression, under the control of the 26S subgenomic promoter. This element is followed by in-
frame insertion of foot-and-mouth-disease virus 2A autoprotease sequence (Ryan and Drew, 1994). 
Located downstream of this cassette, the polylinker allows for the cloning of a gene of interest. The 
firefly luciferase gene (Luc) was amplified by PCR using the pGL3-Basic (Promega) plasmid as a 
template. The primers for amplification were as follows: 5’-
GACCCGGGAAGGATCTCTCGAGGATGGAAGAC-3’ (forward) and 5’-
CCGTTTAAACTATCCTAGAATTACACGGCGATCTTTCCGCCCTTC-3’ (reverse). The Luc 
PCR fragment was cut using SmaI and PmeI restriction enzymes and ligated into the pSFV1/Enh 
vector, which had also been cleaved with the same enzymes. The resulting pSFV1/Enh.Luc vector 
carries the Luc gene fused with the SFV core enhancer and 2A autoprotease-encoding sequence at 
the 5’ end. The presence of the SFV enhancer provides an approximate 10-fold increase in the 
transgene expression in comparison with the classical SFV1 vector (Chikkanna-Gowda et al., 
2005). The foreign N terminal 36 aa, which may affect the luciferase enzymatic activity, are 
removed by the activity of 2A autoprotease. 
2.3 In vitro RNA transcription 
The resulting plasmids were used to produce recRNA and recombinant virus particles. pSFV-
Helper (Liljestrom and Garoff, 1991) and pSIN-DH-EB helper (Bredenbeek et al., 1993) were used 
to produce the SFV and SIN particles, respectively. pSFV/EGFP, pSFV/DS-Red, pSFV1/Enh.Luc 
and pSFV-Helper plasmids were linearized using the SpeI restriction enzyme (Thermo Scientific). 
pSinRep5 and pSIN-DH-EB helper were linearized using XhoI respectively. In vitro RNA 
transcription was performed using 3 µg of linearized DNA and 40 U of SP6 RNA polymerase 
(Thermo Scientific) in a 50 µl reaction mixture. The RNA transcripts were capped during the 
transcription reaction by adding 1mM of the 5’ (ppp)5’G cap-analogue (New England Biolabs). The 
DNA template was removed by digestion using RNase-free DNase (Thermo Scientific). 
2.4 Production of recSFV and recSIN virus particles 
For the packaging of SFV/SIN RNAs into SFV/SIN particles, 20 µg of in vitro transcribed RNAs 
(recSFV RNA + SFV-helper RNA; recSIN RNA +SIN-DH-EB ) were co-electroporated into 1×107 
BHK cells (850 V, 25 mF, 2 pulses) using a Bio-Rad Gene Pulser apparatus (Bio-Rad) without the 
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pulse controller unit. The electroporated cells were resuspended in 15 ml of complete BHK medium 
containing 1% FBS, transferred into tissue culture flasks (75cm2) and incubated at 37ºC (5% CO2). 
After a 24-h incubation, recSFV/rec SIN-containing medium was harvested, rapidly frozen and 
subsequently used as a virus stock. The virus stocks did not contain the replication proficient wild-
type virus (confirmed by cell reinfection). To concentrate recSFV and recSIN particles, 25ml of the 
virus-containing medium was ultracentrifuged through a double sucrose cushion with a top layer 
comprising 3ml of 20% sucrose and a bottom layer comprising 3ml of 50% sucrose (Beckman 
SW32 rotor; 160 000 g for 1.5h at 41C; Beckman Coulter). After ultracentrifugation, the medium 
and 1ml of the upper sucrose cushion were removed and the next 4ml, representing the 
recSFV/recSIN particle-containing fraction, was collected and dialyzed in phosphatebuffered saline 
(PBS) overnight at 4ºC, dialysis membrane: CelluSep H1, 25 kDa cutoff (Orange Scientific). Next, 
the concentrated recSFV stocks were aliquoted and rapidly frozen. The concentration led to an 
approximate fivefold increase in the recombinant particle titer. 
The viral titers (infectious units per ml, iu ml-1) were quantified by infecting BHK-21 cells with 
serial dilutions of viral stock and analyzing EGFP or DS-Red expression via fluorescence 
microscopy on a Leica DM IL microscope (Leica Microsystems). For recSFV/Enh.Lucthe viral titer 
was quantified by Real-time PCR as described below. 
2.5 Real-time PCR for recSFV/Enh.Luc virus quantification 
The method is described in Paper I. 
Briefly, the viral RNA was isolated from recSFV/Enh.Luc virus particles (volume 500 µl) using 
TRI Reagent BD (Sigma) following the manufacturer's protocol. The RNA was reverse transcribed 
using the First-Strand cDNA Synthesis Kit (USB-Affymetrix) applying the random hexamer 
oligonucleotide strategy. A 183-bp DNA fragment was amplified by Real-Time PCR reaction using 
Luc gene-specific primers. To make a quantification of virus titre, the fivefold serial dilutions of the 
plasmid DNA (pSFV1/Enh.Luc) were used to establish a standard curve. The viral samples, 
negative controls (that is, isolated viral RNA without complementary DNA synthesis) and serially 
diluted standards were synchronously processed. The results were analyzed using OpticonMonitor3 
software (Bio-Rad) and expressed as the virus replicon genome copy number ml-1 (virus replicon 
particles, v.p.). 
2.6 Infection of cell lines with recombinant virus particles 
Cells were cultivated in 24-well plates at a density of 2×105 cells per well in a humidified 5% 
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CO2incubator at 37°C. For transduction, the cells were washed twice with PBS containing Mg2+ 
and Ca2+(Invitrogen). Next, 0.3 ml of the solution containing the virus particles was added. The 
recSFV/Enh.Luc, recSFV/EGFP, recSFV/DS-Red and recSIN/EGFP virus particles were diluted in 
PBS (containing Mg2+ and Ca2+) to achieve a multiplicity of infection (MOI) of 10. The cells were 
incubated for 1 h in a humidified 5% CO2incubator at 37°C. The control cells (uninfected) were 
incubated with PBS (containing Mg2+ and Ca2+). After incubation, the solution containing the virus 
was replaced with 0.5 ml of growth medium. The cells were gently washed with PBS and 
transferred to fresh medium every day. 
2.7 MTT cell proliferation assay 
The cell proliferation was quantified using the MTT (3-[4,5- dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide)-based cell viability assay. Cells were infected in 24-well plates as described 
above, and proliferation was analyzed 0, 1, 2, 3, 4 and 5 days after infection. The medium was 
replaced with 0.3 ml of solution containing 0.5 mg ml-1 MTT (Affymetrix) dissolved in D-MEM 
without phenol red (GIBCO/Invitrogen) supplemented with 5% FBS. The cells were incubated for 2 
h in a humidified 5% CO2incubator at 37°C. After incubation, the formazan crystals were dissolved 
by adding 0.3 ml of MTT solubilization solution consisting of 10% Triton X-100 and 0.1 N HCl in 
anhydrous isopropanol. The absorbance was measured using a microplate spectrophotometer 
(BioTek Instruments) at a test wavelength of 570nm and a reference wavelength of 620nm. Cell 
viability (%) was obtained using the following equation: Percent cell viability = (test 570 nm – 620 
nm)/(control 570 nm – 620 nm) × 100, where the control is the value obtained from uninfected 
cells.  
2.8 Fluorescence-activated cell sorting (FACS) analysis 
Cells were infected on 6-well plates with recSFV/EGFP and recSIN/EGFP virus particles at an 
MOI of 10 as described above (1 ml of virus-containing solution was used for the infection). The 
infected cells were harvested 24 h after infection. Detached cells were harvested from the cell 
medium by centrifugation, and attached cells were trypsinized. The collected cells (approximately 
106) were washed with PBS and resuspended in 1 ml of PBS. For propidium iodide (PI) staining, 
the cells were incubated with 10 µl of 50 µg ml -1 PI solution (Becton Dickinson Biosciences) and 
immediately processed for FACS analysis. EGFP and PI fluorescence was measured using a FACS 
Aria II (Becton Dickinson Biosciences). The FACS data were analyzed by BD FACS Diva 6.1.2 
software. Uninfected cells were used as a negative control for both the PI and EGFP FACS analysis 
and contained approximately 1-2% PI-positive cells in 4T1 culture. 
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2.9 Induction of 4T1 and B16 tumor nodules and recSFV virus or recRNA 
administration 
The methods are described in Papers I, II and III 
Briefly, 4T1 or B16-F10 tumor cells were trypsinized, washed with PBS and resuspended in PBS at 
a final concentration of 2.5×106 cells ml-1 and 3×105 cells ml-1 respectively. Two hundred 
microliters of the corresponding cell suspension were subcutaneously injected above the right 
shoulder blade of the mice. After 8-12 days, the tumor diameters were measured using linear 
callipers, and the tumor volume in mm3 was calculated using the following formula: volume = 
shorter measurement2×longer measurement/2 (V=(width)2×length/2) (Tomayko and Reynolds, 
1989). When tumor volumes reached 1000 mm3, 4T1 tumor-bearing mice (n = 5 or more) and 
tumor-free mice were inoculated either i.v. or i.p. of recSFV particle-containing stocks. Two viral 
titers were used: 6×109 v.p. (concentrated and dialyzed as described above) and 2×108 v.p. 
(unconcentrated recSFV particle-containing medium). B16 tumor-bearing mice (n=3) were i.t. 
inoculated with 108 v.p. or i.p. inoculated with 2×108 v.p. of recSFV/Enh.Luc particle-containing 
stocks. 
For in vivo application, recRNA was synthesized as described above. For i.t. administration, 50 µl 
of the transcription mix containing 130 µg of recRNA was diluted in sterile diethylpyrocarbonate-
treated water to a final volume of 250 µl with 5% glucose (w/v) and total volume (250 µl) was 
divided into five portions, and recRNA was injected into five different places in the 4T1 or B16 
tumor.
RecSFV virus/recRNA expression and biodistribution in mice organs and tumors were analyzed 
24h after inoculation. 
2.10 Analysis of Luc gene expression in mice organs 
The method is described in Paper I. 
Briefly, Luc gene expression analysis was performed by measuring the luciferase enzymatic activity 
in tissue homogenates at 24h after vector inoculation (48 h; 72 h or 168 h depending on experiment 
set up). The organs were manually homogenized in a 2× concentration of ice-cold lysis buffer (Cell 
Culture Lysis buffer, Promega) containing a protease inhibitor cocktail (10 µl per 1ml of lysis 
buffer) (Sigma) and the protein concentration was determined in tissue lysates using the RC DC 
Protein Assay (DC Protein Assay, Bio-Rad). The luciferase activity was measured by adding 100 µl 
of freshly reconstituted luciferase assay buffer to 20 µl of the tissue homogenate (Luciferase Assay 
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System, Promega). Luc gene expression was then quantified as relative light units (RLUs) using a 
conventional luminometer (Luminoskan Ascent, Thermo Scientific). The RLU values were 
expressed per 1mg of protein (RLU/mg-1) or total protein content in each organ (RLU per mg total).  
2.11  4T1 cell and tumor treatment with 5-FU 
The methods are described in Paper II.  
Briefly, 4T1 cells were seeded in a 24-well plate (2×105 cells per well) and on the next day, the 
cells were treated with medium containing 5-FU (Sigma) at 13, 26, 65 or 130 µg ml-1. Every day for 
5 days, the cells were gently washed with PBS to remove dead and detached cells, and fresh 
medium containing 5-FU was added. The control cells were not treated with 5-FU. The cell 
proliferation was analyzed by MTT cell proliferation assay at 0, 1, 2, 3, 4 and 5 days after the start 
of 5-FU treatment.  
To access the therapeutic efficacy of 5-FU treatment in vivo, 4T1 tumor-bearing mice (n ≥ 5) were 
treated with 5-FU at different doses (40, 150 or 400 mg kg−1) via peroral administration 4 times 
over a period of 8 days (every other day). For the recSFV and 5-FU combined treatment 
experiments, One hour after the last 5-FU treatment, the mice were inoculated either i.t. 
(intratumoral) or i.p. (intraperitoneal) with 200 μl (4 injections of approximately 50 μl each) or 300 
μl of recSFV/Enh.Luc particle-containing stocks (6 ×109v.p. ml−1), respectively. 
2.12 Analysis of FITC-dextran accumulation in 4T1 tumors 
The method is described in Paper II. 
Briefly, two groups of mice (treated with 150 mg kg−1 5-FU group (n = 3) and untreated control 
group (n = 3)) were inoculated i.v. with 120 μl of FITC-dextran 2000 kDa solution (40 mg/ml in 
PBS) (Sigma) 24h after the last 5-FU treatment. Two hours later tumors were collected and 
incubated overnight in 4% paraformaldehyde and frozen OCT compound (Sigma). Cryosections (10 
μm) were prepared and the intensity of FITC-dextran leakage was visualized by fluorescent 
microscopy. Pixels of images were measured by ImageJ software. 
2.13 Analysis of IFN-alpha in 4T1 tumor lysates 
The method is described in Paper II.  
Briefly, 4T1 tumor-bearing mice were either treated or non-treated with 150 mg kg−1 5-FU and 
inoculated i.t. with 200 μl (4 injections of approximately 50 μl each) of recSFV/EnhLuc particle-
containing stocks (6×109 v.p. ml−1) as described above. 18 hours after the virus administration, 4T1 
tumors were isolated and frozen in liquid nitrogen. Then frozen tumors were manually 
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homogenized in ice cold PB. Tissue lysates were prepared and IFN-alpha expression was analyzed 
according to the manufacturer's protocol of ELISA Kit for Interferon Alpha (Uscn Life Science 
Inc.). The obtained data (pg/ml) were expressed in % relative to lysates non-treated with both the 5-
FU and the virus. 
2.14 Isolation and cultivation of ex vivo B16 cells 
The method is described in Paper III. 
Briefly, freshly isolated B16-F10 tumors were manually homogenized in PBS and filtered through 
40-µm diameter filters. The obtained cells were seeded in 24-well plates at a density of 
approximately 5×105 cells per well in Dulbecco’s GlutaMAX medium (GIBCO/Invitrogen) 
supplemented with 10% FBS, 100 mg ml-1 streptomycin, and 40 µg ml-1 gentamicin and cultivated 
or 5-7 days until the cell monolayer reached 80% confluence. Then, 1st passage of ex vivo cells was 
trypsinized and plated in 24-well plates at a low density of approximately 4×103 cells per well (for 
infection or melanin staining) and in 10-cm Petri dishes at a density of 2×104 cells for further ex 
vivo B16 cell passaging (2nd passage, 3rd passage, etc.).  
2.15 Label-free LC-MS analysis of ex vivo and in vitro B16 cells 
The method is described in Paper III. 
Briefly, for the samples preparation, ex vivo B16 cells were isolated from three B16-F10 tumor-
bearing mice and cultivated for 5-7 days until the monolayer of the first passage reached 80% 
confluence (see above). The control in vitro B16-F10 cells were cultivated as described above until 
the monolayer reached 80% confluence. Both in vitro and ex vivo B16 cells were lysed with 0.1% 
ProteaseMax in 50 mM ammonium bicarbonate buffer (Promega) and sonicated for 15 min at 35 
kHz. The lysate protein concentration was measured using Direct Detect® Assay-free Cards (Merck 
Millipore). For LC-MS analysis, samples were prepared using the FASP protocol (Wiśniewski et 
al., 2012). 
For LC-MS analysis, all experiments were performed on an Easy nLC1000 nano-LC system 
connected to a quadrupole – Orbitrap (QExactive) mass spectrometer (ThermoElectron) equipped 
with a nanoelectrospray ion source (EasySpray/Thermo). For liquid chromatography separation, we 
used an EasySpray column (C18, 2-µm beads, 100 Å, 75-μm inner diameter) (Thermo) capillary 
with a 25-cm bed length. The flow rate was 300 nl/min, and the solvent gradient was 2% B to 5% B 
in 10 min followed by 5% to 26% B in 230 min, and then 90% B wash in 20 min. Solvent A was 
aqueous 0.1% formic acid, whereas solvent B was 100% acetonitrile in 0.1% formic acid. The 
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column temperature was kept at 60°C. 
The mass spectrometer was operated in data-dependent mode to automatically switch between MS 
and MS/MS acquisition. Survey full-scan MS spectra (from m/z 400 to 1.200) were acquired in the 
Orbitrap with resolution R = 70.000 at m/z 200 (after accumulation to a target of 3,000,000 ions in 
the quadruple). The method used allowed for the sequential isolation of the most intense multiply 
charged ions, consisting of up to ten depending on the signal intensity, for fragmentation on the 
HCD cell using high-energy collision dissociation at a target value of 100,000 charges or a 
maximum acquisition time of 100 ms. MS/MS scans were collected at a resolution of 17.500 at the 
Orbitrap cell. Target ions already selected for MS/MS were dynamically excluded for 30 seconds. 
General mass spectrometry conditions were as follows: electrospray voltage of 2.1 kV, no sheath 
and auxiliary gas flow, heated capillary temperature of 250°C, and normalized HCD collision 
energy of 25%. The ion selection threshold was set to 1e4 counts. An isolation width of 3.0 Da was 
used. 
For the protein identification, MS raw files were submitted to MaxQuant software version 1.4.0.5 
for protein identification (Cox et al., 2008). Parameters were set as follows: protein N-acetylation, 
methionine oxidation and pyroglutamate conversion of Glu and Gln as variable modifications. First, 
we used a search error window of 20 ppm and a main search error of 6 ppm. The Lys-C or Trypsin 
enzyme option, both without proline restriction, was used depending on the sample, with two 
allowed miscleavages. Minimal unique peptides were set to 1, and the FDR allowed was 0.01 (1%) 
for peptide and protein identification. Label-free quantitation was set with a retention time 
alignment window of 3 min. The UniProt Reference Proteome mouse database was used (download 
from April 2014). Generation of reversed sequences was selected to assign FDR rates. All 
quantitative analyses were performed using the Perseus suit from MaxQuant. Briefly, MaxLFQ 
values were loaded and log-transformed, and 0 values were replaced by noise detection values using 
an imputation approach based on the normal distribution of the whole data. Differential proteins 
were assigned by a t-test analysis using S0 = 0.5, a p-value threshold of 0.01 and a permutation-
based FDR correction. 
2.16 Bioinformatics analysis 
A total of 277 differentially expressed genes in ex vivo and in vitro B16 cells were selected by 
filtering with confidence at p<0.01 from a total of 4980 proteins with a difference in expression of 
at least 1.4-fold. The biological classification of associated genes in terms of their biologic 
processes and molecular functions was obtained by Gene Ontology (GO) analysis using the Protein 
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Analysis THrough Evolutionary Relationships (PANTHER) classification system (version: 
PANTHER 9.0;http://www.pantherdb.org) (Thomas et al., 2003; Mi et al., 2013).Analysis of the 
cellular localization of selected genes was conducted using the UniProt Knowledgebase 
(http://www.uniprot.org/). 
2.17 Analysis of IFN-alpha and IFN-beta in ex vivo and in vitro B16 cells 
The method is described in Paper III. 
Briefly, control in vitro B16 cells and freshly isolated ex vivo B16 cells were seeded in 24-well 
plates and cultivated until the cell monolayer reached 80% confluence as described above. 
Expression levels of the IFN-alpha and IFN-beta were determined in in vitro and first-passage ex 
vivo B16 cell lysates before SFV infection (0 h) and at 1 h, 3 h, 6 h, 9 h and 18 h after infection with 
SFV/Ds-Red at an MOI of 10. The cells were trypsinized, washed with PBS and resuspended in 100 
µl of PBS. The cell lysates were prepared according to recommended technique described 
in manufacturer's protocols. The protein concentration was equalized in all samples using the BCA 
Protein Assay Kit (Pierce™ BCA Protein Assay Kit, Thermo Scientific). The expression levels of 
IFN-alpha and IFN-beta in the cell lysates were determined using the Interferon Alpha ELISA Kit 
(Uscn Life Science Inc.) and Interferon Beta ELISA Kit (Cusabio Biotech) according to the 
provided protocols. 
2.18 Analysis of cell membrane elasticity by AFM 
The method is described in Paper III. 
Briefly, control in vitro B16 cells and freshly isolated ex vivo B16 cells were seeded in 8-well 
plastic chambers and cultivated until the cell monolayer reached 80% confluence as described 
above. To measure cell membrane hardness, an uncoated atomic force microscope cantilever 
(Olympus AC240TS) with spring constant C=2 N/m and resonant frequency F=70 kHz was used. 
Cantilever calibration was conducted by standard operations using an MFP-3D atomic force 
microscope (Asylum Research) and Igor Pro 6.34A software. The AFM tip with a radius of 10 nm 
was manually positioned at the middle point between the cell nucleus and the elongated cell body 
using an OLYMPUS IX71 inverted optical microscope. After positioning, the tip was engaged 
without scanning the surface of the cell to maintain viability, and single force curves were acquired. 
The force curve data were exported to Microsoft Excel and analyzed as described in Paper III.  
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2.19 Statistical analysis 
Statistical analyses of the results were performed using Microsoft Excel and Statistica7 (StatSoft, 
Tulsa). All error terms presented in the results are representative of minimum 2 or more 
independent experiments or at least 3 different samples. Statistically significant differences were 
determined using Student’s t-test (p<0.05). 
41 
3 Results 
The results are presented here as original publications. 
The author’s contribution to the enclosed original publications: 
Original paper I: Vasilevska J, Skrastina D, Spunde K, Garoff H, Kozlovska T, Zajakina A. 
Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: a 
comparison of transgene delivery by recombinant virus particles and naked RNA replicon. Cancer 
Gene Therapy J 2012 Aug;19(8):579-87. Doi: 10.1038/cgt.2012.37.  
(Performed: alphavirus production, concentration and titration; participated in design and analysis 
of the in vivo experiments; prepared the figures and wrote the manuscript) 
Original paper II: Zajakina A, Vasilevska J*, Zhulenkov D, Skrastina D, Spaks A, Plotniece A, 
Kozlovska T. High efficiency of alphaviral gene transfer in combination with 5-fluorouracil in 
mouse mammary tumor model. BMC Cancer 2014 Jun 20;14:460. Doi: 10.1186/1471-2407-14-460 
(Performed: alphavirus production and titration; all in vitro experiments with alphavirus infections, 
treatment with 5-FU and cell proliferation analysis; participated in design and performance of in 
vivo experiments; prepared the figures for the manuscript)  
Original paper III: Vasilevska J, De Souza GA, Stensland M, Skrastina D, Zhulenkovs D, 
Paplausks R, Kurena B, Kozlovska T, Zajakina A. Comparative protein profiling of B16 mouse 
melanoma cells susceptible and non-susceptible to alphavirus infection: effect of the tumor 
microenvironment. Cancer Biology&Therapy 2016 Aug 11:1-16. Doi: 
10.1080/15384047.2016.1219813 
(Performed: alphavirus production and titration; all in vitro experiments with in vitro and ex vivo 
B16 cells isolation, cultivation and infection; analysis of protein profilingby LC-MS, precipitated in 
in vivo experiments and AFM analysis; prepared the figures and wrote the manuscript) 
Review paper I: Zajakina A, Vasilevska J, Kozlovska T, Lundstrom K. Alphavirus vectors for 
cancer treatment. Book chapter in “Viral Nanotechnology” 2015. Doi: 10.1201/b18596-31 
(Designed the figures; collected the literature and partially wrote the manuscript) 
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3.1 Introduction in the results. 
Transduction efficiency and cytotoxicity of alphaviral vectors in vitro 
In order to determine the most potent vector and the most optimal cancer cell line for further 
preclinical studies in vivo, we have investigated transduction efficiency and oncolytic properties of 
recombinant SFV and SIN vectors in various mouse and human cancer cell lines. Series of 
experiments have been set up where seven cell lines were infected with equal amount of 
recombinant particles (MOI = 20) encoding EGFP gene. FACS analysis of EGFP-positive cells 
was performed at 24 h postinfection.  
Despite both recSFV and recSIN viruses have similar structures and biology, our results indicated 
differences in the infectivity and cytotoxic properties of the vectors in cancer cell lines (Figure 4). 
Four cell lines (Huh-7, PA1, 4T1 and H2-35) could be considered as good targets for both recSFV 
and recSIN vectors. Interestingly, the human C33-A cervical carcinoma was the only cell culture 
that showed exceptional transduction specificity with recSIN vector. Two cell lines (B16-F10 and 
MCF-7) were not susceptible to transduction with applied vectors.  
To evaluate the immediate cytotoxic effect of alphaviral infection (24 h), cells were stained with 
propidium iodide (PI). Percentage of PI-positive cells (dead cells) was measured by FACS and 
presented versus EGFP-positive cells (Figure 4, FACS results). Uninfected cells were used as a 
control for both PI and EGFP FACS analysis and showed 1-4 % of PI-positive cells in population 
for uninfected cell cultures (not shown).The strongest cytopathic effect was detected in PA1 cell 
line for both recSFV and recSIN vectors (36 % and 41 % of dead cells correspondingly), these cells 
were almost completely detached after 24 h postinfection. In contrast to recSFV vector, recSIN 
vector infection was extremely cytotoxic to H2-35 cell line. The EGFP-positive cells could be 
considered as conditionally dead cells, because these cells will die due to active alphaviral 
replication. Therefore among highly susceptible cell lines almost 50% of the cells in population 
were affected by recombinant virus (PI+EGFP-positive cells). Remarkably, two cell lines, which 
did not show the EGFP expression (B16-F10, MCF-7), displayed the increased percentage of dead 
cells in population upon alphaviral infection comparing to uninfected control cells.  
In order to compare the ability of various cancer cell cultures to survive alphaviral infection, we 
evaluated the cell proliferation during 5 days postinfection.For this purpose MTT assay, providing 
the quantitative measurement of viable cells based on the action of mitochondrial dehydrogenase 
enzymes in living cells, was applied. As shown in Figure 4, recSFV vector displayed stronger 
inhibition of 4T1 cell proliferation, whereas, C33-A and H2-35 were more affected by recSIN 
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vector. Proliferation of two cell lines Huh-7 and PA1 was equally inhibited by both recSFV and 
recSIN vectors leading to complete cell death at 4th-5th day.The unsusceptible cell lines were also 
affected by both vectors.  
Summarizing the data, we have showed a significant variation of alphavirus infection ability of 
different cancer cell lines in vitro that let us separate tested cell lines into two groups: i) infection 
susceptible and ii) unsusceptible cell lines. For the further experiments we have separated our 
research into two PARTS, selecting one cell line from infection susceptible or unsusceptible group 
for each part. Thus, as the most susceptible cell line to recSFV vector infection, 4T1 mouse 
mammary carcinoma (60% of positive cells) was selected for PART 1 of the study to investigate 
and to optimize different gene delivery strategies by recSFV vector. In contrast, B16-F10 mouse 
melanoma was chosen for PART 2 as uninfectable cell culture (1% of positive cells) to explore 
intracellular conditions that can facilitate or block alphavirus transduction and replication. The 
recSFV vector has been selected for further studies. 
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Figure 4: Infection efficacy of 
alphaviral vectors in different 
cancer cell lines. Cells were 
infected with recSFV and recSIN 
encoding EGFP. At 24 h post-
infection cells were analyzed by 
FACS: the x-axis and the y-axis 
represent EGFP and propidium 
iodide fluorescence, respectively. 
The percentage of living/dead 
cells and EGFP positive/negative 
cells is indicated on the scatter 
plot. The diagrams on the left 
show the cytotoxic effect of 
recSFV and recSIN infection in 
corresponding cell line. MTT cell 
viability assay was conducted 
during 4-5 days post-infection and 
the results are presented as 
percentage of viable cells relative 
to control (uninfected cells). Error 
bars show the standard deviation 
of three experiments.
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ORIGINAL ARTICLE
Semliki Forest virus biodistribution in tumor-free and 4T1
mammary tumor-bearing mice: a comparison of transgene
delivery by recombinant virus particles and naked
RNA replicon
J Vasilevska1, D Skrastina1, K Spunde1, H Garoff2, T Kozlovska1 and A Zajakina1
Semliki Forest virus (SFV) vectors are promising tools for cancer gene therapy because they ensure a high level of transgene
expression and a rapid and strong cytopathic effect. However, broad tissue tropism and transient expression make it more
difﬁcult to develop an optimal cancer treatment strategy. In this study, we have compared the distribution of recombinant
SFV particles (recSFV) and naked viral RNA replicon (recRNA) in tumor-free and 4T1 mammary tumor-bearing mice as a
consequence of different vector administration strategies. The high potential of SFV recRNA as a biosafe approach for the
development of therapeutic treatment was demonstrated. Intravenous (i.v.) inoculation of recRNA provided primary brain
targeting in both tumor-free and 4T1 tumor mouse models, but local intratumoral inoculation revealed a high expression level
in tumors. Moreover, we observed the predominant tumor targeting of recSFV at a reduced viral dose on i.v. and
intraperitoneal (i.p.) virus inoculation, whereas the dose increase led to a broad virus distribution in mice. To prolong transgene
expression, we have tested several i.v. and i.p. reinoculation strategies. A detailed evaluation of vector distribution and
readministration properties could have an impact on cancer gene therapy clinical trial safety and efﬁcacy.
Cancer Gene Therapy advance online publication, 22 June 2012; doi:10.1038/cgt.2012.37
Keywords: RNA inoculation; SFV distribution; cytopathic effect
INTRODUCTION
The latest virus-based technologies have signiﬁcantly contributed
to the progress of cancer therapy.1,2 Among other recombinant
viruses, alphaviral vectors are efﬁcient mammalian expression
systems, allowing transient high-level transgene expression
and rapid high-titer recombinant particle production.3,4 These
vectors are promising in the ﬁeld of cancer gene therapy because
of their strong cytopathic effects through the induction of p53-
independent apoptosis,5,6 their ability to efﬁciently overcome
immunological tolerance by the activation of innate antiviral
pathways7,8 and the subsequent triggering of the cytotoxic
T-lymphocyte response against tumors.9,10 The advantages also
include a low speciﬁc immune response against the vector itself,
the absence of vector pre-immunity and a high level of
biosafety.11,12
Alphaviruses are enveloped viruses containing a positive-strand
RNA genome and belonging to the Togaviridae family.13 The
classical Semliki Forest virus (SFV) replicon vector is generated in
such a way that the heterologous insert replaces the structural
genes under the control of the 26S viral subgenomic promoter.14
The vector RNA can be packaged into recombinant viral particles
by co-transfection into cells together with a helper RNA that
encodes structural genes (capsid and envelope). On infection, the
SFV RNA can replicate and lead to high expression of the
heterologous gene; however, the vector cannot propagate
because it lacks genes coding for viral structural proteins.
SFV can efﬁciently infect and induce apoptosis in many types of
cancer cells in vitro.15,16 However, in contrast to the closely related
Sindbis virus, speciﬁc tumor targeting by SFV vectors has not been
conﬁrmed in vivo.17 Therefore, the most commonly used approach
has been intratumoral (i.t.) injection of SFV vectors carrying a
reporter and/or a therapeutic gene. Therapeutic efﬁcacy by direct,
repeated i.t. injections of recombinant SFV (recSFV) has been
shown in several mouse tumor models, demonstrating tumor
growth inhibition or complete regression.18--22 Despite the
promising treatment results, local i.t. vector administration has
some disadvantages. For example, many tumors are not readily
accessible for i.t. administration. Furthermore, this inoculation type
is not appropriate for metastasis treatment, and i.t. injection doses
are limited. Systemic administration may be the most effective
method to reach various metastatic sites and is much more
amenable than a surgical procedure from a translational
perspective. However, the systemic application of oncolytic
vectors is limited by their toxicity; therefore, the virus distribution
has to be carefully investigated in tumor-free and tumor-bearing
animal models.
A broad SFV dissemination by systemic administration has been
shown in mouse models.17,23 The intravenous (i.v.) and intra-
peritoneal (i.p.) injection of recSFV particles resulted in a similar
recombinant virus distribution with high infectivity detected in the
heart and lung and moderate infectivity detected in other organs.
To prolong the transgene expression that signiﬁcantly drops on
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just the third day after inoculation, systemic vector reinjection
attempts within a 20-day interval were performed.17 These
reinjection results showed that the vector expression was only
slightly above background in all of the organs tested, indicating
recombinant virus activity inhibition by the immune system.
Nevertheless, the vector injection method (i.v., i.p. and i.t.), dose,
and reinjection strategy may signiﬁcantly contribute to the virus
targeting and transgene expression efﬁcacy, which has not been
evaluated in detail thus far.
Taking into consideration that the SFV replicon vector is based
on in vitro transcribed RNA, the corresponding RNA (recRNA)
(naked or encapsulated into transfection vesicles) can be used as
an alternative vector for cancer therapy. Self-replicating RNA can
provide the same efﬁcient cytoplasmic transgene expression and
induction of apoptosis in the host cells, and it is safe for in vivo
application and does not induce antivector immunity.24--26 The
high potential of recSFV RNA as a tumor vaccine was shown in one
study where intramuscular injection of as little as 1 mg of naked
SFV RNA provided complete tumor protection and extended the
survival of treated mice when tumor cells were injected 2 days
before immunization.27
To develop optimal treatment strategies regarding the viral
dose, the administration method and the regimen, we performed
a detailed study of SFV biodistribution in tumor-free, immuno-
competent Balb/c mice and 4T1 mammary tumor-bearing mice.
4T1 is a mouse transplantable tumor cell line that is highly
tumorigenic and invasive.28 In contrast to previous studies, we
have demonstrated that reduced dosage of recSFV provides
preferential SFV infection in 4T1 tumor nodules, whereas the
dosage increase contributes to broad dissemination of infection in
the organism. Moreover, for the ﬁrst time, the biodistribution of
naked SFV recRNA in tumor-free and tumor-bearing mice was
investigated on i.v., i.p. and i.t. RNA administration. Finally, we
have tested several readministration strategies using recSFV
particles and recRNA. This study emphasizes the importance of
the vector inoculation method and highlights the relevance of
systemic SFV injection (viral particles and naked RNA) in the
context of transgene distribution and tumor delivery.
MATERIALS AND METHODS
Cell lines and animals
The BHK-21 cells (baby hamster kidney cells) and the tumor cell line 4T1
(metastasizing mammary carcinoma from BALB/c mouse) were obtained
from the American Type Culture Collection (ATCC/LGC Prochem, Boras,
Sweden). BHK-21 cells were propagated in BHK---Glasgow MEM (GIBCO/
Invitrogen, Paisley, UK) supplemented with 5% fetal bovine serum (FBS),
10% tryptose phosphate broth, 2mM L-glutamine, 20mM HEPES and
antibiotics (streptomycin 100mgml--1 and penicillin 100Uml--1). The 4T1
cell line was cultured in Dulbecco’s minimal essential medium (GIBCO/
Invitrogen) supplemented with 10% FBS, 2mM L-glutamine and antibiotics.
Speciﬁc pathogen-free 4- to 6-week-old female BALB/c mice were
obtained from Latvian Experimental Animal Laboratory of Riga Stradins
University and maintained under pathogen-free conditions in accordance
with the principles of the Latvian and European Community laws. All
experiments were approved by the local Animal Protection Ethical
Committee and the Latvian Food and Veterinary Service (permission for
animal experiments no. 32/23.12.2010).
Construction of the pSFV1/Enh.Luc expression vector
The pSFV1/Enh vector was generated based on the pSFV1 vector14 by
insertion of the 50 region of SFV capsid gene sequence (36 codons), acting
as a translational enhancer for efﬁcient heterologous gene expression,
under the control of the 26S subgenomic promoter. This element is
followed by in-frame insertion of foot-and-mouth-disease virus 2A
autoprotease sequence.29 Located downstream of this cassette, the
polylinker allows for the cloning of a gene of interest. The ﬁreﬂy luciferase
gene (Luc) was ampliﬁed by PCR using the pGL3-Basic (Promega, Madison,
WI, USA) plasmid as a template. The primers for ampliﬁcation were
as follows: 50-GACCCGGGAAGGATCTCTCGAGGATGGAAGAC-30 (forward)
and 50-CCGTTTAAACTATCCTAGAATTACACGGCGATCTTTCCGCCCTTC-30 (re-
verse). The Luc PCR fragment was cut using SmaI and PmeI restriction
enzymes and ligated into the pSFV1/Enh vector, which had also been
cleaved with the same enzymes. The resulting pSFV1/Enh.Luc vector
carries the Luc gene fused with the SFV core enhancer and 2A
autoprotease-encoding sequence at the 50 end. The presence of the SFV
enhancer provides an approximate 10-fold increase in the transgene
expression in comparison with the classical SFV1 vector.18 The foreign N-
terminal 36 aa, which may affect the luciferase enzymatic activity, are
removed by the activity of 2A autoprotease.
In vitro RNA transcription and recSFV virus production
The synthesis of recSFV RNA and the generation of infectious vector
particles have been previously described.30 Brieﬂy, pSFV1/Enh.Luc and
pSFV-helper14 plasmids were linearized using the SpeI restriction enzyme
(Fermentas, Vilnius, Lithuania). In vitro RNA transcription was performed
using 3 mg of linearized DNA and 40U of SP6 RNA polymerase (Fermentas)
in a 50 ml reaction mixture. The RNA transcripts were capped during the
transcription reaction by adding 1mM of the 50(ppp)50G cap-analogue
(New England Biolabs, Hitchin, UK). The DNA template was removed by
digestion using RNase-free DNase (Fermentas).
For the packaging of pSFV1/Enh.Luc RNA (recRNA) into SFV particles
(recSFV), in vitro transcribed RNAs (recRNA and SFV-helper RNA, 20mg
each) were co-electroporated into 1 107 BHK cells (850 V, 25mF, 2 pulses)
using a Bio-Rad Gene Pulser apparatus (Bio-Rad, Hercules, CA, USA) with-
out the pulse controller unit. The electroporated cells were resuspended
in 15ml of complete BHK medium containing 1% FBS, transferred into
tissue culture ﬂasks (75 cm2) and incubated at 37 1C (5% CO2). After a 24-h
incubation, recSFV-containing medium was harvested, rapidly frozen and
subsequently used as a virus stock. The virus stocks did not contain the
replication proﬁcient wild-type virus (conﬁrmed by cell reinfection).
To concentrate recSFV particles, 25ml of the virus-containing medium was
ultracentrifuged through a double sucrose cushion with a top layer
comprising 3ml of 20% sucrose and a bottom layer comprising 3ml of
50% sucrose (Beckman SW32 rotor; 160 000g for 1.5 h at 4 1C; Beckman
Coulter, Fullerton, CA, USA). After ultracentrifugation, the medium and 1ml of
the upper sucrose cushion were removed and the next 4ml, representing the
recSFV particle-containing fraction, was collected and dialyzed in phosphate-
buffered saline (PBS) overnight at 4 1C, dialysis membrane: CelluSep H1,
25 kDa cutoff (Orange Scientiﬁc, Braine-I’Alleud, Belgium). Next, the concen-
trated recSFV stocks were aliquoted and rapidly frozen. The concentration
led to an approximate ﬁvefold increase in the recombinant particle titer.
Real-time PCR recSFV virus quantiﬁcation
To determine the genome copy number (that is, virus titer) of recSFV, viral
RNA was isolated from the recSFV particle-containing aliquots (500ml) using
TRI Reagent BD (Sigma, St Louis, MO, USA) and dissolved in 30ml of
diethylpyrocarbonate-treated water. In all, 11ml of RNA was reverse-
transcribed using the First-Strand cDNA Synthesis Kit (USB-Affymetrix,
Santa Clara, CA, USA) applying the random hexamer oligonucleotide
strategy. The following Luc gene-speciﬁc primers were generated using
Beacon Designer 7 software (Premier Biosoft, Palo Alto, CA, USA): 50-
ACGGATTACCAGGGATTTC-30 (forward) and 50-GCAGGCAGTTCTATGAGG-30
(reverse). The PCR produced a 183-bp DNA fragment using the MiniOpticon
system (Bio-Rad). The reaction mixture contained the VeriQuest SYBR Green
qPCR Master Mix (USB-Affymetrix), 600 nmol of each primer and 0.5ml of
complementary DNA in a 25ml reaction volume under the following
conditions: pre-denaturation at 95 1C for 10min, followed by 40 cycles at
95 1C for 15 s and 60 1C for 60 s. Fivefold serial dilutions of the plasmid DNA
(pSFV1/Enh.Luc) were used to establish a standard curve. A linear range was
observed when 102--107 copies of plasmid DNA were used as a template in
the ampliﬁcation reaction. The assay detection limit was 20 plasmid DNA
copies per reaction, and the ampliﬁcation efﬁciency was 80--90%. Triplicate
PCR reactions were performed for all standards and samples. The viral
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samples, negative controls (that is, isolated viral RNA without complemen-
tary DNA synthesis) and serially diluted standards were synchronously
processed. The ampliﬁcation product was conﬁrmed by melting curve
analysis (product melting temperature 78.2--79.2 1C). The results were
analyzed using OpticonMonitor3 software (Bio-Rad) and expressed as the
virus replicon genome copy numberml--1 (virus replicon particles, v.p.).
Induction of tumor nodules and recSFV virus or recRNA
administration
4T1 tumor cells were trypsinized, washed with PBS and resuspended in
PBS at a ﬁnal concentration of 2.5x106 cellsml--1. Two hundred microliters
of the 4T1 cell suspension were subcutaneously injected above the right
shoulder blade of the mice. After 10 days, the tumor diameters were
measured using linear callipers, and the tumor volume in mm3 was
calculated using the following formula: volume ¼ shorter measurement2
 longer measurement/2 (V¼ (width)2  length/2).31 All obtained tumor
volumes reached at least 1000mm3.
Tumor-free and 4T1 tumor-bearing mice (n¼ 5 or more) were inoculated
either i.v. or i.p. with 1ml of recSFV particle-containing stocks. Two viral titers
were used: 6 109 per ml (concentrated and dialyzed as described above)
and 2 108 per ml (unconcentrated recSFV particle-containing medium).
For in vivo application, recRNA was synthesized as described above. For
i.v. and i.p. administration, 50ml of the transcription mix containing 130mg
of recRNA was diluted in sterile diethylpyrocarbonate-treated water to a
ﬁnal volume of 250ml with 5% glucose (w/v). The same amount of recRNA
was applied for i.t. injection; however, the total volume (250 ml) was divided
into ﬁve portions, and recRNA was injected into ﬁve different places in the
tumor.
Analysis of Luc gene expression in mice organs
Luc gene expression analysis was performed by measuring the luciferase
enzymatic activity in tissue homogenates at 24 (ﬁrst day), 48 (second day)
and 72 h (third day) or 7 days after recSFV virus administration and on the
ﬁrst and second day after recRNA administration. The organs were excised
and manually homogenized in a 2 concentration of ice-cold lysis buffer
(Cell Culture Lysis buffer, Promega) containing a protease inhibitor cocktail
(10ml per 1ml of lysis buffer) (Sigma). The volume of lysis buffer used for
each organ (or pairs of bilateral organs) is indicated in Table 1. After
homogenization, the samples were centrifuged for 10min at 9000 g, and
the protein concentration was determined in tissue lysates using the RC
DC Protein Assay (DC Protein Assay, Bio-Rad). The luciferase activity was
measured by adding 100ml of freshly reconstituted luciferase assay buffer
to 20ml of the tissue homogenate (Luciferase Assay System, Promega). Luc
gene expression was then quantiﬁed as relative light units (RLUs) using a
conventional luminometer (Luminoskan Ascent, Thermo Scientiﬁc, Welwyn
Garden City, UK). As a result of the different 4T1 tumor sizes and the high
tissue density, tumors were weighed and homogenized in lysis buffer
using a ratio of 200ml of lysis buffer per 100mg of tumor tissue (2:1).
To evaluate the vector distribution in the entire organism and to
determine the viral dose per organ in general, rather than the viral dose
per 1mg of protein (RLUmg--1) as presented in other studies,17,32 the RLU
values were expressed per total protein content in each organ (RLU per mg
total). Nevertheless, using the data in Table 1, where the total mg of
proteins for each organ are indicated, the ‘RLU per mg total’ can be easily
transformed into ‘RLUmg--1’ by dividing the RLU value presented in each
diagram (see ﬁgures) by the total protein amount in the organs. RLUs were
calculated as an average mean from the mice in a group (n¼ 5 or more).
As a negative control, mice were inoculated with PBS, and the maximal
negative values in mice group n¼ 7 (Table 1) were subtracted in the
presented diagrams. Each experiment was repeated at least twice.
Statistical analysis
The RLU results are presented as the mean±s.e. The data were
transformed to the logarithmic scale. Statistical analyses of the results
were performed using Microsoft Excel and Statistica7 (StatSoft, Tulsa, OK,
USA). Statistically signiﬁcant differences were determined using Student’s
t-test (Po0.05).
RESULTS
Comparison of the recSFV virus biodistribution in tumor-free and
4T1 tumor-bearing mice
To investigate the biodistribution of recSFV in vivo, immunocom-
petent, tumor-free mice were i.v. or i.p. inoculated with 2 108 v.p.
recSFV/Enh.Luc (recSFV) particles. Luciferase expression analysis in
the organ homogenates was performed on the ﬁrst (24 h), second
(48 h) or seventh day after virus inoculation (Figures 1a and b). The
results are presented as the amount of RLUs per total protein (mg)
in each organ homogenate, allowing for the evaluation of the
recombinant virus distribution and Luc expression level in organs
in general (see Materials and methods section).
On the ﬁrst day, i.v. recombinant virus injection resulted in the
highest level of transgene expression in the heart, moderate
expression in the brain and lung, and low expression in the liver,
kidney and ovary (Figure 1a). On the second day, a rapid drop in
the Luc expression was observed in all of the examined organs,
with a further decrease on the seventh day, conﬁrming the
transient expression of luciferase by recSFV in vivo. In contrast to
the results obtained after i.v. injection of the virus, i.p. adminis-
tration revealed high levels of transgene expression on the ﬁrst
and second days (Figure 1b). Nevertheless, starting from the third
day, we observed a signiﬁcant (Po0.05) decrease in the
expression of the transgene in all organs (data not shown).
Comparing the level of the Luc gene expression in all organs on i.v.
and i.p. administration, the i.v. method provided a considerably
higher level of Luc expression in the heart and lungs (that is, active
blood circulation), whereas i.p. administration provided higher
expression in the ovary, liver and kidney (more accessible organs
by i.p. injection), and the Luc expression level in the brain was
similar for both types of injections. In addition, the overall
remaining level of Luc expression on the seventh day was
noticeably higher after i.p. virus administration compared with i.v.
injection (Figures 1a and b), demonstrating the prolonged
expression in the case of i.p. administration.
To evaluate the recSFV distribution in 4T1 tumor-bearing mice,
animals were i.v. and i.p. inoculated using the same 2 108
amount of recSFV v.p., and Luc gene expression was analyzed in
organ and tumor homogenates on the ﬁrst day after injection.
Surprisingly, the most predominant tumor targeting (the highest
RLU value in tumor) was detected after i.v. and i.p. recSFV
Table 1. Protein concentration and negative values of luciferase
detection system in organ homogenates
Organ
Protein
concentration
(mg ml--1)a
Lysis buffer
volume (ml)
Total protein
amount in
organ (mg)a
Luciferase-
negative values
per organ (RLU
per mg total)b
Heart 11.97±0.04 200 2.39±0.009 255
Lung 9.82±0.05 200 1.96±0.01 143
Brain 12.00±0.08 400 4.80±0.03 121
Kidney 22.23±0.05 300 6.67±0.01 215
Liver 36.97±0.06 1000 36.97±0.06 700
Ovary 1.04±0.05 50 0.05±0.03 373
Tumor 4.69--9.58 400--1600 2.14--8.61 1315
Abbreviation: RLU, relative light unit.
aMean±s.e.
bIn mice group, the negative values varied from zero to indicated maximal
value.
The organs of Balb/c mice were manually homogenized in 2 lysis buffer.
The insoluble fraction was separated by centrifugation, and the protein
concentration was measured using the RC DC Protein Assay (Bio-Rad,
Hercules, CA, USA). The minimal and maximal values for the tumors are
indicated. The background of luciferase detection system was measured in
tissue homogenates on the first day after mice inoculation with PBS (mock).
The maximal RLU values per mg total in mice group (n¼ 7) are indicated.
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administration (Figures 1c and d), which provided a high level of
transgene expression in tumors compared with the heart and
lungs. As the absolute RLU values in the organs of tumor-bearing
mice were signiﬁcantly lower than the values observed in tumor-
free mice (resembling some organs 7-day after inoculation), we
did not analyze the subsequent days (that is, days second, third
and seventh) after 2 108 recSFV particles inoculation. Therefore,
to evaluate the recSFV distribution in 4T1 tumor-bearing mice, the
viral load was increased, and the results of i.v. and i.p. inoculations
were investigated on the ﬁrst, second and seventh days.
As shown in Figures 1e and f, no preferential Luc gene tumor
expression was observed at high doses of recSFV (that is, 6 109
v.p.), which were applied via i.v. and i.p. injection, as all organs
received a high dose of the virus. Interestingly, we did not detect a
strong decrease in Luc expression on the second day after i.v.
administration (Figure 1e), as was shown in the tumor-free animals
with the low virus dose, and the expression indexes in all organs
widely ﬂuctuated. The ovary and liver can be efﬁciently targeted
by i.p. administration (Figure 1f). Remarkably, the transgene
expression level in subcutaneous 4T1 tumors was not affected by
the method of virus administration, demonstrating a similar Luc
expression on i.v. and i.p. injections. However, i.p. administration
provided a higher level of the Luc expression on the seventh day
after inoculation in almost all organs and tumors. These data
conﬁrm that i.p. inoculation is able to provide prolonged
transgene expression in tumor-free and tumor-bearing mice.
Finally, despite the high virus dose, the overall expression level in
tumor-bearing mice was signiﬁcantly lower than that observed in
tumor-free animals using a lower virus dose, whereas in tumor-
free mice the same high virus dose provided the expected
increase in Luc expression in all organs (data not shown).
Comparison of recRNA biodistribution in tumor-free and 4T1
tumor-bearing mice
In addition to recombinant virus particle (recSFV) application,
the unpacked self-replicating SFV RNA may be considered an
Figure 1. Luc gene expression in tumor-free Balb/c and 4T1 tumor-bearing mice inoculated intravenously (i.v.) and intraperitoneally (i.p.) with
recSFV/Enh.Luc virus particles (recSFV). The luciferase activity was measured in organ homogenates from tumor-free mice (n¼ 5) on the first
(24 h), second (48 h) and seventh days after i.v. (a) and i.p. (b) inoculation with 2 108 recSFV virus replicon particles (v.p.). Luciferase
expression in 4T1 tumor-bearing mouse organs (n¼ 5) was analyzed on the first day after i.v. (c) and i.p. (d) injections of 2 108 recSFV v.p.
and on the first, second and seventh days after i.v. (e) and i.p. (f ) inoculation with high viral dose (6 109 recSFV v.p.). The graphs present the
RLUs per total mg protein in each organ or tumor (see Materials and methods section). The results are presented as the mean±s.e. The
average RLU values are indicated in the tables. *Significant differences vs the seventh day (Po0.05). NS, nonsignificant differences; RLU,
relative light unit.
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alternative gene transfer vector for cancer gene therapy. Based on
this assumption, we investigated the biodistribution of recSFV/
Enh.Luc RNA (recRNA) by determining Luc gene expression in
selected organs of tumor-free and 4T1 tumor-bearing mice. For
this purpose, 130mg of in vitro prepared recRNA was used for i.v.
and i.p. mouse injections. The luciferase activity was measured in
organ homogenates on the ﬁrst (24 h) and second (48 h) days after
RNA inoculations.
The luciferase production in mouse organs after systemic
recRNA administration is shown in Figures 2a and b. Surprisingly,
in contrast to the virus distribution, where the maximal expression
was detected in the heart, the highest recRNA expression was
observed in the brain as a consequence of both i.v. and i.p. recRNA
administrations. Other organs demonstrated a much lower
transgene expression level compared with that of virus inocula-
tion. Moreover, the injection type signiﬁcantly inﬂuences the level
of recRNA activity: only i.v. inoculation provides a relatively high
level of Luc gene expression.
The recRNA distribution in 4T1 tumor-bearing mice was
investigated only for i.v. inoculation (Figure 2c), as the i.p. route
did not demonstrate a high expression level. The results showed
the highest recRNA expression in the brain, as was also detected
in tumor-free animals. We observed low Luc gene expression in
other examined organs and tumors on i.v. injection. Moreover, a
rapid decrease in transgene expression in all examined organs,
excluding the tumors, was observed on the second day after
recRNA inoculation. Interestingly, the Luc gene expression in
tumor-bearing mice was signiﬁcantly lower compared with the
tumor-free animals, and the same was observed for the
recombinant virus vector expression.
In addition, the recRNA expression after i.t. administration was
examined (Figure 2d). For this purpose, i.t. injections consisting of
130mg of recRNA were performed each day for 2 days, and Luc
gene expression was analyzed in tumor and organ homogenates 1
day after the second injection (ﬁrst day). Our results showed
extremely high Luc gene expression in 4T1 tumors (Figure 2d).
Low vector activity in other organs showed poor RNA distribution
in mice on i.t. administration. However, obvious transgene
expression was found in the brain even after i.t. RNA vector
inoculation.
recSFV virus and recRNA reinjection in Balb/c mice
The transient mode of SFV-driven gene expression in vivo is
demonstrated by the strong transgene expression decrease on the
third day after inoculation. Virus readministration usually does not
provide a signiﬁcant enhancement or prolongation of transgene
expression in mice.17,33 It is possible that the viral vector
provoking the immune response is the reason for readministration
failure. To develop an optimal strategy to increase and prolong
transgene expression, several vector reinjection schemes using
recSFV virus and recRNA combinations and different injection
methods were evaluated (Figures 3a and b).
Initially, (Figure 3a), Balb/c mice were i.v. inoculated with 2 108
recSFV virus, and 7 days later, one group (n¼ 5) was i.p.
readministered with the same amount of recSFV virus, the second
group (n¼ 5) was i.v. readministered with 130 mg of recRNA.
Luciferase expression analysis was performed in tissue homo-
genates 24 h after recSFV virus or recRNA reinjection. To observe
the increase in the transgene expression level, the results were
compared with the values of the remaining Luc expression on the
seventh day after the ﬁrst recSFV virus inoculation. In both
reinjection combinations (that is, recSFV virus and recRNA), we
succeeded in signiﬁcantly increasing the Luc expression in all
Figure 2. recSFV/Enh.Luc RNA (recRNA) biodistribution in tumor-free Balb/c and 4T1 tumor-bearing mice. The luciferase activity was measured
in organ homogenates from tumor-free mice (a, b) and 4T1 tumor-bearing mice (c, d) on the first or first and second day after recRNA
intravenous (i.v.) (a, c), intraperitoneal (i.p.) (b) and intratumoral (i.t.) (d) (n¼ 5) inoculations with 130 mg of Semliki Forest virus (SFV) recRNA
expressing firefly luciferase. In the case of i.t. inoculation, recRNA was sequentially injected for two days (that is, 130 mg each day), and Luc
gene expression was analyzed in tumor and organ homogenates one day after the last injection (first day). The graphs present the RLUs per
total mg protein in each organ or tumor (see Materials and methods section). The results are presented as the mean±s.e. The average RLU
values are indicated in the tables. *Significant differences (Po0.05). NS, nonsignificant differences; RLU, relative light unit.
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examined tissues; however, this level did not reach the values of
the primary i.p. recSFV virus or i.v. recRNA inoculations on the ﬁrst
day (Figures 1b and 2a). Nevertheless, the recRNA i.v. read-
ministration values were comparable with the recSFV virus i.p.
reinjection results, demonstrating the high potential of recRNA
application, particularly if the brain is the targeted organ.
According to another combination, the effect of recSFV virus/
recRNA reinjections using the i.p. method was investigated
(Figure 3b). For this purpose, Balb/c mice were i.p. inoculated
with 2 108 recSFV virus, and 7 days later, one group (n¼ 5)
received a readministration of the same amount of recSFV virus
i.p., and the second group (n¼ 5) received a readministration of
130mg of recRNA i.p. Luciferase expression was measured in the
organ homogenates that were collected on the ﬁrst day (24 h)
after reinoculation. Compared with the values on the seventh day,
the repeated i.p. recSFV virus injection ensured a signiﬁcant
increase in the transgene expression only in the liver. In contrast
with the i.v. recSFV virus readministration (Figure 3a), the repeated
i.p. method is much less effective for increasing the transgene
expression at least with 7-day time interval. The recRNA i.p.
reinjection also did not provide a remarkable increase in the
transgene expression. As shown in Figures 1a and b (seventh day),
i.p. virus inoculation, in contrast to i.v. inoculation, provided
prolonged Luc gene expression in all organs. Therefore, the
relatively high values remaining on the seventh day after i.p.
inoculation were not signiﬁcantly increased by the recSFV virus
and recRNA reinjections.
recSFV virus and recRNA reinjection in 4T1 tumor-bearing mice
As the recRNA i.v. reinoculation in tumor-free mice demonstrated
the signiﬁcant increase in transgene expression that resembled
recSFV reinoculation (Figure 3a), we were interested in evaluating
the recRNA readministration properties and transgene expression
biodistribution in tumor-bearing mice that were primary i.v.
injected with a high (6 109) virus dose. For this purpose, 4T1
tumor-bearing mice were i.v. inoculated with 6 109 recSFV virus,
and after 7 days, the mice were i.v. inoculated with 130mg of
recRNA (Figure 4a). Luc gene expression was measured in tissue
homogenates 24 h after recRNA inoculation and compared with
the Luc values on the seventh day after the ﬁrst recSFV virus
inoculation (that is, the remaining values). Using i.v. recRNA
readministration, a signiﬁcant increase in transgene expression
was observed in the brain and heart. All other organs and tumors
demonstrated statistically insigniﬁcant Luc expression differences.
Moreover, to investigate the ability of recRNA to prolong Luc
gene expression, we evaluated repeated i.v. recRNA administra-
tion (Figure 4b). For this purpose, 4T1 tumor-bearing mice were i.v.
Figure 3. Semliki Forest virus (SFV) vector administration strategies in Balb/c mice using SFV/Enh.Luc virus particles (recSFV) and SFV/Enh.Luc
RNA (recRNA) reinjection combinations. (a) Balb/c mice were intravenously (i.v.) inoculated with 2 108 virus replicon particles (v.p.) of the
recSFV. After 7 days, one group of mice (n¼ 5) was intraperitoneally (i.p.) reinoculated with 2 108 v.p. of the recSFV, and another group
(n¼ 5) was i.v. reinoculated with 130 mg recRNA. (b) Balb/c mice were i.p. inoculated with 2 108 v.p. of the recSFV. After 7 days, one group of
mice (n¼ 5) was i.p. reinoculated with 2 108 v.p. of the recSFV, and another group (n¼ 5) was i.p. reinoculated with 130 mg of recRNA. The
Luc gene expression was analyzed in tissue homogenates on the seventh day after the first recSFV inoculation and on the first day after
the recSFV or recRNA reinoculations. The graphs demonstrate RLUs per total mg protein in each organ (see Materials and methods section).
The results are presented as the mean±s.e. The average RLU values are indicated in the tables. *Significant differences vs the seventh day
(Po0.05). RLU, relative light unit.
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inoculated with 130 mg of recRNA and 7 days later the second
130mg recRNA dose was i.v. reinjected. In addition, another group
of mice was used to examine the prolongation of transgene
expression by daily i.v. injections with 130mg recRNA for 7 days
(Figure 4b). Luc expression was measured in tissue homogenates
24 h after the last recRNA injection.
The recRNA reinjection with 7-day interval provided the
same level (that is, statistically insigniﬁcant differences) of Luc
expression in all organs and tumors as was observed on the
second day after the ﬁrst recRNA inoculation. This observation
indicates that recRNA is able to prolong transgene expression on
systemic reinjection during a 7-day interval, since without
reinjection the luciferase level dropped to the background
(not shown). Remarkably, the daily reinjection of 130 mg recRNA
did not enhance the transgene expression, demonstrating
generally the same result as reinjection using 7-day interval
(Figure 4b).
Despite the fact that recRNA administration did not show
high values of transgene expression, repeated i.v. recRNA injection
resulted in the same level of expression in tumors (or even
higher) as was detected after the ﬁrst (primary) recRNA inocula-
tion. Therefore, repeated recRNA injection could provide
prolonged expression in contrast with repeated administration
of recSFV, which does not result in the same level of transgene
expression as was achieved after the ﬁrst (primary) virus
inoculation.
DISCUSSION
Biodistribution studies are important for the validation of viral
vector tumor uptake and the assessment of their potential toxicity
to normal tissues. In this study, we were interested in comparing
the recSFV vector biodistribution in tumor-free and 4T1 tumor-
bearing mice after i.v. and i.p. administration of recombinant viral
particles. Our results conﬁrmed the broad in vivo recSFV
dissemination that has been described by other authors,17,23
showing the highest SFV-driven transgene expression in organs
with active blood circulation, including the heart and lung.
Nevertheless, the virus dose may affect the vector distribution,
toxicity and therapeutic effect.34
In this study, we observed a signiﬁcant correlation between
recSFV dose and biodistribution in a 4T1 tumor model: the lower
virus dose provided predominant tumor recSFV targeting as a
consequence of both types (that is, i.v. and i.p.) of recombinant
virus administration (Figures 1c and d). Moreover, the increase in
the recSFV dose changed not only the biodistribution pattern of
the vector (the main expression switches to the heart), but also led
to a decrease in transgene expression in tumors, whereas other
organs demonstrated a high level of expression. Therefore, we
conclude that the increase in recSFV titer does not provide
predominant virus tumor targeting and enhancement of the i.t.
transgene expression level in the 4T1 tumor model. In contrast,
the abundant virus circulation more efﬁciently promotes the
Figure 4. Semliki Forest virus (SFV) vector administration strategies in 4T1 tumor-bearing mice using SFV/Enh.Luc virus particles (recSFV) and
SFV/Enh.Luc RNA (recRNA) reinjection combinations. (a) 4T1 tumor-bearing mice were intravenously (i.v.) inoculated with 6 109 virus
replicon particles (v.p.) recSFV. After 7 days, one group of mice (n¼ 5) was i.v. inoculated with 130 mg recRNA. Luciferase expression was
analyzed in tissue homogenates on the seventh day after the first recSFV virus inoculation and on the first day after the recRNA inoculation.
(b) 4T1 tumor mice were i.v. inoculated with 130 mg of recRNA. After 7 days, one group of mice (n¼ 5) was i.v. reinoculated with 130 mg of
recRNA. Another group of mice (n¼ 5) was daily i.v. inoculated with 130 mg of recRNA for 7 days. Luciferase expression was analyzed in tissue
homogenates on the 2nd day after the first recRNA inoculation and on the first day after the last recRNA reinoculation. The graphs
demonstrate RLUs per total mg protein in each organ or tumor (see Materials and methods section). The results are presented as the
mean±s.e. The average RLU values are indicated in the tables. *Significant differences (Po0.05), NS, nonsignificant differences; RLU, relative
light unit.
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infection of the organs but not the tumors. A possible explanation
for this difference could be the hypothesis that after virus
injection, the majority of the virus particles circulating in blood
infect cancer cells, which are more accessible for infection, and the
rest of the virus disseminates to other organs, primarily leading to
infection in the heart (and other organs depending on the method
of administration).
The serum is known to inhibit alphavirus infectivity in vitro.
One of the reasons is that components in serum (complement,
immunoglobulins, and so on) interfere with the virus adsorption.
In our experiments, the low recSFV dose represents the virus
preparation containing cell culture medium with 1% FBS, in
contrast to the high dose recSFV, which was puriﬁed by sucrose
gradient and dialyzed in PBS. These two virus preparations
(low dose and high dose) did not demonstrate the signiﬁcant
differences in recSFV distribution in tumor-free mice (not
shown), only the level of Luc expression was higher using high
virus dose, as was expected. We assume that the infectivity
also is not affected signiﬁcantly by FBS presence (10 ml per 1ml
dose) in low virus dose preparation, because the native mouse
serum components already present in blood and equally interfere
with the virus infection. Nevertheless, we do not exclude the
inﬂuence of FBS and other factors of cell culture medium on
immunity and transgene expression properties that have to
be evaluated in longer period of time after recSFV inoculation
(47 days).
In all experiments, we veriﬁed the higher transgene expression
level in tumor-free animals as compared with 4T1 tumor-bearing
mice. This was observed for the i.v. and i.p. methods and for the
recSFV and recRNA inoculation experiments. The low level of viral
expression in tumor-bearing mice may be affected by the
upregulation of tumor stress factors and immune-related genes
that suppress the virus entry and replication. We may also assume
that vector uptake by tumor nodules in tumor-bearing mice leads
to a decrease in the viral dose that is available for other organs,
therefore reducing the total transgene expression level in tumor-
bearing mice.
The virus injection method (i.v. and i.p.) may signiﬁcantly
contribute to the virus allocation and affect the duration of
transgene expression in an organism. Although recSFV did not
demonstrate the most predominant tumor targeting at high doses,
the ability of the vector to disseminate throughout the body may
be important for gene delivery to a speciﬁc organ where
metastases may be expected. With regard to our results, the liver,
ovary and kidney were more efﬁciently targeted by i.p. recSFV
administration, whereas the i.v. method targeted the other organs.
Moreover, in contrast to i.v. administration, i.p. recSFV inocula-
tion revealed a higher Luc gene expression level on the seventh
day, ensuring prolonged transgene synthesis. To solve the problem
of transgene expression prolongation, other authors have
attempted repeated vector administration.33,35,36 It is likely that
the repeated virus inoculation is suppressed by induction of
antivector immune response. To avoid this, the recSFV particles
were incapsulated into cationic liposomes.36 Possibly, the liposome
protects the incapsulated SFV particle from inactivation by immune
system.
On the other hand, a naked recRNA vector could be used as an
alternative strategy for repeated transgene delivery. In this study,
we investigated the recRNA biodistribution on i.p., i.v. and i.t.
administration. The use of naked RNA represents a safe, promising
transgene delivery option,37 but suffers from poor stability and
lack of efﬁcient and clinically feasible delivery technologies. In
contrast, alphavirus replicon RNA probably has an increased
stability because of its secondary structure, which may protect it
from degradation.38 In addition to high expression levels of
inserted gene provided by self-replicating RNA, the various RNA-
species produced by the replicon ampliﬁcation initiates antiviral
program resulting in type I interferon production and induction
of apoptosis.6,39 Therefore, the RNA-based vectors are potent
immunostimulatory ligands providing excellent adjuvant proper-
ties and inducing strong cytopathic effect. As shown in previous
studies, recRNA vectors have been used successfully for vaccine
development through intramuscular injections.26,27,40
Here, we demonstrated for the ﬁrst time that i.t. administration
of self-replicating recRNA provides efﬁcient transgene expression
in tumors without signiﬁcant vector dissemination to organs
(Figure 2d), in contrast to recSFV particles i.t. inoculation.32
Therefore, recRNA is a safe vector for i.t. application. As the i.t.
recSFV administration was applied in numerous studies, we did
not investigate this type of vector inoculation. However, the
transgene expression efﬁciency of recSFV and recRNA vectors has
to be compared in future.
Surprisingly, systemic recRNA inoculation revealed predominant
transgene expression in brains of tumor-free and 4T1 tumor-
bearing mice (Figures 2a and c). It is tempting to speculate that in
contrast to the recSFV particles, recRNA molecules may cross the
hematoencephalic barrier more efﬁciently. This recRNA property
may potentially be used for brain-targeted gene delivery.
However, the mechanisms of naked RNA delivery into target cells
in vivo remain to be explored.
In this study, we showed that recRNA i.v. readministration can
be successfully applied to prolong transgene expression without
the risk of deterioration of viral vectors associated with the
immune response. Nevertheless, for unknown reasons, neither
recRNA reinjections nor recSFV particles reinjections allow for
increasing the transgene expression up to values obtained after
the primary vector inoculation (ﬁrst day).
Here, we describe a comprehensive study of SFV vector
distribution with regard to the vector injection type, viral dose,
expression time and vector readministration. These results may be
analyzed from a different point of view, depending on the priority
of the vector application. In conclusion, we would like to
emphasize the observed recSFV tropism in 4T1 tumors at certain
doses of systemic viral inoculation. Thus far, only the Sindbis virus
of the alphavirus genus has been considered to have tumor-
targeting properties;41--44 however, a correlation with the virus
dose has not been investigated in that case. Another important
observation indicates a high potential for the self-replicating
recRNA application for gene delivery demonstrated in this paper.
The main advantages of recRNA vectors over the recSFV particles
application include safety, reinoculation efﬁciency, reduced
injection volume and simple preparation (that is, in vitro RNA
synthesis over virus production). Our ﬁndings make SFV vectors
attractive for future studies with respect to tumor targeting and
gene delivery into organs that may be applied in combination
with the recSFV virus and recRNA administration.
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http://www.biomedcentral.com/1471-2407/14/460RESEARCH ARTICLE Open AccessHigh efficiency of alphaviral gene transfer in
combination with 5-fluorouracil in a mouse
mammary tumor model
Anna Zajakina1*†, Jelena Vasilevska1†, Dmitry Zhulenkovs1, Dace Skrastina1, Artjoms Spaks2, Aiva Plotniece3
and Tatjana Kozlovska1Abstract
Background: The combination of virotherapy and chemotherapy may enable efficient tumor regression that would
be unachievable using either therapy alone. In this study, we investigated the efficiency of transgene delivery and
the cytotoxic effects of alphaviral vector in combination with 5-fluorouracil (5-FU) in a mouse mammary tumor
model (4 T1).
Methods: Replication-deficient Semliki Forest virus (SFV) vectors carrying genes encoding fluorescent proteins were
used to infect 4 T1 cell cultures treated with different doses of 5-FU. The efficiency of infection was monitored via
fluorescence microscopy and quantified by fluorometry. The cytotoxicity of the combined treatment with 5-FU and
alphaviral vector was measured using an MTT-based cell viability assay. In vivo experiments were performed in a
subcutaneous 4 T1 mouse mammary tumor model with different 5-FU doses and an SFV vector encoding firefly
luciferase.
Results: Infection of 4 T1 cells with SFV prior to 5-FU treatment did not produce a synergistic anti-proliferative
effect. An alternative treatment strategy, in which 5-FU was used prior to virus infection, strongly inhibited SFV
expression. Nevertheless, in vivo experiments showed a significant enhancement in SFV-driven transgene (luciferase)
expression upon intratumoral and intraperitoneal vector administration in 4 T1 tumor-bearing mice pretreated with
5-FU: here, we observed a positive correlation between 5-FU dose and the level of luciferase expression.
Conclusions: Although 5-FU inhibited SFV-mediated transgene expression in 4 T1 cells in vitro, application of the
drug in a mouse model revealed a significant enhancement of intratumoral transgene synthesis compared with 5-FU
untreated mice. These results may have implications for efficient transgene delivery and the development of potent
cancer treatment strategies using alphaviral vectors and 5-FU.
Keywords: Semliki Forest virus, Cytotoxic effect, 5-fluorouracil, Combined cancer treatment, 4 T1 tumorBackground
Several preclinical studies in recent years have demon-
strated therapeutic synergy between viral vectors and
chemotherapy [1,2]. As reported previously, chemical
compounds might be acting as adjuvants for the applied
genetic vaccines [3] and/or could enhance the infectivity
and gene transfer efficiency of the viral vector [4]. Among* Correspondence: anna@biomed.lu.lv
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Dedication waiver (http://creativecommons.or
unless otherwise stated.the potential therapeutic viruses, alphaviral vectors are
good candidates for cancer therapy because of the high
level of transgene expression and their ability to mediate
strong cytotoxic effects through the induction of p53-
independent apoptosis [5,6]. The advantages of alphaviral
vectors also include a low specific immune response
against the vector itself, the absence of vector pre-
immunity and a high level of biosafety [7,8].
Alphaviruses are enveloped viruses that belong to the
Togaviridae family and contain a positive-strand RNA
genome. The classic vectors for the expression of heter-
ologous genes were developed primarily based on Semlikil Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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these vectors, a heterologous insert replaces the structural
genes under the control of the 26S viral subgenomic pro-
moter [9,10]. The vector RNA can be packaged into re-
combinant alphaviral particles in cells via co-transfection
with a helper RNA encoding structural genes (capsid and
envelope). Upon infection, the vector RNA replicates and
generates a high level of expression of the heterologous
gene. The vector cannot propagate because it lacks the
genes encoding the required viral structural proteins.
Replication of the recombinant alphaviral genome, which
occurs on the cytoplasmic membrane, causes cellular
apoptosis, even in the absence of viral structural gene
expression [11].
Due to the rapid induction of apoptosis in infected
cells, treatment with natural oncolytic alphaviral vectors
results in tumor regression [12-15]. Administration of
replication-deficient vectors encoding reporter or immu-
nomodulator genes, such as cytokines or growth factors,
has also been demonstrated. This leads to successful
tumor inhibition or complete regression in animal models
[16-19]. Nevertheless, the application of alphaviral immu-
nogene therapy in a clinical study using Venezuelan
equine encephalitis (VEE) virus (VEE/CEA) in phase I/II
demonstrated insufficient anti-tumor efficacy in patients,
most likely due to the inefficient induction of anti-tumor
immune responses in patients with end-stage disease [20].
Moreover, the alphaviral vectors were administered to pa-
tients after standard treatment (usually chemotherapy),
which may significantly reduce the efficiency of alphavirus
infection and transgene expression. Remarkably, the ma-
jority of the successful preclinical studies using alphaviral
vectors were performed in animal cancer models that did
not involve pretreatment with chemical drugs. Therefore,
the effect of combined chemotherapy and alphaviral ther-
apy has not been comprehensively studied.
The efficacy of virotherapy depends on specific tumor
targeting and the level of viral replication [21]. It has
been reported that the application of classical chemical
drugs, e.g., 5-fluorouracil (5-FU) and gemcitabine, in
combination with oncolytic herpes or adenoviral vectors
make cancer cells more prone to virus infection and rep-
lication [4,22], thereby enhancing the therapeutic effects
of the viral vector. Alternatively, the viruses may improve
the chemotherapy outcomes. For example, Newcastle dis-
ease virus has been shown to assist in overcoming cis-
platin resistance in a lung cancer mouse model [23].
Moreover, the use of herpes simplex virus following doxo-
rubicin treatment was demonstrated to eradicate che-
moresistant cancer stem cells in a murine breast cancer
model [24]. Also co-administration of reovirus with doce-
taxel synergistically enhanced chemotherapy in a human
prostate cancer model [25], allowing reduced doses of che-
motherapeutics to be used. Furthermore, the combinationof an asymptomatic low dose of 5-FU with recombinant
adenoviruses produces a synergistic effect in various cell
lines and in vivo tumor models [26-30]. Although the de-
tailed molecular mechanism underlying the therapeutic
benefits of the combined treatment remains unknown,
such a treatment has already demonstrated promising re-
sults in a clinical setting [31,32].
Whether the synergistic anti-tumor effect can be
achieved using a drug combination that includes alpha-
viral vectors has been poorly investigated. One study
showed that application of a Sindbis vector with oncoly-
tic properties in combination with the topoisomerase in-
hibitor irinotecan in SCID mice bearing human ovarian
cancer resulted in prolonged animal survival [33]. The
authors highlight the role of natural killer cells in the
induction of the anti-cancer effect by the combined treat-
ment. Targeting of different anti-cancer mechanisms in-
volving immune cell activation could lead to effective
combinatorial therapies, though these would have to be
evaluated in immunocompetent tumor models.
Using a 4 T1 mouse mammary tumor model, we in-
vestigated the efficiency of combined 5-FU and SFV vec-
tor treatment. We focused on the inhibition of cell
proliferation and efficiency of transgene delivery under
combined treatment in vitro and in vivo.
Methods
Cell lines and animals
BHK-21 (baby hamster kidney cells) and 4 T1 cells (me-
tastasizing mammary carcinoma from BALB/c mice) were
obtained from the American Type Culture Collection
(ATCC/LGC Prochem, Boras, Sweden). BHK-21 cells were
propagated in BHK - Glasgow MEM (GIBCO/Invitrogen,
Paisley, UK) supplemented with 5% fetal bovine serum
(FBS), 10% tryptose phosphate broth, 2 mM L-glutamine,
20 mM HEPES, streptomycin 100 mg ml−1 and penicillin
100 U ml−1. The 4 T1 cell line was cultured in Dulbecco’s
minimal essential medium (GIBCO/Invitrogen) supple-
mented with 10% FBS, 2 mM L-glutamine, streptomycin
100 mg ml−1 and penicillin 100 U ml−1. Specific pathogen-
free 4- to 6-week-old female BALB/c mice were obtained
from Latvian Experimental Animal Laboratory of Riga
Stradin’s University and maintained under pathogen-
free conditions in accordance with the principles and
guidelines of the Latvian and European Community laws.
All experiments were approved by the local Animal Pro-
tection Ethical Committee of the Latvian Food and Vet-
erinary Service (permission for animal experiments no.
32/23.12.2010).
Production of SFV (SFV/EGFP, SFV/DS-Red, SFV/EnhLuc)
and SIN (SIN/EGFP) recombinant virus particles
The pSFV1 [9] and pSinRep5 [10] vectors were used in
this study. The enhanced green fluorescent protein (EGFP)
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subgenomic promoter. The EGFP gene was cut out of
the pEGFP-C1 plasmid (Clontech, CA, USA) with NheI
and HpaI restriction endonucleases, treated with T4
DNA polymerase (Thermo Scientific, Lithuania) to blunt
the DNA ends and ligated with the pSFV1 and pSinRep5
vectors, which were cleaved with SmaI and PmlI, re-
spectively. Additionally, a pSFV1/DS-Red construct car-
rying the red fluorescent protein gene (DS-Red) [34]
was generated. The DS-Red gene was amplified by
PCR (primers: 5′-ATTAGGATCCACCGGTCGCCAC
CATG-3′ and 5′-TATCCCGGGCTACAGGAACAGG
TGGTG-3′) using the pDsRed-Monomer-C1 plasmid as a
template (Clontech, CA, USA). The PCR fragment was
cleaved with BamHI and SmaI and ligated into a pSFV1
vector cleaved with the same enzymes. An SFV vector
carrying the firefly luciferase gene was used for the in vivo
experiments [35].
The resulting plasmids were used to produce recom-
binant virus particles as previously described [35]. pSFV-
Helper [9] and pSIN-DH-EB helper [10] were used to
produce the SFV and SIN particles, respectively. The DNA
template was removed by digestion with RNase-free DNase
(Fermentas, Lithuania). The viral titers (infectious units
per ml, iu ml−1) were quantified by infecting BHK-21
cells with serial dilutions of viral stock and analyzing
EGFP or DS-Red expression via fluorescence micros-
copy on a Leica DM IL microscope (Leica Microsystems
Wetzlar GmbH, Germany). For the in vivo application,
SFV/EnhLuc viral particles (v.p.) were concentrated, and
the viral titer was quantified by Real-time PCR as previ-
ously described [35].
Infection of cell lines with recombinant virus particles
Cells were cultivated in 24-well plates at a density of
2 × 105 cells per well in a humidified 5% CO2 incubator
at 37°C. For transduction, the cells were washed twice
with PBS containing Mg2+ and Ca2+ (Invitrogen, UK).
Next, 0.3 ml of the solution containing the virus particles
was added. The SFV/EGFP, SFV/DS-Red and SIN/EGFP
virus particles were diluted in PBS (containing Mg2+
and Ca2+) to achieve a multiplicity of infection (MOI) of
10. The cells were incubated for 1 h in a humidified 5%
CO2 incubator at 37°C. The control cells (uninfected)
were incubated with PBS (containing Mg2+ and Ca2+).
After incubation, the solution containing the virus was
replaced with 0.5 ml of growth medium. The cells were
gently washed with PBS and transferred to fresh medium
every day.
MTT cell proliferation assay
The cytotoxicity was quantified using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)-
based cell viability assay. Cells were infected in 24-wellplates as described above, and proliferation was analyzed
0, 1, 2, 3, 4 and 5 days after infection. The medium was
replaced with 0.3 ml of solution containing 0.5 mg ml−1
MTT (Affymetrix, Cleveland, USA) dissolved in D-MEM
without phenol red (GIBCO/Invitrogen, UK) supple-
mented with 5% FBS. The cells were incubated for 2 h
in a humidified 5% CO2 incubator at 37°C. After incuba-
tion, the formazan crystals were dissolved by adding
0.3 ml of MTT solubilization solution consisting of 10%
Triton X-100 and 0.1 N HCl in anhydrous isopropanol.
The absorbance was measured using a microplate spec-
trophotometer (BioTek Instruments, Winooski, USA) at
a test wavelength of 570 nm and a reference wavelength
of 620 nm. Cell viability (%) was obtained using the fol-
lowing equation: Percent cell viability = (test 570 nm –
620 nm)/(control 570 nm – 620 nm) × 100, where the
control is the value obtained from uninfected cells (the
standard error of the control was less than 3% for days
0–3 and less than 6% for days 4–5 in three independ-
ent experiments).
Fluorescence-activated cell sorting (FACS) analysis
Cells were infected on 6-well plates with SFV/EGFP and
SIN/EGFP virus particles at an MOI of 10 as described
above (1 ml of virus-containing solution was used for
the infection). The infected cells were harvested 24 h
after infection. Detached cells were harvested from the
cell medium by centrifugation, and attached cells were
trypsinized. The collected cells (approximately 106) were
washed with PBS and resuspended in 1 ml of PBS. For
propidium iodide (PI) staining, the cells were incubated
with 10 μl of 50 μg ml−1 PI solution (Becton Dickinson
Biosciences, San Jose, California, USA) and immediately
processed for FACS analysis. EGFP and PI fluorescence
was measured using a FACSAria II (Becton Dickinson
Biosciences, San Jose, California, USA). The FACS data
were analyzed by BD FACSDiva 6.1.2 software. Unin-
fected cells were used as a negative control for both the
PI and EGFP FACS analysis and contained approxi-
mately 1-2% PI-positive cells in 4 T1 culture.
Fluorometry of infected/reinfected cells
Cells were seeded on 24-well plates and infected with
SFV/EGFP as described above. After 24, 48 and 72 h,
the infected cells were reinfected with the SFV/DS-Red
virus. DS-Red fluorescence was measured 24 h after
each reinfection using a fluorometric plate reader (Tecan
Infinite M 200, Austria) with an excitation wavelength of
535 nm and an emission wavelength of 590 nm. The
fluorometry data were expressed as the percentage of the
reinfected cell fluorescence units relative to the fluores-
cence units obtained from the control cells infected with
SFV/DS-Red alone (positive control, 100%). The experi-
ments were performed in triplicate.
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5-FU powder (Sigma, St. Louis, MO, USA) was dissolved
in DMSO at a concentration of 70 mg ml−1 and further
diluted in filtered water to 7 mg ml−1. 4 T1 cells were
seeded in a 24-well plate (2 × 105 cells per well). The
next day, the cells were treated with medium containing
5-FU at 13, 26, 65 or 130 μg ml−1. Every day for 5 days,
the cells were gently washed with PBS to remove dead
and detached cells, and fresh medium containing 5-FU
was added. The control cells were not treated with
5-FU. The MTT cell proliferation assay was performed 0,
1, 2, 3, 4 and 5 days after the start of 5-FU treatment.
The presence of DMSO traces did not affect 4 T1 cell
proliferation.
Induction of tumor nodules
A 4 T1 mouse mammary tumor model was established
as previously described [35]. Briefly, 4 T1 tumor cells
were resuspended in PBS at a final concentration of
2.5 × 106 cells ml−1. Two hundred microliters of the
4 T1 cell suspension were subcutaneously injected above
the right shoulder blade of the mice. After 10 days, the
obtained tumor volumes reached at least 1000 mm3.
5-FU treatment and SFV/EnhLuc injection in vivo
5-FU powder (Sigma, St. Louis, MO, USA) was dissolved
in DMSO at a concentration of 300 mg ml−1 and then
diluted in filtered water to 30 mg ml−1. 4 T1 tumor-
bearing mice (n ≥ 5) were treated with 5-FU at different
doses (40, 150 or 400 mg kg−1) via peroral administra-
tion 4 times over a period of 8 days (every other day).
One hour after the last 5-FU treatment, the mice were
inoculated either i.t. (intratumoral) or i.p. (intraperito-
neal) with 200 μl (4 injections of approximately 50 μl
each) or 300 μl of SFV1/EnhLuc particle-containing
stocks (6 × 109 v.p. ml−1), respectively. As a control,
4 T1 tumor-bearing mice not treated with 5-FU were i.t
or i.p. inoculated with the same dose and volume of
SFV1/EnhLuc.
Analysis of luciferase gene expression in mouse organs
and tumors
The Luc gene expression level was estimated by measur-
ing luciferase enzymatic activity in tissue homogenates
24 h after SFV/EnhLuc virus administration. The tumors
and organs were excised and manually homogenized in a
1x concentration of ice-cold lysis buffer (Cell Culture
Lysis buffer, Promega) containing a protease inhibitor
cocktail (10 μl per 1 ml of lysis buffer) (Sigma, St. Louis,
MO, USA). After homogenization, the samples were
centrifuged for 10 min at 9000 × g, and the protein con-
centration was determined in tissue lysates using the
BCA Protein Assay Kit (Pierce™ BCA Protein Assay Kit,
Thermo Scientific, UK). Luciferase activity was measuredby adding 100 μl of freshly reconstituted luciferase assay
buffer to 20 μl of the tissue homogenate (Luciferase Assay
System, Promega, USA) and then was quantified as rela-
tive light units (RLUs) using a luminometer (Luminoskan
Ascent, Thermo Scientific, UK). The RLU values were
expressed per mg of protein in the lysates. As a negative
control, 4 T1 tumor-bearing mice were inoculated with
PBS, and the maximal negative values were subtracted
from the presented results.
The efficacy index of the 5-FU and SFV combined
treatment was calculated using the formula (RLU in
5-FU treated mice/RLU in 5-FU non-treated mice)/
(tumor weight in 5-FU treated mice/tumor weight in
5-FU non-treated mice). For example: the efficacy
index = (3497925.0/1397062.5)/(681.3/690.9) = 2.5. The effi-
cacy index thus reflects the level of SFV expression
(increase in RLU) and the effect of the 5-FU treatment (re-
duction in tumor weight).
Analysis of FITC-dextran accumulation
The first group of 4 T1 tumor-bearing mice (n = 3) was
treated with 150 mg kg−1 5-FU as described above and
the second group (n = 3) was untreated with 5-FU. Next
day after the last 5-FU treatment the mice from both
groups were inoculated i.v. with 120 μl of FITC-dextran
2000 kDa solution (40 mg ml−1 in PBS) (Sigma). Two
hours later tumors were collected and incubated over-
night in 4% paraformaldehyde. After cryoprotection in
20% sucrose tumors were frozen in OCT compound
(Sigma). Cryosections (10 μm) were prepared and the in-
tensity of FITC-dextran leakage was visualized by fluor-
escent microscopy. Pixels of images were measured by
ImageJ software.
Analysis of IFN-alpha in tumor lysates
Two groups of 4 T1 tumor-bearing mice (n = 6 each)
were either treated or non-treated with 150 mg kg−1
5-FU as described above. One hour after the last 5-FU
treatment, three mice from each group (n = 3) were in-
oculated i.t. with 200 μl (4 injections of approximately
50 μl each) of SFV1/EnhLuc particle-containing stocks
(6 × 109 v.p. ml−1). 18 hours after the virus administration,
4 T1 tumors were isolated and frozen in liquid nitrogen.
Frozen tumors were manually homogenized with homo-
genization hammer and tissue powders were resuspended
in 500 μl of PBS. To provide better tumors homo-
genization, two freeze-thaw cycles were performed. After
homogenization, samples were centrifuged for 10 min at
5000 × g and the protein concentration was equalized in all
tissue lysates using the BCA Protein Assay Kit (Pierce™
BCA Protein Assay Kit, Thermo Scientific, UK). Expression
of IFN-alpha in 4 T1 lisates was determined using ELISA
Kit for Interferon Alpha (Uscn Life Science Inc., China),
according provided protocol. The obtained data (pg/ml)
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both the 5-FU and the virus.
Statistical analysis
The cell viability and RLU results are presented as the
means ± standard error of 3 independent experiments.
The statistical analysis of the results was performed
using Microsoft Excel and Statistica7 (StatSoft, Tulsa,
OK, USA). Statistically significant differences were deter-
mined using Student’s t-test (P < 0.05).
Results
Transduction efficiency and cytotoxicity of alphaviral
vectors in 4 T1 cells
To select the most efficient cytotoxic alphaviral vector
for 4 T1 mouse mammary carcinoma cells, we compared
cell survival and transduction efficiency for two com-
monly used vectors based on SFV and SIN replicons.
4 T1 cells were infected with equal amounts of recom-
binant particles (multiplicity of infection, MOI = 10) en-
coding the EGFP gene. FACS analysis of EGFP-positive
cells was performed at 24 h post-infection. As shown in
Figure 1a (FACS assay), the SFV vector yielded a higher
proportion of EGFP-positive cells (60%) compared with
the SIN vector (38%).
The percentage of EGFP-positive cells measured via
FACS indicates the transduction efficiency and the abil-
ity of the vector to express the gene of interest. However,
alphaviral vectors may provoke cytopathic effects with-
out generating observable transgene expression. This
discrepancy is due to the strong induction of rapid apop-
tosis, which prevents the accumulation of the recombin-
ant product within the cell. To evaluate the immediate
(24 h after infection) cytotoxic effects of alphaviral infec-
tion, 4 T1 cells were stained with propidium iodide (PI),
a membrane-impermeable fluorescent dye that is gener-
ally excluded from viable cells. The percentage of PI-
positive (dead) cells measured by FACS was similar
for the SFV and SIN vectors (7%) (Figure 1a). Never-
theless, the SFV vector provoked a stronger inhibition
of cell proliferation than the SIN vector in 4 T1 cells,
as demonstrated by the MTT cell viability assays per-
formed over the 5 days following infection (Figure 1a).
Despite the strong cytotoxic effect of the SFV vector,
the 4 T1 cell culture (in contrast with other highly
infectable cancer cell lines, e.g., Huh-7, PA1, H2-35,
not shown) survived infection at present conditions,
and cell proliferation was completely restored within
8–10 days.
Repeated infections were next tested as a means of
enhancing the infectivity and cytotoxicity of the alpha-
virus. Remarkably, repeated infection of surviving cell
culture with the same or a different alphaviral vector
(SFV or SIN, respectively) did not produce a significantenhancement of transgene production or prolongation
of cytotoxicity. As shown in Figure 1b, the 4 T1 cell
culture infected with SFV/EGFP were less susceptible
to repeated infection with SFV/DS-Red particles encod-
ing the DS-Red fluorescent protein [34]. Only a very
small number of EGFP-negative cells (which did not
express the transgene after the first infection) were able
to express the DS-Red gene, indicating that the cells
could not be doubly infected by both alphaviruses. Simi-
lar results were obtained with the SIN vector and with
other combinations of SFV/SIN and SIN/SFV reinfection
(not shown). Moreover, an MTT cell viability analysis did
not reveal a difference in the cell proliferation patterns of
singly and doubly-infected cells (not shown). We con-
clude that the repeated application of alphaviral vectors
is not an efficient strategy to achieve complete inhibition
of cancer cell proliferation. This effect may be attribut-
able to the overall cellular protein synthesis down regula-
tion [11] and strong induction of an anti-viral response
[36,37] that makes the repeated application of the vector
inefficient.
The SFV vector was selected for further cytotoxicity
analysis in combination with 5-FU.
Combined treatment of 4 T1 cells with SFV and 5-FU
The low efficiency of oncolytic virotherapy in pre-
clinical studies might be associated with anti-vector
immunity or the resistance of tumors to repeated in-
fections. Recently, multiple strategies involving the com-
bination of oncolytic vectors with classic cytotoxic drugs
have proven to be advantageous for certain types of can-
cer (for review, see Wennier et al. 2012) [1]. Here, we an-
alyzed whether the combination of the SFV alphaviral
vector and 5-FU exerts a synergetic effect on cancer cell
proliferation.
To analyze the cytotoxic effect of 5-FU on 4 T1 cells,
cell monolayers were exposed to different concentrations
of 5-FU for 5 days (Figure 2a). After 5 days of incuba-
tion, high concentrations of 5-FU (65 and 130 μg ml−1)
resulted in complete inhibition of cell proliferation on
days 5 and 4, respectively. Cells incubated with a low
concentration of 5-FU (13 μg ml−1) displayed approxi-
mately 25% viability on day 5, but further incubation did
not lead to complete cell death under these conditions.
For the combined treatment, the highest (130 μg ml−1)
and the lowest (13 μg ml−1) 5-FU doses were tested.
The notion that recombinant alphaviruses expressing,
e.g., anti-tumor genes and/or inducing anti-tumor im-
mune responses must be applied prior to chemical drug
treatment is rational. Therefore, we first tested whether
5-FU could inhibit the proliferation of cells previously
infected with SFV. As shown in Figure 2b, 4 T1 cells
were infected with SFV/EGFP 2 days prior to treatment
with 5-FU. The kinetics of 4 T1 cell proliferation in the
Figure 1 Transduction efficiency and cytotoxicity of SFV and SIN alphaviral vectors in 4 T1 cells. (a) 4 T1 cells were infected with SFV and
SIN particles encoding EGFP. At 24 h post-infection, the cells were harvested, stained with PI and subjected to dual FACS analysis. The x-axis and
the y-axis represent EGFP and PI fluorescence, respectively. The percentage of living/dead cells and EGFP-positive/negative cells is indicated on
the plot. The FACS data shown are from representative experiments (n = 3). The diagram on the left (MTT assay) demonstrates the cytotoxic effects
of SFV and SIN infection. An MTT cell viability assay was performed every day for 5 days post-infection. The results are presented as the percentage
of viable cells relative to the control (uninfected cells). The error bars indicate the standard error of 3 independent experiments. (b) Repeated
infection of 4 T1 cells. The cells were infected with SFV expressing EGFP (pictures show green fluorescence) and then re-infected 24, 48 and
72 h later with SFV expressing DS-Red (pictures show red fluorescence). Fluorometry of DS-Red fluorescence was performed 1 day after each
re-infection. The diagrams represent the percentage of fluorescence units in re-infected cells relative to control cells (100%), which were primarily infected
with only SFV/DS-Red. The error bars indicate the standard error of three experiments.
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similar to those of infected 4 T1 cells. The SFV infection
of 4 T1 cells alone resulted in 55% of cell viability on
day 5 after infection (Figure 1a, MTT-test, SFV). In the
case of combined treatment, the cell viability was not
significantly changed and resulted in 50% and 40% via-
bility after treatment with 13 μg and 130 μg of 5-FU on
day 5, respectively (Figure 2b). Therefore, the application
of 5-FU after SFV did not significantly influence the sur-
vival of the 4 T1 cell culture, even at the high drug dose(130 μg ml−1), providing the evidence for infected cell cul-
ture resistance to further treatment with cytotoxic agent.
Short pretreatment of cancer cells with 5-FU has re-
cently been shown to significantly enhance the infectivity
of adenoviruses [30,38]. To investigate the effect of 5-FU
on alphavirus infection, 4 T1 cells were pretreated with
high (130 μg ml−1) and low (13 μg ml−1) concentrations
of 5-FU for 2 days and then infected with SFV/DS-Red.
As shown in Figure 3, preincubation of cells with 5-FU
almost completely inhibited alphaviral infection. Moreover,
Figure 2 (See legend on next page.)
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Figure 2 Evaluation of 4 T1 cell proliferation after 5-FU treatment and in combination with SFV infection. (a) 5-FU treatment. 4 T1 cells
were grown in cell culture medium (24-well plates) containing the indicated concentrations of 5-FU. The MTT cell viability assay was performed
every day for 5 days. The diagram shows the cytotoxic effect of 5-FU on 4 T1 cells as the percentage of viable cells relative to the control
(untreated cells). (b) Schematic representation of the combined treatment with SFV and 5-FU. The cells were infected with SFV/EGFP particles, and
the medium was replaced 2 days later with medium containing 5-FU. The MTT cell viability assay was performed every day for 5 days. The arrows
designate the day of infection (SFV) and the beginning of the drug treatment (5-FU). The diagram shows the cytotoxic effect of 5-FU following SFV
infection as the percentage of viable cells relative to the control (untreated cells). The error bars indicate the standard error of 3 independent
experiments. The microscopy image shows a 4 T1 cell monolayer at day 5 after treatment with SFV and the highest concentration of 5-FU.
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ment of 4 T1 cells with a low dose of 5-FU (13 μg ml−1)
slightly inhibited alphaviral infection, with a total de-
crease in fluorescence of approximately 10-15% com-
pared with infected cells not treated with 5-FU (not
shown). Lower 5-FU concentrations (below 13 μg ml−1)
had no significant effect on alphaviral infectivity in 4 T1
cells (not shown).
To measure the inhibition of cell proliferation pro-
duced by the combined treatment, 5-FU-pretreated 4 T1
cells were infected with SFV and subjected to cell viabil-
ity analysis over a period of 5 days (Figure 4). Pretreat-
ment of 4 T1 cells for 2 h with a high dose of 5-FU
(130 μg ml−1) followed by infection with SFV did not
significantly impair cell proliferation compared with
4 T1 cells that were only infected with SFV (Figure 4b).
On day 5, the cell viability was approximately 52%.
In a similar way, application of a low dose of 5-FU
(13 μg ml−1) for 2 h did not provoke a significant en-
hancement of cytotoxic effect of SFV (70% on day 5)
compared to the SFV infection alone (60% on day 5), in-
dicating the absence of synergy between 5-FU and SFV.
Furthermore, prolonged incubation with 5-FU (for 2 days)
also did not produce a significant difference in infected
cell proliferation at either dose tested, comparing to un-
infected cells under similar conditions (Figure 4c). The
cells that were pretreated with a low dose of 5-FU began
to resume cell division (49% cell viability) by day 5,
whereas the cells treated with a high dose reached 24%
cell viability, similar to the controls: cells that were
treated with 5-FU but not infected with SFV (64% and
23%, respectively). Therefore, the treatment strategy, in
which 5-FU was used prior to virus infection, strongly
inhibited SFV expression and did not produce synergistic
cytotoxic effect in 4 T1 cells.
The effect of 5-FU treatment on SFV expression in 4 T1
tumor-bearing mice
To investigate the efficiency of SFV-driven transgene ex-
pression after 5-FU chemotherapy, 4 T1 tumor-bearing
mice were perorally (p.o.) treated with 5-FU and then in-
oculated with SFV/EnhLuc by intratumoral (i.t.) injec-
tion of 3 × 108 virus particles encoding firefly luciferase.
The mice were treated with different doses of 5-FU 4times, every other day (Figure 5a). The lower dose
(40 mg kg−1) resulted in no visible toxic effects or any
significant tumor inhibition; this dose is therefore consid-
ered asymptomatic. The medium dose (150 mg kg−1)
produced a minimal tumor size reduction and medium
toxicity (loss of appetite). The high dose (400 mg kg−1),
by contrast, yielded significant tumor inhibition and
strong side effects (watery diarrhea, weight loss, hunched
posture). After the last 5-FU treatment (1 h later), the
mice were i.t. inoculated with SFV/EnhLuc virus parti-
cles, and Luc gene expression was measured 24 h later
via luminometry on tumor lysates. The highest luciferase
activity was detected in the tumors of mice treated with
the highest dose of 5-FU (400 mg kg−1) (Figure 5b), with
increases in transgene production of approximately
50-fold compared with mice not treated with 5-FU and
approximately 14-fold compared with the low dose treat-
ment (40 mg kg−1). Remarkably, this asymptomatic low
dose also produced a statistically significant 3.6-fold in-
crease in luciferase activity (p < 0.05).
Because the low dose improved transgene expression
and had no signs of toxicity, this dose was used to evaluate
the tumor targeting and biodistribution of SFV particles
upon intraperitoneal (i.p. 1.8 × 109 v.p.) administration in
combination with 5-FU. As presented in Figure 5c, the
highest levels of Luc gene expression were detected in the
tumors and hearts of mice treated with 40 mg kg−1 5-FU.
Although significantly lower total Luc expression was
observed with i.p. inoculation compared with the i.t.
route, the Luc level in the tumors was still 2.1-fold
higher (p < 0.05) in i.p. inoculated mice relative to 5-FU
untreated mice. Among the other organs, only the heart
showed an increase in Luc expression after 5-FU treat-
ment (1.4-fold; not significant). Remarkably, there were no
significant changes in vector biodistribution observed in
the case of i.t. administration (not shown). The i.t. inocula-
tion provided no further distribution of the vector to or-
gans in both 5-FU treated and untreated mice, confirming
therefore the enhancement of vector expression specific-
ally in tumor of 5-FU treated animals.
Discussion
One strategy to enhance cancer virotherapy is to
apply viral vectors in combination with standard and
Figure 3 Inhibition of SFV/DS-Red infection in 4 T1 cells pretreated with 5-FU. 4 T1 cells were treated with high (130 μg ml−1) or low
(13 μg ml−1) concentrations of 5-FU for 2 days, then infected with SFV/DS-Red particles. (a) Fluorescence and phase contrast microscopy pictures.
(b) Fluorometric measurement of DS-Red fluorescence in infected cells at 24 h post-infection. The diagram shows the percentage of fluorescence
units measured in the cells pretreated with 5-FU (13 μg ml−1 or 130 μg ml−1) and then infected with SFV/DS-Red relative to 4 T1 control cells
(100%) that were only infected with SFV/DS-Red. The error bars indicate the standard error of three independent experiments.
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Figure 4 Evaluation of cytotoxicity in 4 T1 cells treated with 5-FU and then infected with SFV. (a) Schematic representation of the
experiment. 4 T1 cells were pretreated with high (130 μg ml−1) or low (13 μg ml−1) doses of 5-FU for 2 h or 2 days and then infected with
SFV/EGFP particles. (b) 4 T1 cells treated with 5-FU for 2 h and infected with SFV/EGFP particles (solid lines). The dotted lines (red) show the
controls: cells treated with 5-FU for 2 h and then incubated in complete medium for 5 days. The dashed line (green) shows the cells infected with
SFV/EGFP particles. (c) 4 T1 cells treated with 5-FU for 2 days and infected with SFV/EGFP particles (solid lines). The dotted lines (red) show the
controls: cells treated with 5-FU for 2 days (day 0–2) and then incubated in complete medium for further three days. An MTT cell viability assay
was performed every day for 5 days. The diagrams show the cytotoxic effects of 5-FU and SFV/EGFP, which are expressed as the percentage
of viable cells relative to the untreated cells. Arrows indicate the beginning of drug treatment (5-FU) and the day of infection (SFV). Error
bars show the standard error of three experiments. Fluorescent images demonstrate the efficiency of SFV/EGFP expression on the day after
infection of 5-FU pretreated 4 T1 cells.
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tions and potentially lead to effective therapy outcomes.
Classic alphaviral vectors based on SFV and SIN repli-
cons have been used for in vitro and in vivo cancer gene
therapy experiments and have shown promising results
in different cancer models [39,40]. Nevertheless, the
problems of tumor recovery and the inefficiency of
repeated vector administration remain to be solved.
In this study, we explored the efficiency of SFV-mediated
gene transfer in combination with 5-FU and the possi-
bility of a synergistic cytotoxic effect of the combined
treatment in the highly proliferative 4 T1 mouse breast
cancer model.
5-FU is an antitumor drug typically included in breast
carcinoma chemotherapeutic regimens [41,42]. The cyto-
toxic effect of 5-FU occurs through the inhibition of the
synthesis and functioning of DNA and RNA. Although the
general mechanism of 5-FU action as an anti-metabolitehas been investigated [43], little is known about the intra-
cellular molecular changes that lead to apoptosis in the
presence of 5-FU. Protein kinase R (PKR) has been shown
to be a molecular target of 5-FU-induced apoptosis [44],
suggesting that 5-FU might induce apoptosis via a mech-
anism similar to that of alphaviruses: the double-stranded
RNA intermediates made during alphavirus genome/
subgenome replication also activate PKR, which con-
tributes to the inhibition of protein synthesis [45]. PKR
has also been shown to play an important role in the in-
duction of apoptosis by other drugs, such as doxorubicin
and etoposide [46,47], which have been successfully used
in combination with other viruses [48,49]. Therefore, the
combined treatment with alphavirus and 5-FU presented
herein could potentially produce a synergistic effect due
to the targeting of similar pathways that may work to-
gether to enhance cytotoxicity in cancer cells. Neverthe-
less, this combined treatment showed poor efficiency in
Figure 5 (See legend on next page.)
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Figure 5 SFV expression in 4 T1 tumor-bearing mice treated with 5-FU. (a) Experiment design: Balb/c mice (n = 5 in each group) were
subcutaneously inoculated with 4 T1 cells; beginning on day 14, the mice were treated four times with 5-FU, every other day (40 mg kg−1,
150 mg kg−1 or 400 mg kg−1). On day 20, after the last 5-FU administration, the mice were i.t. or i.p. inoculated with SFV/EnhLuc virus particles.
Tumor weight and Luc gene expression were measured 24 h after viral inoculation. (b) Intratumoral Luc gene expression after i.t injection of SFV/
EnhLuc virus particles in 5-FU-treated mice. Luciferase activity was measured in tumor homogenates 24 h after virus inoculation. Tumor weights
were measured prior to homogenization (scale on the right). (c) SFV/EnhLuc virus biodistribution in 4 T1 tumor-bearing mice treated with
40 mg kg−1 5-FU. Luciferase activity was measured in tumor and organ homogenates 24 h after i.p. virus inoculation. The graphs present the RLUs
per mg protein in each organ or tumor (see Methods section). The results are presented as the means ± s.e. The average RLU values and tumor
weights are indicated in the tables. RLU, relative light unit.
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5-FU treatment (Figure 2b) nor the opposite strategy of
pretreatment with 5-FU and later infection with SFV
(Figure 4) produced a more efficient inhibition of cell
proliferation compared with SFV or 5-FU alone (Figures 1a
and 2a). Moreover, pretreatment of cells with 5-FU signifi-
cantly inhibited SFV infection and transgene expression
(Figure 3).
The basis for the resistance of the surviving cell popu-
lation to high 5-FU doses and SFV infection in the
combined treatment remains unclear. Cabrele et al. [4]
and others demonstrated stimulation of adenoviral vec-
tor infection via 2 h of low-dose pretreatment with 5-FU
in human colon carcinoma cell lines. In contrast to
adenoviruses, RNA containing alphaviruses replicate
their genome in the cytoplasm. The extremely efficient
alphaviral RNA replication is regulated by the virus-
encoded replicase complex and the specific secondary
structure of the RNA genome [50]. As previously de-
scribed, incorporation of 5-FU metabolites into RNA
may change RNA structure and/or affect tRNA and
rRNA function [43]. It is thus possible that a similar
incorporation of 5-FU metabolites into alphaviral gen-
omic and subgenomic RNAs may likewise alter RNA
secondary structure and inhibit its replication and
translation. The presence of 5-FU and its metabolites
could also inhibit the viral replicase in a similar manner
to that observed in the inhibition of the active center of
thymidylate synthetase by 5-fluorodeoxyuridine mono-
phosphate [51]. We conclude that this combined treat-
ment produces no synergy in the induction of apoptosis
but rather inhibits alphaviral replication and transgene
production.
Several oncolytic viruses have been applied in com-
bined treatments in mouse tumor models [1]. However,
less is known about the efficiency of infection or the kin-
etics of virus persistence under combined treatment in
mice because most studies focused on the significant
therapeutic effects and tumor growth inhibition. The fact
that multiple different combinations of viruses (enveloped,
unenveloped, dsDNA, RNA, ssDNA) and cytotoxic chem-
ical drugs (antimetabolites, antibiotics) all produce syner-
gistic therapeutic effects implies a common non-specificmechanism underlying such a benefit. Here, we observed a
significant enhancement of intratumoral SFV-mediated
transgene expression in mice treated with 5-FU (Figure 5).
The low dose (suboptimal) of 5-FU provoked a 3.6-fold in-
crease in Luc gene expression, whereas the high dose
(400 mg kg−1, which is close to the maximum-tolerated
dose of chemotherapy regimens) yielded a 50-fold increase.
This positive correlation between 5-FU dose and the level
of Luc expression contradicts the in vitro results; however,
this correlation is in line with the promising results ob-
tained using other viruses in combination with 5-FU in
mouse models [52-54].
5-FU is widely distributed to all tissues, including sites
of active cell proliferation [55]. In addition to the tumor,
the primary target cells are endothelial cells in blood
vessels. Therefore, 5-FU treatment leads to massive cell
death in places with high vascularization (including the
tumor), which may increase tissue permeability to mac-
romolecules and viruses in particular. The high level of
SFV expression observed following 5-FU treatment
might be explained by the enhanced permeability and
retention (EPR) effect [56,57], which leads to passive
and preferential accumulation and more efficient intratu-
moral distribution of the virus at sites of enhanced vascu-
lar permeability. To compare tumor vascular leakage in
mice treated and untreatedwith 5-FU, we used fluores-
cein isothiocianate-conjugated dextran 2000 kDa (FITC-
dextran 2000), a polysaccharide with a high molecular
mass that is used as a model of permeability and reten-
tion for macromolecular structures such as nanopar-
ticles, liposomes and viruses [58]. FITC-dextran 2000
was injected via the tail vein in 4 T1 tumor bearing mice
and 2 h later the tumor cryosections were subjected to
fluorescence analysis. As shown in Figure 6a and b, the
distribution intensity of FITC-dextran 2000 within the
tumor was significantly higher in 5-FU treated mice
(150 mg kg−1) comparing to the untreated control. This
observation supports the idea that 5-FU treatment ele-
vates tumor vascular permeability of macromolecular
structures that might lead to enhanced virus distribution
and high level of transgene production in 5-FU treated
animals. The concept of enhanced virus intratumoral dis-
tribution after drug treatment is also supported by the
Figure 6 Evaluation of vascular permeability and intratumoral level of IFN-alpha in 4 T1 tumor-bearing mice treated with 5-FU.
(a) Fluorescent microscopy of 4 T1 tumor cryosections demonstrating a FITC-dextran 2000 kDa accumulation in untreated (left) and 5-FU treated
(right) tumors. FITC-dextran 2000 kDa (green) was intravenously-administrated and 2 h later tumors were processed as described in methods. FITC,
fluorescein isothiocyanate. H&E, hematoxylin and eosin staining of cryosections. The 5-FU exhibited morphological changes in tumor sections,
microvessel density was significantly lower than that in the untreated control, large patchy necrosis was visualized. (b) The diagram shows the
data from three tumors, evaluating ten sections per tumor. (c) IFN-alpha response to intratumoral SFV/EnhLuc injections in tumor-bearing mice
treated and untreated with 5-FU. The IFN-alpha level is expressed in % relative to tumors non-treated with 5-FU and virus. Two groups of mice
(n = 6) were treated and non-treated with 5-FU, respectively, then a half of each group of mice was subjected to intratumoral injections of SFV/
EnhLuc. The IFN-alpha response was measured in tumor homogenates after 18 h of virus injection. NS – non-significant differences; * - significant
differences (p < 0.05), mean ± SD; bar 200 μm.
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http://www.biomedcentral.com/1471-2407/14/460results of Tseng et al. [59], who demonstrated a signifi-
cant enhancement in tumor vascular permeability and
oncolytic Sindbis vector targeting following chemo-
therapy. Notably, those authors also did not observe apositive effect of the drug treatment (paclitaxel) on virus
infection and replication in vitro.
Besides the changes in tumor vascular permeability
mediated by 5-FU treatment, an antiviral immune response
Figure 7 The efficacy index of SFV and 5-FU combined treatment of 4 T1 tumor-bearing mice. The mice were treated with different doses
of 5-FU and then i.t. inoculated with SFV/EnhLuc virus particles. The efficacy index reflects the correlation of tumor growth inhibition with the
level of SFV expression in 5-FU treated mice. The calculations are described in the Methods section.
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At the early step of infection alphaviruses are sensitive to
type I IFN production [60,61]. We have examined the
intratumoral level of IFN-alpha in 5-FU treated and un-
treated tumor bearing mice as a response to i.t. adminis-
trated SFV (Figure 6c). The results indicate a significant
inhibition of IFN-alpha antiviral response in 5-FU treated
tumors, evidencing the innate immunity inhibition by
5-FU that at the same time might lead to enhanced virus
replication.
Therefore, we propose that pretreatment with a cyto-
toxic drug may enhance the efficiency of alphaviral-
mediated transgene delivery through the EPR effect and
the inhibition of antiviral IFN-alpha response. Here we
have demonstrated a significant 3.6-50.0 fold increase in
Luc transgene expression that can be regulated by 5-FU
dose. Although we did not observe any differences in
tumor growth and survival rates (not shown) between
the groups of animals treated with 5-FU and treated
with combination of 5-FU and SFV/EnhLuc, the ob-
served enhancement of intratumoral virus expression
mediated by 5-FU pretreatment has a potential to ad-
vance the alphavirus-driven transgene delivery field. The
insertion of proinflammatory transgenes into the vector
instead of reporter luc gene could be promising for fur-
ther optimization of SFV-based virotherapy of cancer to
enhance the effect of chemotherapy and to prevent
tumor recurrence and metastasis.
Conclusions
In this study, we describe the enhanced intratumoral
expression of a replication-deficient SFV vector fol-
lowing 5-FU treatment in the 4 T1 mouse mammary
tumor model. To illustrate the efficacy of the combinedtreatment, we introduced “the efficacy index”, which re-
vealed a decrease in tumor weight upon 5-FU treatment
that was correlated with an increase in SFV expression. As
presented in Figure 7, the highest efficacy index (89.8) was
observed with the high 400 mg kg−1 5-FU treatment, which
provoked a significant inhibition of tumor growth and the
most efficient intratumoral SFV expression. The applica-
tion of a subtherapeutic dose (40 mg kg−1) of 5-FU also led
to a 3.6-fold enhancement of SFV expression upon i.t. vec-
tor administration. Moreover, 5-FU treatment did not
change the distribution of SFV upon i.p. inoculation, allow-
ing preferential vector expression in the tumor and heart
and leading to a 2.1-fold increase in intratumoral SFV
expression.
Although the combined treatment did not show a syn-
ergistic anti-proliferative effect in vitro due to the strong
inhibition of SFV replication by 5-FU, the significant in-
crease observed in intratumoral SFV expression (even at a
low drug dose) might enhance the transgene delivery of
alphaviral vectors and their general therapeutic potential.
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ABSTRACT
Alphavirus vectors are promising tools for cancer treatment. However, relevant entry mechanisms and
interactions with host cells are still not clearly understood. The ﬁrst step toward a more effective therapy is
the identiﬁcation of novel intracellular alterations that could be associated with cancer aggressiveness and
could affect the therapeutic potential of these vectors. In this study, we observed that alphaviruses
efﬁciently infected B16 mouse melanoma tumors/tumor cells in vivo, whereas their transduction efﬁciency
in B16 cells under in vitro conditions was blocked. Therefore, we further aimed to understand the
mechanisms pertaining to the differential transduction efﬁcacy of alphaviruses in B16 tumor cells under
varying growth conditions. We hypothesized that the tumor microenvironment might alter gene
expression in B16 cells, leading to an up-regulation of the expression of virus-binding receptors or factors
associated with virus entry and replication. To test our hypothesis, we performed a proteomics analysis of
B16 cells cultured in vitro and of B16 cells isolated from tumors, and we identiﬁed 277 differentially
regulated proteins. A further in-depth analysis to identify the biological and molecular functions of the
detected proteins revealed a set of candidate genes that could affect virus infectivity. Importantly, we
observed a decrease in the expression of interferon a (IFN-a) in tumor-isolated cells that resulted in the
suppression of several IFN-regulated genes, thereby abrogating host cell antiviral defense. Additionally,
differences in the expression of genes that regulate cytoskeletal organization caused signiﬁcant
alterations in cell membrane elasticity. Taken together, our ﬁndings demonstrated favorable intracellular
conditions for alphavirus transduction/replication that occurred during tumor transformation. These
results pave the way for optimizing the development of strategies for the application of alphaviral vectors
as a potent cancer therapy.
KEYWORDS
Alphavirus; B16 melanoma;
cancer; intracellular
alterations; tumor
microenvironment
Introduction
The application of recombinant viral vectors has become one of
the most intensively developed strategies in cancer gene therapy.
Such therapy is based on the ability of the viruses to preferentially
infect and kill cancer cells. Alphaviral vectors function as efﬁcient
mammalian expression systems because of their high-level trans-
genic expression and induction of p53-independent apoptosis in
infected cells.1,2 These vectors also have a broad range of hosts
and induce a weak immune response against the vector.3 Alphavi-
ruses are small, enveloped, positive-stranded RNA viruses that
belong to the Togaviridae family. The classical Semliki Forest
virus (SFV) replicon vector is generated by replacing the struc-
tural genes under the control of the 26S viral subgenomic pro-
moter with a heterologous insert of interest.4 The vector RNA can
be packaged into recombinant viral particles during co-transfec-
tion of the host cells with a helper RNA that encodes structural
genes, i.e., capsid and envelope proteins. SFV RNA replicates
actively during infection, and the heterologous gene is expressed
at a high level. However, the vector cannot propagate because it
lacks genes encoding the viral structural proteins.
The expression efﬁcacy of all viral vectors relies on the virus
transduction, replication and distribution ability. Alphaviruses are
able to infect a broad range of cancer cell lines with widely diver-
gent biochemical and genetic environments both in vitro and in
vivo.5-7 However, the tumor microenvironments are capable of
forming a barrier that is highly impermeable to the virus.8 Viral
penetration, persistence and spreadingmay be impeded alone or in
combination, thus causing a wide variation in viral transduction/
replication capacity even within a single cell line under in vitro and
in vivo conditions. We and other authors have found that alphavi-
ruses can efﬁciently infect B16 mouse melanoma tumors in vivo,
whereas the infection in vitro is blocked for unknown reasons.6
This observation has encouraged us to perform an in-depth analy-
sis of intracellular factors that could vary in the same cells before
and after administration in mice. Melanoma is a complex multi-
step heterogeneous disease in which most of the steps in the tumor
transformation process, such as proliferation, invasion, angiogene-
sis and metastasis, are modulated by microenvironmental factors
such as growth factors and proteolytic enzymes produced by stro-
mal cells.9 However, the ability of these factors to affect viral
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infectivity has yet to be explored. Taking into consideration that the
tumor microenvironment is able to inﬂuence gene expression in
cancer cells, we hypothesized that it might also play a role in the
upregulation of virus-binding receptors or other factors, which in
turn affect viral entry and replication. To date, only Sindbis virus
has demonstrated tumor tropism in vivo.10-11 We recently demon-
strated that SFV is capable of predominant tumor infection upon
systemic vector administration at an optimized dose.12 However,
the interaction/entry mechanisms have not been investigated in
detail.
Various studies have reported that alphaviruses enter the cell
via receptor-mediated endocytosis, involving multiple proteins
implicated in virus absorption/transduction, such as heparan
sulfate, laminin receptor, the major histocompatibility complex
(MHC), DC-SIGN, L-SIGN, heat shock 70 protein, and a1b1
integrin, among others.13-18 However, it is most likely that
alphaviruses may utilize multiple surface proteins as receptors
or alternative entry pathways in different cells. In addition to
receptors, cytoskeletal organization plays an essential role in the
interaction of viruses with the host cell, affecting penetration
through the membrane and further development of infection
and viral expression.19,20 The microtubule network regulates
several processes, including intracellular transport, transcrip-
tion, replication and secretion of progeny virions, as well as
assembly and cell-to-cell spread.21 Recent studies indicate that
the cell membrane interacts with the attached cytoskeleton/asso-
ciated motor proteins, thus controlling endocytosis/exocytosis
and modulating physical features of the cell such as its shape,
motility and membrane elasticity.21 All these processes could
potentially affect viral activity;22 however, the mechanism(s)
associated with the alphaviruses remain to be elucidated.
Efﬁcient viral replication is one the most important prereq-
uisites for successful gene therapy. Alphaviral replication is
extremely high under favorable intracellular conditions, result-
ing in expression levels of nearly 20% of the total cell protein.23
However, infection triggers cellular defenses induced by a com-
bination of different factors. Thus, the up-regulation of several
immune system proteins or stress factors, such as interferon-
stimulated genes (ISGs),24 zinc-ﬁnger antiviral proteins25 or
eukaryotic translation initiation factors,26 can signiﬁcantly sup-
press alphavirus-driven gene expression. Interferons were
shown to be the major players in the modulation of the perva-
sive antiviral environment, leading to the prevention of viral
spread and replication. Several studies have shown that
enhanced alphavirus infectivity is mediated by a decrease in the
intracellular level of type I IFNs, which is true both in vitro and
in vivo.27,28 Interesting results, which are consistent with the
current research, have been shown for Vesicular Stomatitis
Indiana virus (VSV). Ovarian and breast cancer cells were
highly susceptible to VSV infection in vitro, but the infection of
the developed tumors in vivo was inefﬁcient due to activation
of the JAK/STAT pathways and overexpression of interferon-
stimulated genes induced by tumor-inﬁltrating macrophages.29
This study conﬁrms our hypothesis that the tumor microenvi-
ronment is able to induce intracellular changes in cancer cells,
thus leading to variation in viral activity in vivo.
In this current study, we performed a proteomics analysis of
B16 cells cultivated in vitro and of tumor-isolated B16 cells and
the results were compared. Our goal was to identify genes that
are differentially expressed in mouse melanoma cells before and
after their inoculation in mice. Based on a quantitative analysis
of the detected proteins, we report a list of gene candidates
(S100b, Pycard, CD97, Pdcd4, Gpx1, Csnk2b, Gstz1, Gsto1, Scrib,
Hsp90aa1, Hspb1, Cryab, Csf1, Adh7, Sgtb, Aif1l, Crem, Etv6,
Nfe2l2, Stat1, IFI35, S100a11, Txnl1) that may be involved in the
antiviral response. We also identiﬁed cytoskeletal organization
gene candidates (Tmod, Dst, Dynll2, Opa1, Mlph, Actc1, Myo18a,
Dynlt1, Myo5a, Map7, Csnk2b, Lmna, Dync1h1, Timm10b,
Kif1a, Gfap, Capg, Flnc, Aspm, Hist1h1a, Ss18, Hist1h1t, Cﬂ1,
Cald1, Rps21, Tubb6), which might provide optimal intracellular
conditions for the infection and further expression of transgenes.
Our ﬁndings could extend what is currently known about the
alterations in the melanoma microenvironment during tumor
development. In turn, this information could provide a signiﬁ-
cant contribution toward the modulation of more efﬁcient strate-
gies for cancer gene therapy.
Results
Comparison of SFV infectivity in B16 cells and B16 tumors
To compare the efﬁciency of SFV-driven transgene expression
in mouse melanoma cells in vitro and in vivo, cultured B16 cells
were infected (in vitro) with the SFV/Enh.Luc vector at a multi-
plicity of infection (MOI) of 10. To examine SFV infectivity in
vivo, immunocompetent B16 tumor-bearing mice were inocu-
lated intratumorally (i.t.) with 108 SFV/Enh.Luc particles.
Luciferase expression was analyzed in the cell lysates and tumor
homogenates at 24 h post-infection.
In vitro, very low expression of the transgene was detected in
B16 cells post-infection, revealing the transduction/replication
inefﬁciency of the SFV vector under such conditions. By con-
trast, intratumoral administration of the same recombinant
virus resulted in high expression of the transgene in B16 mela-
noma tumors (Fig. 1A). These data indicate that there is varia-
tion in the genetic background between in vitro-cultivated B16
cells and B16 cells in tumor-bearing mice, which facilitates
transduction or replication of the SFV vector.
To determine the vector distribution within a subcutaneous
melanoma tumor nodule, 2 SFV vectors expressing green ﬂuo-
rescence protein (SFV/EGFP) and red ﬂuorescence protein
(SFV/DS-Red) were inoculated into different points of a B16
tumor nodule (Fig. 1B). The analysis of tumor cryosections
revealed only local expression of the corresponding ﬂuorescent
protein at the location of the intratumoral injections, with no
broad intratumoral dissemination of the virus due to the absence
of SFV/EGFP expression at locations of SFV/DS-Red injection
and vice versa. Therefore, it is possible to conclude that although
the SFV vector is capable of a high level of expression of the
transgenes in B16 tumors, the efﬁcacy of the alphavirus-based
therapy could be increased by enhancing the tumor permeabil-
ity, thus promoting the wide intratumoral spread of the vector.
Comparison of SFV infectivity of in vitro B16 cells and ex
vivo B16 cells
To investigate whether B16 cells were modiﬁed by the tumor
microenvironment, rendering them susceptible to SFV vector
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infection, we conducted a series of SFV transduction experi-
ments using 2 types of melanoma cells: i) B16 in vitro cells – a
standard B16-F10 cell line cultured under ordinary cell cultur-
ing conditions in vitro, and ii) B16 ex vivo cells - melanoma
cells isolated from B16-F10 tumors. The susceptibility of B16
ex vivo cells to SFV infection was analyzed over time at differ-
ent cell passages. In vitro and ex vivo B16 cells were infected
with SFV/Ds-Red at an MOI of 10. Ds-Red gene expression
was analyzed 24 h post-infection by ﬂuorescence microscopy.
Our results demonstrated extremely high SFV-mediated
transgene expression during the ﬁrst passage of B16 ex vivo
cells in contrast to control B16 cells in vitro (Fig. 2). Surpris-
ingly, further cultivation of the ex vivo cells led to a dramatic
inhibition of SFV vector infection. We hypothesize that the
tumor microenvironment can induce alterations at the level of
gene expression, which affect the morphology and physical
parameters of cells, such as cell shape, motility and membrane
elasticity. In turn, these changes provide conditions favorable
for SFV vector transduction/replication. Notably, although the
ex vivo B16 cells displayed these features for a short period,
these cells subsequently began to lose susceptibility to SFV
infection by the second passage upon splitting. Remarkably, the
replacement of fetal bovine serum to freshly prepared autolo-
gous mouse serum for cultivation of ex vivo and in vitro B16
cells had no effect on SFV infectivity. We did not observe any
signiﬁcant increase in SFV/Ds-Red activity in B16 cells culti-
vated in cell medium supplemented with mouse serum (not
shown).
To demonstrate that the ex vivo-isolated cells were B16 mel-
anoma cells, we performed melanin staining using the classical
Fontana-Manson method (Fig. 2B). The results revealed mela-
nin production in the isolated cells. Moreover, in contrast to in
vitro B16 cells, the level of expression of melanin in ex vivo cells
was signiﬁcantly increased. Further cultivation of ex vivo cells
led to a decrease in melanin synthesis (data not shown).
Protein proﬁle analysis of ex vivo and in vitro B16 cells
To determine the intracellular conditions that could enhance
SFV infection, we performed a comparative proteomics analysis
of ex vivo B16 (ﬁrst passage) and in vitro B16 cells using liquid
chromatography-mass spectrometry (LC-MS). To characterize
the in vitro and ex vivo B16 cells, we identiﬁed individual pro-
teomes of 3 in vitro B16 cell samples and 3 ex vivo B16 samples
(isolated from 3 different mice). A total of 4980 proteins were
identiﬁed using the UniProt database, among which 277 pro-
teins were differentially regulated (165 up-regulated and 112
down-regulated), with a fold change >1.4 in ex vivo B16 cells
in comparison to the in vitro B16 cells (p < 0.01; Table S1 and
Table S2). All these proteins were identiﬁed in triplicate for
each sample. The quantiﬁed proteins were functionally anno-
tated using the PANTHER bioinformatics resource (version
PANTHER 9.0; http://www.pantherdb.org/) and further classi-
ﬁed according to their functions in biological processes
(Fig. 3A-B) and molecular mechanisms (Fig. 3C-D).30 The cel-
lular localization of the detected proteins were determined by
manual classiﬁcation using the UniProt database (http://www.
uniprot.org/) (Fig. 3E-F).
We identiﬁed 165 proteins that were upregulated in the ex
vivo B16 cells during tumor development in comparison to the
in vitro B16 cells. According to the analysis of the biological
functions, the majority of the identiﬁed proteins belonged to dif-
ferent metabolic processes (37.8%). Smaller groups comprised
cellular process proteins (19.3%), cell component organization
and biogenesis proteins (8.2%), biological regulation proteins
(7.7%), developmental process proteins (7.7%) and localization
proteins (7.3%). Several other identiﬁed proteins were classiﬁed
as multicellular organismal process (4.7%), response to stimulus
(3%), immune system process (2.1%), reproduction (1.3%) and
apoptotic process (0.9%) proteins (Fig. 3A).
Regarding molecular functions, more that 70% of all up-reg-
ulated proteins were grouped into 2 leading categories: catalytic
activity proteins (47%) and binding proteins (25.5%). The other
overexpressed gene products were functionally distributed as
structural molecule activity proteins (12.1%), enzyme regulator
activity proteins (7.4%), receptor activity (2%), translation reg-
ulators (2%), nucleic acid binding/transcription factor activity
(2.7%), transporters (0.7%) and antioxidant activity (0.7%) pro-
teins (Fig. 3C).
Proteins perform their functions in speciﬁc cellular loca-
tions. Careful analysis of their subcellular localization revealed
that the majority of the upregulated proteins were localized in
the mitochondria (27%) and the cytoplasm (21%) (Fig. 3E).
Importantly, a large portion of the mitochondrial proteins were
NADH dehydrogenases, which are fundamentally crucial for
growth signaling and transcription in a broad array of
Figure 1. SFV expression and intratumoral spread in a melanoma mouse model.
(A) Infection of B16 melanoma cells in vitro and B16 tumor cells in vivo with SFV/
Enh.Luc vector. The B16 cells were infected with SFV at an MOI of 10 in vitro. For
the in vivo experiment, B16 tumor-bearing mice were i.t. inoculated with 108 SFV
v.p. The luciferase expression analysis in cell lysates and tumor homogenates was
performed 24 h post-infection by luminometry. The bar graph presents the RLUs
per 1 mg protein in the cell lysate/tumor homogenate. The results represent the
mean § s.e. RLU - relative light unit. (B) Administration strategy of SFV vectors
and ﬂuorescence microscopy of B16 tumor cryosections, demonstrating SFV/FGFP
and SFV/Ds-Red virus spread in the tumor. A total of 106 v.p. of SFV/EGFP and SFV/
Ds-Red were injected in different tumor sides by direct intratumoral injections. The
tumors were cryosectioned and analyzed 24 h after SFV vector administration.
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melanoma tumors,31 indicating enhanced aggressiveness of the
ex vivo B16 cells in contrast to the control in vitro cells. The
intracellular distribution of the other proteins was predicted to
be localized in the nucleus (13%), cellular components (12%),
endoplasmic reticulum (7%), cell membrane (5%), Golgi appa-
ratus (3%) and both lysosomal and secreted (2%). More strin-
gent analysis was performed for the proteins localized in
melanosomes (4%), which are unique organelles in melanoma
cells. The ex vivo B16 cells overexpressed genes such us Typr1,
Tyr, Dct, Mlph and Myo5a, which are involved in melanin syn-
thesis, explaining the enhanced pigmentation of the ex vivo
cells, which resulted in the histological difference between the
ex vivo and in vitro B16 cells (Fig. 2B).
LC-MS analysis identiﬁed 112 downregulated proteins in the
ex vivo B16 cells. Regarding their involvement in biological pro-
cesses, the majority of the down-regulated proteins were also
categorized into different metabolic and cellular processes
(32% and 20.3%, respectively) in a similar manner as the up-
regulated proteins (see above). The other proteins were
involved in biological regulation (10.5%), developmental pro-
cess (9.8%), response to stimulus (7.8%), biogenesis (6.5%),
immune system process (5.2%), multicellular organismal pro-
cess (3.9%), localization (3.3%), biological adhesion (1%) and
apoptotic process (0.7%) (Fig. 3B).
Biological classiﬁcation of the downregulated proteins in
terms of their molecular mechanisms revealed that most of
them had binding (44.3%) and catalytic activity (22.7%)
functions. A signiﬁcantly smaller number of proteins were
related to nucleic acid binding transcription factor activity
(13.6%) and structural molecule activity (11.4%) proteins,
respectively. The smallest number of proteins were catego-
rized as enzyme regulator (3.4%), protein binding transcrip-
tion factor (2.3%), and receptor and transporter (1.1%)
activity proteins (Fig. 3D).
Figure 2. Comparison of SFV infection susceptibility and melanin expression of in vitro and ex vivo B16 cells. (A) Schematic illustration of the isolation, propagation and
infection of ex vivo B16 cells with SFV vector compared with the control in vitro B16 cells. The control in vitro B16 cultured cells were subcutaneously injected into immu-
nocompetent C57BL/6 mice. Ten days after cell inoculation, B16 tumor nodules were isolated, homogenized and plated as ex vivo B16 cells in 2 plates as the ﬁrst cell pas-
sage. When the cell monolayer reached 80% conﬂuency, the 1st plate of cells was split for further cultivation (second cell passage), whereas the 2nd plate of cells was
infected with SFV/Ds-Red vector for transgene expression analysis, which is presented as ﬂuorescence and phase contrast microscopy images. (B) Melanin staining of in
vitro and ex vivo B16 cells. The cells were treated with Fontana-Masson silver stain to detect melanin (dark brown, black color). Negative control – non-stained cells. The
nuclei were counterstained with nuclear fast red.
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Most of the down-regulated proteins were predicted to
be localized in the nucleus (36%) and the cytoplasm (31%)
(Fig. 3F). A total of 6% were classiﬁed as cell membrane
and cellular component proteins. Interestingly, only 4% of
the downregulated proteins exhibited mitochondrial locali-
zation, which is in contrast to 27% of the upregulated pro-
teins (see above), indicating decreased mitochondrial
activity in the in vitro B16 cells. A total of 3% of the pro-
teins were localized in the endoplasmic reticulum and Golgi
apparatus, and 2% of the proteins were identiﬁed as
secreted proteins.
In summary, a functional analysis of the biological processes
of differentially regulated proteins revealed a similar distribu-
tion, in which more than 50% of all up/down-regulated pro-
teins participated in different metabolic processes (mostly in
primary metabolic processes such as protein, nucleobase-con-
taining compound, lipid, carbohydrate and tricarboxylic acid
cycle metabolic processes) and cellular processes, which
included cell communication, cell cycle, movement of cellular
components, chromosome segregation and cytokinesis (PAN-
THER annotation). According to the molecular mechanisms,
most of the detected up-regulated proteins were related to
Figure 3. Functional classiﬁcation of 277 differentially regulated proteins in ex vivo B16 cells identiﬁed in total protein extracts by LC-MS. Protein proﬁle analysis of both in
vitro and ex vivo B16 cells was performed by LC-MS, and in vitro B16 cells were used as reference cells. The pie charts demonstrate the distribution of 165 upregulated (left
panel) and 112 downregulated (right panel) proteins in ex vivo B16 cells according to their biological processes (A-B) and molecular mechanisms (C-D). Categorizations
were based on information provided by the PANTHER classiﬁcation system (see methods). The subcellular localization prediction of up-regulated (E) and down-regulated
(F) proteins in B16 ex vivo cells was annotated manually using the UniProt database. The percentages shown in the pie and bar charts represent the percentage of genes
belonging to each group.
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catalytic activity proteins, indicating enzyme regulator, hydro-
lase, isomerase, ligase, oxidoreductase and transferase activity.
By contrast, the majority of the downregulated proteins were
responsible for binding calcium ions, calcium-dependent phos-
pholipids, chromatin, nucleic acids and other proteins. The dif-
ference in molecular functions between the up- and down-
regulated proteins was the reason for the different predominant
intracellular localization of these proteins.
Classical alphavirus-recognizing receptors, such as mem-
brane heparan sulfate, laminin receptor, major histocompat-
ibility complex (MHC), DC-sign, L-sign, heat shock 70
protein, and a1b1 integrin,13-18 which are implicated in
virus absorption/transduction and are described in several
studies, were not identiﬁed by LC-MS analysis in our exper-
iment or were not found to be signiﬁcantly up/downregu-
lated. In addition, real-time PCR analysis did not
demonstrate any signiﬁcant differences in the gene expres-
sion of some of these candidates (data not shown).
Antiviral response genes
The main biological processes that initiate intracellular
responses to viral infection and could potentially block replica-
tion primarily comprise the response to a stimulus, immune
system processes and apoptosis.32 The category of responses to
environmental stimuli (such as stress, endogenous or external
stimuli) displays considerable overlap with the immune
response category, usually regulating the expression of the
same genes. The induction of apoptosis is often a consequence
of such processes because all these features largely overlap.
Some of the genes could be classiﬁed into 2 or 3 biological pro-
cesses by the PANTHER classiﬁcation system. Based on our
proteomics classiﬁcation results (as mentioned above), we per-
formed a detailed analysis of the up/down-regulated genes that
participated in 3 biological processes, response to stimulus,
immune system response and apoptosis, summarizing these
genes in one “antiviral response genes” category (Fig. 4A). In
total, we identiﬁed 10 upregulated antiviral response genes in
the ex vivo B16 cells: S100b (6.2-fold increase), Pycard (4.9-fold
increase), CD97 (4-fold increase), Pdcd4 (3.1-fold increase),
Gpx1 (2.3-fold increase), Csnk2b (2.2-fold increase), Gstz1 (2.2-
fold increase), Gsto1 (1.9-fold increase), Scrib (1.7-fold
increase) and Hsp90aa1 (1.6-fold increase).
Overexpression of casein kinase II Csnk2b, scribble protein
Scrib and heat shock protein Hsp90aa1 has been reported to
potentially improve alphavirus-host cell binding and transduc-
tion (see Discussion). Additionally, all these proteins are corre-
lated with high tumor aggressiveness and poor prognosis.
Overexpression of S100b (S100b) in the ex vivo B16 cells
could be explained by active B16 tumor development because
S100b is generally synthesized only under pathological circum-
stances and not under normal physiological conditions.33
Figure 4. Up/downregulated genes in ex vivo B16 cells classiﬁed as antiviral response genes and cytoskeletal organization genes. (A) Based on the LC-MS data classiﬁca-
tion by PANTHER, genes that participated in apoptosis, response to stimulus and immune system processes were summarized in the antiviral response genes group. (B)
Genes responsible for cellular component organization. The graph shows the fold-change in the expression of corresponding genes in ex vivo B16 cells compared with in
vitro B16 cells. The results represent the mean § s.e.
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Moreover, a high level of the S100B protein serves as a reliable
prognostic biomarker in patients with malignant melanoma.34
The overexpressed glutathione peroxidase 1 Gpx1, maleyla-
cetoacetate isomerase Gstz1 and glutathione S-transferase
omega-1 Gsto were sub-classiﬁed as toxic substance responsible
genes (PANTHER classiﬁcation). Because there is limited infor-
mation available regarding these multifunctional enzyme activi-
ties in cancer models, the upregulation of the genes could be
explained as a consequence of a stress response caused by B16
cells upon transfer from the mice (in vivo conditions) to the
plates (ex vivo conditions).
Although the up-regulation of CD97 antigen in melanoma
cells has not been previously described, it was overexpressed in
advanced stages of different cancers. The protein is mostly
located in invasive tumors with higher cell motility than the
cells in solid tumors.35-37
The up-regulated apoptotic genes, Pycard (apoptosis-associ-
ated speck-like protein containing a CARD) and Pdcd4 (pro-
grammed cell death protein 4), in the ex vivo B16 cells could
act as key mediators in apoptosis and inﬂammation; however,
no studies have described their roles in melanoma or their
impacts on viral infectivity and replication.
In addition to the 10 upregulated genes described above, 13
downregulated genes involved in apoptosis, response to stimuli
and immune system processes have been identiﬁed: Hspb1
(5.3-fold decrease), Cryab (4.6-fold decrease), Csf1 (4.3-fold
decrease), Adh7 (3.7-fold decrease), Sgtb (3.4-fold decrease),
Aif1l (3.2-fold decrease), Crem (3-fold decrease), Etv6 (2.9-fold
decrease), Nfe2l2 (2.8-fold decrease), Stat1 (2.6-fold decrease),
IFI35 (2.6-fold decrease), S100a11 (2.5-fold decrease) and
Txnl1 (1.7-fold decrease) (Fig. 4A).
The roles of genes such as alcohol dehydrogenase 7 (Adh7,
also known as Adh3) and small glutamine-rich tetratricopep-
tide repeat-containing protein Sgtb have not been described for
alphavirus infection/replication. However, reduced Adh7
expression has been implicated in oncogenesis and might inﬂu-
ence viral life cycles through increased S-nitrosylation and
formaldehyde-induced changes in cellular redox.38,39 By con-
trast, the down-regulation of SGT proteins remarkably enhan-
ces the activity of HIV-1 virus.40
An in-depth analysis of other down-regulated genes
showed that most of them participated in 3 IFN-regulated
pathways: JAK-STAT, p38 MAPK and PI3K. Speciﬁcally,
those genes were the heat shock protein Hspb1, a-B crystal-
lin Cryab, macrophage colony-stimulating factor 1 Csf1,
cAMP-responsive element modulator Crem, allograft
inﬂammatory factor 1 Aif1l, transcription factor Etv6,
nuclear factor erythroid 2-related factor 2 Nfe2l2, signal
transducer and activator of transcription 1 Stat1, protein
S100-A11 S100a11 and thioredoxin-like protein 1 Txnl1
(Table S3). These ﬁndings indicated that the described sig-
naling pathways were suppressed in the ex vivo B16 cells.
The expression of interferon-inducible 35 kDa protein
(IFI35) was also signiﬁcantly inhibited. These results present
a network of downregulated genes modulated by IFN that
could cooperatively provide favorable conditions for SFV
transduction/replication.
Cytoskeletal organization genes
The cytoskeleton plays an important role in the life cycle of
every virus during attachment, internalization, endocytosis,
nuclear targeting, transcription, replication, transport of prog-
eny subviral particles, assembly, exocytosis or cell to-cell
spread.21 To investigate the genes regulating cytoskeletal orga-
nization that could facilitate alphavirus activity in ex vivo B16
cells, we performed a detailed analysis of the up/down-regu-
lated proteins that participated in cellular component organiza-
tion (or biogenesis) categorized by the PANTHER classiﬁcation
system (Fig. 4B). We identiﬁed 17 up-regulated genes: Tmod
(5.3-fold increase), Dst (4.3-fold increase), Dynll2 (3.7-fold
increase), Opa1 (3.5-fold increase), Mlph (3.1-fold increase),
Actc1 (2.9-fold increase), Myo18a (2.7-fold increase), Dynlt1
(2.5-fold increase), Myo5a (2.4-fold increase), Map7 (2.3-fold
increase), Csnk2b (2.2-fold increase), Lmna (1.9-fold increase),
Dync1h1 (1.8-fold increase), Timm10b (1.8-fold increase),
Kif1a (1.7-fold increase), Gfap (1.7-fold increase), and Capg
(1.7-fold increase).
The cytoskeleton has 3 major types of ﬁlaments: actin, inter-
mediate ﬁlaments and microtubules. Each type of ﬁlament has
its own speciﬁc stabilization and motor proteins. In this experi-
ment, we identiﬁed the upregulation of the ﬁlamentous protein
a actin, Actc1. Moreover, both tropomodulin 1 (Tmod1) and
macrophage-capping protein (Capg), which serve as actin ﬁla-
ment stabilization proteins,41,42 were also found to be overex-
pressed in B16 ex vivo cells. The up-regulation of the
intermediate ﬁlament protein Laminin (Lmna) was shown to
increase the stiffness matrix, to confer nuclear mechanical
properties, and to inﬂuence the differentiation of mesenchymal
stem cells.43 Conversely, tubulin, which is the main component
of microtubules, was found to be 1.4-fold downregulated in the
ex vivo B16 cells (see below). However, the microtubule-stabi-
lizing protein, Map7, which might play an important role dur-
ing the reorganization of microtubules, was found to be 2.3-
fold overexpressed.
Interestingly, in the ex vivo B16 cells, all the major motor
proteins involved in movement on cytoskeletal ﬁlaments were
upregulated. The myosins, Myo18a and Myo5a, are the only
motor proteins that are able to bind to actin. Myosin acts upon
actin ﬁlaments to generate cell surface contractions and other
morphological changes, including vesicle motility and cyto-
plasmic streaming. Additionally,Myo5a has been considered to
regulate melanosome transport in cooperation with the up-reg-
ulated Mlph.44 Both the upregulated kinesin, Kif1a, and the
dyneins, Dynll2, Dynlt1, and Dync1h1, act as the main microtu-
bule motor proteins, providing the intracellular retrograde
motility of vesicles and organelles along microtubules.45 There
are no known motor proteins for intermediate ﬁlaments.
Up to 4.3-fold upregulation of dystonin (Dst), which acts as
an integrator of intermediate ﬁlaments and actin and microtu-
bule cytoskeleton networks, facilitates intracellular transport by
regulating organelle organization.46 The overexpression of
another cytoskeletal organization factor, glial ﬁbrillary acidic pro-
tein (Gfap), could be associated with cell mechanical strength
and shape, but its exact function remains poorly understood.47
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Casein kinase II subunit b (Csnk2b) is the only common
protein that was detected in both categories of antiviral
response genes and cellular component organization genes
(Fig. 3A-B). Several studies have shown that casein kinase II is
able to phosphorylate cytoskeletal proteins including tubulin48
or microtubule-associated protein 1B,49 thus contributing to
morphological changes that occur during mitosis and cytokine-
sis in differentiating cells. Additionally, we identiﬁed the up-
regulation of 2 mitochondrial membrane organization proteins,
Opa1 and Timm10b, which are responsible for multi-pass
transmembrane protein transport.50,51
Nine down-regulated genes responsible for cytoskeletal
organization have been identiﬁed in the ex vivo B16 cells: Flnc
(5.6-fold decrease), Aspm (3.1-fold decrease), Hist1h1a (2.9-
fold decrease), Ss18 (1.6-fold decrease), Hist1h1t (1.6-fold
decrease), Cﬂ1 (1.6-fold decrease), Cald1 (1.5-fold decrease),
Rps21 (1.4-fold decrease) and Tubb6 (1.4-fold decrease). In this
gene category, the muscle-speciﬁc ﬁlamin-C (Flnc) was
detected as one of the most downregulated genes in B16 ex vivo
cells that could potentially affect melanoma cell structure. The
reduced expression of Flnc in myoblast cells has been shown to
lead to defects in cell differentiation and fusion ability. These
cells form multinucleated “myoballs” rather than maintaining
an elongated morphology.52 Interestingly, the elongation of
B16 ex vivo cells could also be impeded by a low level of the
protein SSXT (Ss18), which has been described as a cytoskeletal
phenotype-associated protein that plays a role in the elongation
of the cell body via the induction of detyrosinated Glu tubu-
lin.53 Our results demonstrate the downregulation of abnormal
spindle-like microcephaly-associated (Aspm) protein in B16 ex
vivo cells. Some studies have suggested that mutations or dereg-
ulation of Aspm could cause microcephaly due to the dysregu-
lation of mitotic spindle activity, which increases the
probability of asymmetric cell division.54
Caldesmon (Cald1) and coﬁlin (Cﬂ1), which are important
for cytoskeletal organization and dynamics, were also found to
be down-regulated up to 1.5- and 1.6-fold, respectively. Caldes-
mon is a multifunctional ubiquitous regulator of the actin cyto-
skeleton that when expressed at low levels, determines the
bipolar shape and linear migration of cells.55 By contrast,
defects in coﬁlin expression alter the morphology of actin net-
works in vivo and reduce the rate of actin ﬂux through actin
networks. The consequences of decreasing actin ﬂux are mani-
fested by decreased, but not blocked, endocytic internalization
at the plasma membrane.56 Additionally, inhibition of the pro-
duction of the 40S ribosomal protein S21 (Rps21) was also
detected in B16 ex vivo cells.
Finally, suppression of H1 histone expression was detected
in B16 ex vivo cells (2.9-fold decrease in Hist and 1.6-fold
decrease in Hist1h1t), which could signiﬁcantly impair the cell
differentiation capacity. H1 histones have been shown to con-
tribute to efﬁcient repression of the expression of pluripotency
factors and to participate in the establishment and maintenance
of the epigenetic marks necessary for silencing pluripotency
genes during embryogenesis and stem cell differentiation.57
Comparison of membrane elasticity between in vitro and
ex vivo B16 cells
The transition of a tumor cell from ﬂuid to adhesive conditions
involves an early polarization event and major rearrangements
of the submembrane cytoskeleton. This process can change the
mechanical properties of the membrane, for example by
increasing its elastic properties, which could affect cell endocy-
tosis,58 virus-cell interactions and transduction.22 In our study,
we used atomic force microscopy (AFM) to compare the cell
membrane elasticity (or hardness)59 of the in vitro B16 cells
and the ﬁrst passage of the ex vivo B16 cells.
Several AFM force measurements were performed in which
equal contact points of the AFM tip and cell surface were
selected (the middle point between the cell nucleus and the
elongated cell body) (Fig. 5A). After tip-cell contact, the
Figure 5. Comparison of cell membrane elasticity and IFN-a/b expression between in vitro and ﬁrst-passage ex vivo B16 cells. The principle of AFM measurement is sche-
matically demonstrated in panel A. The middle point between the cell nucleus and the elongated cell body was selected as the contact point of the AFM tip and the cell
surface. The pushing force was increased slowly until the membrane was punctured. The acquired maximal forces essential for membrane puncturing of in vitro and ex
vivo B16 cells are shown in panel B. The membrane resistance force indicates the elasticity of the sample surface; higher maximal force indicates higher membrane hard-
ness. The results represent the mean § s.e. Expression levels of IFN-a (C) and IFN-b (D) were determined in in vitro and ﬁrst-passage ex vivo B16 cell lysates before SFV
infection (0 h) and at 1 h, 3 h, 6 h, 9 h and 18 h post-infection. The results represent the concentration of IFN protein per 1 ml of cell lysate (pg/ml).
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pushing force was slowly increased until the membrane was
punctured. The elasticity (or hardness) deﬁned by the resis-
tance of the cell to the changes was measured. The greater the
resistance, the greater was the elasticity of the material and the
faster it regained its original shape or conﬁguration upon with-
drawal of the deforming force.
In this experiment, the membrane resistance force indicated the
elasticity of the sample surface. A higher maximal force indicated a
greater membrane hardness. The AFM data demonstrated that the
ex vivo B16 cells had signiﬁcantly lower cell membrane elasticity
(Fig. 5B), with an average maximal force of 38 nN compared with
the control cells with maximal forces within the range of 120–180
nN. The low level of membrane hardness in the case of the ex vivo
B16 cells could be one of the reasons for the improved alphavirus-
cell interaction and transduction by endocytosis.
IFN-a/b analysis
Type I interferon (IFN) is an extremely powerful antiviral
response factor that is capable of affecting alphavirus infec-
tions.60 We compared the expression levels of IFN-a and IFN-
b in the in vitro B16 cells and the ﬁrst passage of the ex vivo
B16 cells before infection (0 h) and at different time points dur-
ing infection and replication (1 h, 3 h, 6 h, 9 h, and 18 h)
(Fig. 5C-D). Our data demonstrated a signiﬁcant down-regula-
tion of IFN-a expression (4-fold decrease) in the ex vivo B16
cells before infection compared with the control in vitro cells.
Melanoma cells do not secrete IFN under normal conditions,
which results in the accumulation of IFN within the cells. In
our experiment, we observed an equal tendency of IFN-a accu-
mulation in both in vitro and ex vivo B16 cells starting from 1 h
after infection (Fig. 5C). However, the expression level of IFN-
a in in vitro cells was remarkably higher 1 h post-infection and
increased over time to reach a maximum of 576 pg/ml at 6 h
post-infection. By contrast, the maximum expression in ex vivo
cells reached only 269 pg/ml at the same time point. The inhib-
ited expression of IFN-a could be the main cause of the
enhanced alphavirus replication in the ex vivo melanoma cells.
There were no signiﬁcant differences in the expression and
accumulation of IFN-b in either the in vitro or the ex vivo B16
cells, thus providing evidence that IFN-b might play a less
important role in host cell protection against alphaviral
infection.
Discussion
Although alphaviruses are successfully used as tumor-targeting
agents in cancer gene therapy, the key factors providing intra-
cellular conditions that are favorable for more efﬁcient viral
activity as well as the virus-host interaction dynamics are not
well understood. The tumor microenvironment and innate
immune responses could cause a wide range of variations in
viral activity, blocking or facilitating the replication and spread
of the viral particles. We obtained interesting results demon-
strating an extremely high infectiousness of alphaviruses in B16
melanoma tumors in vivo, whereas delivery of the marker
transgenes was inefﬁcient for the same cells in vitro (Fig. 1A).
These data corresponded well with the results of other authors.6
We hypothesized that this difference resulted from the
inﬂuence of the tumor microenvironment on the total cellular
proteome.
Alphavirus infectivity and spread in vivo
Although a high level of alphavirus-driven transgene expres-
sion was determined, the SFV vector displayed a limited distri-
bution in B16 tumors, demonstrating patchy expression of the
virus only in local injection areas (Fig. 1B). Several factors affect
the capacity of the virus to spread within the tumor, such as
virus neutralization by blood components or rapid generation
of an antiviral immune response; however, the main factor is
the intratumoral stromal barriers. For alphaviruses, it is possi-
ble to increase the tissue permeability and promote their intra-
tumoral distribution, simultaneously using synergic
chemotherapeutic drugs.27,61 However, the slow kinetics of viral
spread after intratumoral injections is a common disadvantage
that has also been reported for other vectors, e.g., adenovi-
ruses62 and retroviruses.63 The oncolytic properties of alphavi-
ruses make them a promising tool with the potential to
signiﬁcantly improve the ﬁeld of cancer treatment. Thus, it is
clearly important to investigate the details of the processes that
determine the efﬁciency of virus spread and infection within
tumor microenvironments.
Alphavirus infectivity in vitro
The ex vivo B16 tumor cells clearly demonstrated a high efﬁ-
cacy of SFV infection in the ﬁrst passage after isolation, whereas
the control B16 cells cultivated in vitro did not support the viral
activity. However, the ex vivo cells were not able to retain these
properties for a long time during the cultivation in vitro
(Fig. 2A). This observation indicated that the B16 tumor micro-
environment was able to provide favorable conditions for
alphaviral transduction and replication that were not present in
the in vitro culture.
The ability to support virus entry and subsequent expression
of the marker transgene is most likely determined by differen-
ces between the protein proﬁle of the cells residing in the tumor
microenvironment and the cells cultivated in a monolayer. The
alterations of cellular protein levels might be reﬂected in
numerous ways, from changes in metabolic activity to the phys-
ical parameters of the cell membranes, which facilitate endocy-
tosis. Moreover, it is likely that a combination of several
appropriate properties is required simultaneously, which is
why we focused our efforts on the systematic top-down analysis
of the proteomic differences between ex vivo and in vitro cells.
Role of antiviral response genes in viral activity
The comparative analysis of the protein proﬁle of B16 ex vivo
cells yielded the list of up/downregulated gene candidates,
which were classiﬁed into several groups based on their func-
tions and roles in biological processes and molecular mecha-
nisms (Fig. 3A-D). The statistical analysis showed that none of
the designated subgroups representing speciﬁc biological pro-
cesses and molecular mechanisms was signiﬁcantly up- or
down-regulated in the ex vivo cells in general. This result was
expected because although the ex vivo and in vivo cells
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demonstrate altered properties, they still exhibit similar pheno-
types and thus similar expression patterns.
Because the main biological processes capable of dramati-
cally affecting viral activity are the response to stimuli, immune
system processes and apoptosis,32 it is very likely that altera-
tions of the expression and translation levels of these speciﬁc
proteins could ensure favorable conditions for viral activity
(Fig. 4A). The most interesting candidate genes that were found
to be up-regulated were Csnk2b ((CK2) family member), Scrib
and Hsp90aa1. Overexpression of all these genes not only
serves as an indicator of the increased aggressiveness of the ex
vivo B16 cells by facilitating malignant transformation64,65 but
also potentially facilitates viral vector activity. Recent studies
have shown that CK2 is essential for the infectious cycle of
alphaviruses and other different DNA/RNA viruses.66,67 The
inhibition of Hsp90 reduces chikungunya virus infection and
inﬂammation in vivo.68 Scrib acts as a binding protein and plays
a role in virus-host cell interactions in the case of several viral
infections.69 Moreover, Scrib is important for cell polarity, act-
ing as a crucial factor in cell membrane architecture and physi-
ology.70,71 Therefore, upregulation of Scrib could play a
signiﬁcant role in the increased membrane elasticity of ex vivo
cells, which could in turn impact the process of viral entry.
Among the downregulated proteins, one of the most attrac-
tive candidates was IFN-a because it is one of the main negative
regulators of tumor growth. Inhibition of IFN-a expression has
been shown to cause transcriptional downregulation of several
anti-proliferative IFN-a-inducible signaling pathways, namely,
PI3K, p38 MAPK and JAK-STAT,72,73 which was correlated
with extremely high alphavirus activity.74,75 A detailed analysis
of down-regulated antiviral response genes in B16 ex vivo cells
showed that most of them participate in the PI3K, p38 MAPK
and JAK-STAT pathways (Table S3), but the expression of
genes such as Hspb1 (Hsp27), Cryab, Csf1, Stat1 and S100a11 is
mediated by all 3 pathways. The PI3K pathway has been shown
to be essential for the replication of different viruses. However,
inhibition of the activity of PI3K in B16 ex vivo cells apparently
did not function as a key factor affecting SFV vector-driven
expression. Alphaviruses are able to auto-activate and auto-reg-
ulate PI3K signaling during infection, providing essential con-
ditions for cap-dependent translation of viral proteins.76 By
contrast, down-regulation of p38 MAPK and JAK-STAT sig-
naling has a remarkable effect on the virulence potential of
alphaviruses. Both of these pathways can promote apoptosis,
thereby enhancing the cytopathic properties of the virus during
infection.74,75 The inhibited activity of both the p38 MAPK and
JAK-STAT pathways in B16 ex vivo cells facilitated alphavirus
replication and transgene expression, possibly by delaying the
onset of apoptosis during infection. The downregulation of sev-
eral genes coordinated by the IFN-inducible pathways shown
in Table S3 such us Nfe2l,77-79 Iﬁ35,80 S100A1181 has been
shown to promote different levels of virus infectivity.
Role of genes regulating cytoskeletal organization during
virus entry
An additional group, which might be responsible for the
improved viral activity, comprises the cytoskeleton-related pro-
teins. Genes regulating cytoskeletal organization are essential
during the virus life cycle. Up-regulation of several cytoskeleton
motor proteins such us dynein and kinesin in ex vivo B16 cells
facilitates the activity of various virus vectors. Generally, invad-
ing viruses use dynein to reach the nucleus for replication. In
turn, kinesin is used to reach the cell membrane where viral
budding and exit occur.82 Dynein has been reported to interact
with puriﬁed adenovirus,83 adeno-associated virus,84 parvovi-
rus,85 herpes virus86 and HIV-1.87 Kinesin appears to have sev-
eral important roles during the replication cycle of vaccinia
virus88 and to provide cellular transport for herpes virus
(HSV)89 along microtubules.90 Interestingly, the release of
enveloped HSV virions at the plasma membrane was promoted
by Myosin 5A (Myo5a), which is another overexpressed gene
candidate detected in ex vivo B16 cells.91 Additionally, a delay
of HSV replication and inhibition of capsid movement in the
cytoplasm during egress was observed under the condition of
dystonin (Dst) depletion, suggesting that this non-motor pro-
tein is an important part of the virus transport machinery.92
Furthermore, changes in the expression of cellular component
organization genes could also affect virus entry by altering the
physical features of the cell membrane, such as the elasticity
and the rigidness. During the endocytosis process, the cell
membrane must deform and accommodate a high degree of
curvature that requires low elastic features. We presume that
the reduced elasticity of the ex vivo B16 cells observed by AFM
analysis (Fig. 5B) was responsible for the improved alphavirus
transduction, whereas the re-organized cytoskeleton facilitated
its replication and spread.
In summary, we presented candidate genes (Fig. 4) that pro-
vided favorable conditions in combination for increased alphavi-
rus infectivity, thereby providing new possibilities for the
enhanced efﬁcacy of alphavirus-based cancer gene therapy. Based
on the results of this study, we emphasize the role of combined
alterations in gene expression. Individual functional experiments
of the identiﬁed genes were not a focus of this study because
such experiments fail to reproduce the full network of different
factors that occur during malignant tumor development and
affect alphavirus infection. However, continuous progress in
these investigations in the future might impact our understand-
ing of the alphavirus transduction/replication process.
Materials and methods
Cell lines and animals
The BHK-21 (baby hamster kidney cells) and B16-F10 (meta-
static mouse melanoma) cells were obtained from the American
Type Culture Collection (ATCC/LGC Prochem). The BHK-21
cells were propagated in BHK - Glasgow MEM (GIBCO) sup-
plemented with 5% fetal bovine serum (FBS), 10% tryptose
phosphate broth, 2 mM L-glutamine, 20 mM HEPES and anti-
biotics (streptomycin 100 mg ml¡1 and penicillin 100 U ml¡1).
The B16-F10 cell line was cultured in Dulbecco’s GlutaMAX
medium (GIBCO) supplemented with 10% FBS and antibiotics
streptomycin 100 mg ml¡1 and 40 mg ml¡1 gentamicin. Speciﬁc
pathogen-free 4- to 6-week-old female C57BL/6 mice were
obtained from Latvian Experimental Animal Laboratory of
Riga Stradins University and maintained under pathogen-free
conditions in the accordance with the principles of the Latvian
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and European Community laws. All experiments were
approved by the local Animal Protection Ethical Committee
and the Latvian Food and Veterinary Service (permission for
animal experiments no. 32/23.12.2010).
Production of SFV (SFV/EGFP, SFV/DS-Red and SFV/Enh.
Luc) recombinant virus particles
The pSFV193 vector was used in this study. The pSFV/EGFP,
pSFV/Ds-Red and pSFV/Enh.Luc vectors were generated as
described previously.12,27 The resulting plasmids were used to
produce SFV/EGFP, SFV/DS-Red and SFV/Enh.Luc virus par-
ticles. Brieﬂy, the pSFV/EGFP, pSFV/DS-Red, pSFV/Enh.Luc
and pSFV-Helper93 plasmids were linearized using the SpeI
restriction enzyme. In vitro RNA transcription was performed
using 1–2 mg of linearized DNA and 40 U of SP6 RNA poly-
merase (Thermo Scientiﬁc) in a 50 ml reaction mixture, as
described by the manufacturer. The RNA transcripts were
capped during the transcription reaction by adding 1 mM of
the 50(ppp)50G cap-analog (New England Biolabs). The DNA
template was removed by digestion with RNase-free DNase
(Thermo Scientiﬁc).
For packaging, the corresponding in vitro transcribed
recombinant RNA (20 mg each) were co-electroporated with
the helper RNA into 1 £ 107 BHK-21 cells (850 V, 25 mF, 2
pulses) using a Bio-Rad Gene Pulser apparatus without the
pulse controller unit. The electroporated cells were resuspended
in 15 ml of complete BHK medium, transferred into tissue cul-
ture ﬂasks (75 cm2) and incubated at 37C (5% CO2). After
24 h, the recombinant SFV particle-containing medium was
harvested, rapidly frozen and subsequently used as the virus
stock for cell culture infection.
The virus titer (infectious units per ml, iu ml¡1) was quanti-
ﬁed by infection of BHK-21 cells with serial dilutions of viral
stock and analysis of EGFP or DS-Red expression by ﬂuores-
cence microscopy on a Leica DM IL microscope (Leica Micro-
systems Wetzlar GmbH). SFV/Enh.Luc virus titer was
quantiﬁed by Real-time PCR as previously described.12
Infection of cell lines with recombinant virus particles
The BHK-21 and B16-F10 cells were cultivated in 24-well plates
at a density of 2 £ 105 cells per well in a humidiﬁed 5% CO2
incubator at 37C. For transduction, the cells were washed
twice with PBS containing Mg2C and Ca2C (Invitrogen). Then,
0.3 ml of the medium containing the virus particles was added.
The SFV/DS-Red and SFV/Enh.Luc virus particles were diluted
in PBS (containing Mg2C and Ca2C) to achieve a multiplicity of
infection (MOI) of 10. The cells were incubated for 1 h in a
humidiﬁed 5% CO2 incubator at 37C. The control cells (unin-
fected) were incubated with PBS (containing Mg2C and Ca2C).
After incubation, the solution containing virus was replaced
with 0.5 ml of growth medium.
Induction of tumor nodules
The B16-F10 cells were trypsinized, washed with PBS and
resuspended in PBS at a ﬁnal concentration of 3 £ 105 cells
ml¡1. Two hundred microliters of the B16-F10 cell suspension
was subcutaneously injected above the right shoulder blade of
the mice. After 8–12 days, when tumor volumes reached
1000 mm3, the B16 nodules were i.t. injected with SFV particles
or isolated for further tumor cell cultivation.
SFV/Enh.Luc administration and analysis of luciferase
gene expression in tumors
B16 tumor-bearing mice (n D 3) were i.t. inoculated with
0.25 ml of SFV/Enh.Luc particle-containing stocks (4 £ 108 i.u.
per ml). The Luc gene expression level was estimated by mea-
suring luciferase enzymatic activity in tumor homogenates 24h
after SFV/EnhLuc virus administration. The tumors were
excised and manually homogenized in a 1x concentration of
ice-cold lysis buffer (Cell Culture Lysis buffer, Promega) con-
taining a protease inhibitor cocktail (10 ml per 1 ml of lysis
buffer) (Sigma). After homogenization, the samples were cen-
trifuged for 10 min at 9000 £ g, and the protein concentration
was determined in tissue lysates using the BCA Protein Assay
Kit (Thermo Scientiﬁc). Luciferase activity was measured by
adding 100 ml of freshly reconstituted luciferase assay buffer to
20 ml of the tissue homogenate (Luciferase Assay System,
Promega) and then was quantiﬁed as relative light units
(RLUs) using a luminometer (Luminoskan Ascent, Thermo
Scientiﬁc). The RLU values were expressed per mg of protein in
the lysates. As a negative control, B16 tumor-bearing mice were
inoculated with PBS, and the maximal negative value was sub-
tracted from the presented results.
SFV/EGFP, SFV/Ds-Red administration and analysis of
vector intratumoral spread
B16 tumor-bearing mice were i.t. inoculated with 106 i.u. of
SFV/EGFP and SFV/Ds-Red in different tumor sides (SFV/
EGFP was injected into right side of tumor, where SFV/Ds-Red
was injected into tumor left side). 24h after vectors administra-
tions the tumors were isolated and frozen in OCT compound
(Sigma). The cryosections (5–10 mm) were prepared and EGFP
and Ds-Red expression was visualized by ﬂuorescent
microscopy.
Isolation and cultivation of ex vivo B16 cells
Freshly isolated B16-F10 tumors were manually homogenized
in PBS and ﬁltered through 40-mm diameter ﬁlters. The
obtained cells were washed twice with PBS and seeded in 24-
well plates at a density of approximately 5 £ 105 cells per well
in Dulbecco’s GlutaMAX medium (GIBCO/Invitrogen) supple-
mented with 10% FBS, 100 mg ml¡1 streptomycin, and 40 mg
ml¡1 gentamicin. Two days later, the cells were washed with
PBS to remove unattached cells and cultivated in Dulbecco’s
GlutaMAX medium containing 10% FBS, 100 mg ml¡1 strepto-
mycin, and 40 mg ml¡1 gentamicin for 5–7 d until the cell
monolayer reached 80% conﬂuency. The medium was replaced
every 2 d during cultivation. Next, the 80% monolayer 1st pas-
sage of ex vivo cells was trypsinized and plated in 24-well plates
at a low density of approximately 4 £ 103 cells per well (for
infection or melanin staining) and in 10-cm Petri dishes at a
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density of 2 £ 104 cells for further ex vivo B16 cell passaging
(2nd passage, 3rd passage, etc.).
Melanin staining of B16 cells was performed using a Fon-
tana-Masson Stain kit according to the protocol provided by
the manufacturer (Abcam). Brieﬂy, 80–100% monolayered cells
were washed with PBS and ﬁxed with 3% paraformaldehyde for
10 min. The cells were then washed with PBS and treated
according to the Fontana-Masson staining protocol. The cell
nuclei were counterstained with nuclear fast red.
Sample preparation for label-free LC-MS analysis
Ex vivo B16 cells were isolated from 3 B16-F10 tumor-bearingmice
and cultivated for 5–7 d until the monolayer of the ﬁrst passage
reached 80% conﬂuency (see above). The control in vitro B16-F10
cells were cultivated as described above until the monolayer
reached 80% conﬂuency. Both in vitro and ex vivo B16 cells were
lysed with 0.1% ProteaseMax in 50 mM ammonium bicarbonate
buffer (Promega) and sonicated for 15 min at 35 kHz. The lysate
protein concentration was measured using Direct Detect Assay-
free Cards (Merck Millipore). For LC-MS analysis, samples were
prepared using the FASP protocol.94 Brieﬂy, 80 mg of proteins
from each sample were mixed with DTT at a ﬁnal concentration of
10 mM and incubated for 15 min at 56C. The cell lysate was then
incubatedwith 6Murea and ﬁltered through a YM-30 spin column
(Millipore). The sample-containing columns were washed twice
with 100 mM Tris pH 8.5 and then digested by addition of lysyl
endopeptidase (Lys-C) (Wako) solution or trypsin to the column
overnight at 37C. The resulting Lys-C and trypsin fractions were
eluted with H2O by centrifugation and mixed with 0.1% triﬂuoro-
acetic acid (TFA). All samples were puriﬁed using microcolumns
prepared by placing a C18 Empore Extraction Disk (Varian, St.
Paul, MN) into 200-ml pipet tips. Peptides were eluted by applying
80 ml of 80% acetonitrile (ACN) and 0.1% formic acid in water.
ACN was evaporated in a vacuum drier, and the samples were
diluted in 0.1% formic acid in water.
LC-MS
All experiments were performed on an Easy nLC1000 nano-LC
system connected to a quadrupole – Orbitrap (QExactive) mass
spectrometer (ThermoElectron) equipped with a nanoelectros-
pray ion source (EasySpray/Thermo). For liquid chromatography
separation, we used an EasySpray column (C18, 2-mm beads,
100 A

, 75-mm inner diameter) (Thermo) capillary with a 25-cm
bed length. The ﬂow rate was 300 nl/min, and the solvent gradi-
ent was 2% B to 5% B in 10 min followed by 5% to 26% B in
230 min, and then 90% B wash in 20 min. Solvent A was aque-
ous 0.1% formic acid, whereas solvent B was 100% acetonitrile
in 0.1% formic acid. The column temperature was kept at 60C.
The mass spectrometer was operated in data-dependent
mode to automatically switch between MS and MS/MS acquisi-
tion. Survey full-scan MS spectra (from m/z 400 to 1,200) were
acquired in the Orbitrap with resolution R D 70,000 at m/z 200
(after accumulation to a target of 3,000,000 ions in the quadru-
ple). The method used allowed for the sequential isolation of
the most intense multiply charged ions, consisting of up to 10
depending on the signal intensity, for fragmentation on the
HCD cell using high-energy collision dissociation at a target
value of 100,000 charges or a maximum acquisition time of
100 ms. MS/MS scans were collected at a resolution of 17,500
at the Orbitrap cell. Target ions already selected for MS/MS
were dynamically excluded for 30 seconds. General mass spec-
trometry conditions were as follows: electrospray voltage of
2.1 kV, no sheath and auxiliary gas ﬂow, heated capillary tem-
perature of 250C, and normalized HCD collision energy of
25%. The ion selection threshold was set to 1e4 counts. An iso-
lation width of 3.0 Da was used.
Protein identiﬁcation and label-free quantitation
MS raw ﬁles were submitted to MaxQuant software version
1.4.0.5 for protein identiﬁcation.95 Parameters were set as fol-
lows: protein N-acetylation, methionine oxidation and pyroglu-
tamate conversion of Glu and Gln as variable modiﬁcations.
First, we used a search error window of 20 ppm and a main
search error of 6 ppm. The Lys-C or Trypsin enzyme option,
both without proline restriction, was used depending on the
sample, with 2 allowed miscleavages. Minimal unique peptides
were set to 1, and the FDR allowed was 0.01 (1%) for peptide
and protein identiﬁcation. Label-free quantitation was set with
a retention time alignment window of 3 min. The UniProt Ref-
erence Proteome mouse database was used (download from
April 2014). Generation of reversed sequences was selected to
assign FDR rates. All quantitative analyses were performed
using the Perseus suit from MaxQuant. Brieﬂy, MaxLFQ values
were loaded and log-transformed, and 0 values were replaced
by noise detection values using an imputation approach based
on the normal distribution of the whole data. Differential pro-
teins were assigned by a t-test analysis using S0 D 0.5, a p-value
threshold of 0.01 and a permutation-based FDR correction.
Bioinformatics analysis
A total of 277 differentially expressed genes in ex vivo and in
vitro B16 cells were selected by ﬁltering with conﬁdence at
p < 0.01 from a total of 4980 proteins with a difference in
expression of at least 1.4-fold. The biological classiﬁcation of
associated genes in terms of their biologic processes and molec-
ular functions was obtained by Gene Ontology (GO) analysis
using the Protein ANalysis THrough Evolutionary Relation-
ships (PANTHER) classiﬁcation system (version: PANTHER
9.0; http://www.pantherdb.org).30,96 Analysis of the cellular
localization of selected genes was conducted using the UniProt
Knowledgebase (http://www.uniprot.org/).
Analysis of IFN-a and IFN-b in ex vivo and in vitro B16
cells
Control in vitro B16 cells and freshly isolated ex vivo B16 cells
were seeded in 24-well plates and cultivated until the cell
monolayer reached 80% conﬂuency as described above. Expres-
sion levels of the IFN-a and IFN-b were determined in in vitro
and ﬁrst-passage ex vivo B16 cell lysates before SFV infection
(0 h) and at 1 h, 3 h, 6 h, 9 h and 18 h after infection with SFV/
Ds-Red at an MOI of 10. The cells were trypsinized, washed
with PBS and resuspended in 100 ml of PBS. For the lysates, 3
freeze-thaw cycles of the cell suspensions were performed. The
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cell lysates were centrifuged for 10 min at 5000 £ g, and the
protein concentration was equalized in all samples using the
BCA Protein Assay Kit (PierceTM BCA Protein Assay Kit,
Thermo Scientiﬁc). The expression levels of IFN-a and IFN-b
in the cell lysates were determined using the Interferon Alpha
ELISA Kit (Uscn Life Science Inc.) and Interferon Beta ELISA
Kit (Cusabio Biotech) according to the manufacturers’
protocols.
Analysis of cell membrane elasticity by AFM
Control in vitro B16 cells and freshly isolated ex vivo B16 cells
were seeded in 8-well plastic chambers and cultivated until the
cell monolayer reached 80% conﬂuency as described above. To
measure cell membrane hardness, an uncoated atomic force
microscope cantilever (Olympus AC240TS) with spring constant
C D 2 N/m and resonant frequency F D 70 kHz was used. Can-
tilever calibration was conducted by standard operations using
an MFP-3D atomic force microscope (Asylum Research) and
Igor Pro 6.34A software. The AFM tip with a radius of 10 nm
was manually positioned at the middle point between the cell
nucleus and the elongated cell body (Fig. 5A) using an OLYM-
PUS IX71 inverted optical microscope. After positioning, the tip
was engaged without scanning the surface of the cell to maintain
viability, and single force curves were acquired. Single force curve
data were exported to Microsoft Excel. For each cell, a particular
force curve was acquired using only trace data, where x was the
distance to the cell and y was the applied force. The maximum
force that could be endured by a cell was calculated by identify-
ing the intersection point of 2 linear trendlines: one describing
the tip approach region and the second describing the cell perfo-
ration region. The trendlines ﬁt the experimental data with a
coefﬁcient of determination of no less than 95%.
Statistical analysis
The RLU results of the in vivo and in vitro experiments pre-
sented in Fig. 1A are presented as the mean § s.e. of replicate
analyses and are representative of 2 independent experiments.
The data were transformed to the logarithmic scale. All error
terms shown in Figs. 4 and 5B are expressed as the standard
error of the mean from at least 3 different samples. Statistical
analyses of the results were performed using Microsoft Excel and
Statistica7 (StatSoft, Tulsa). Statistically signiﬁcant differences
were determined using Student’s t-test (p < 0.05).
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4. Discussion
Efficient gene delivery and high transgene expression via alphavirus vectors make them an 
excellent platform for the development of anticancer vaccines. However, these vectors need to be 
well characterized and the conditions that provide selective infection of cancerous tissues without 
causing harm to normal tissues have to be determined. Classic alphaviral vectors, based on SFV and 
SIN replicons, have been used for cancer gene therapy experiments in vitro and in vivo and have 
shown promising results in different cancer models (for reference see Review paper I 
in attachment). Nevertheless, the problems of targeted gene delivery, concerning inefficiency 
of repeated vector administration and tumor recovery, remain to be solved. Moreover, relevant 
entry mechanisms of alphaviruses and their interactions with host cells remain unclear. 
In the studies presented in this thesis we delineate the potential of alphavirus for targeted cancer 
gene therapy. In depth analysis of these vectors’ infectivity in several cancer cell lines in vitro, SFV 
vector distribution in vivo with regard to the vector injection mode, viral dose, expression time and 
vector re-administration is provided. To develop more effective therapeutic strategy for cancer 
treatment, we also have explored the efficiency of SFV-mediated gene transfer alone in 
combination with 5-FU with respect to possible synergistic cytotoxic effects. Additionally, we 
identified and characterized intracellular mechanisms that occur during the tumor development and 
may contribute to the capacity of alphaviruses to target tumor cells more specifically. 
4.1 Alphavirus distribution and biosafaty 
Investigation of virus biodistribution is a key step in understanding virus-host associations and 
development of novel therapies for clinical application. The most important technical challenges, 
continuing to attract the attention of the virotherapy research community, are the optimization and 
enhancement of systemic virus delivery, degree of intratumoral virus spread and extent of transgene 
production. In Paper I, we have evaluated recSFV vector propagation in tumor-free and 4T1 
tumor-bearing mice after i.v. and i.p. administration of recombinant viral particles. As an additional 
tumor model, B16 melanoma tumor-bearing mice were used to examine dissemination of recSFV 
vectors after direct (i.t) and systemic (i.p.) inoculation (Supplementary Poster 1). Despite we 
could confirm the data published by others (Rodriguez-Madoz et al., 2007; Colmenero et al., 2001), 
demonstrating a broad spread of recSFV in vivo, we would like to emphasize our observations 
regarding recSFV predominantly targeting 4T1 and B16 tumors. It should also be noted that the 
highest transgene expression in both tumor models was achieved at specific doses of systemic viral 
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inoculation, indicating a dose-depended tumor tropism of recSFV. Thus far, only the Sindbis virus 
of the alphavirus genus has been considered to have tumor targeting properties (Meruelo, 2004; 
Tseng et al., 2004b; Tseng et al., 2010; Unno et al., 2005). However, this study did not address a 
potential dependence of distribution patterns with the dose virus inoculated. Despite several 
ongoing trials underline the advantages of intratumoral delivery, systemic delivery and tumor-
specificity of viral vectors is extremely important; both for clinical trials in general and for 
treatment of metastatic cancer in particular. 
The continued innovation of new therapeutic modalities based on gene therapy holds promise 
for improving treatment of cancer patients. Here we show the high potential of self-replicating 
recRNA vector for gene delivery. The main advantages of recRNA vectors over recSFV particles 
include safety, reinoculation efficiency, reduced injection volume and the more simple preparation 
of RNA synthesis in vitro compared to virus production. Before, self-replicating alphavirus RNA 
was used as a vaccine in order to induce specific immune response. As shown by Cheng et al., 
immunization with Sindbis virus RNA replicon vectors fused with herpes simplex virus type 1 
protein VP22 and human papillomavirus type 16 E7, resulted in significant E7-specific T-cell-
mediated immune responses. In this study the authors noted, that due to the inability of RNA 
vectors to spread in vivo, they facilitate the vectors’ capability to distribute via linkage of VP22 
(Cheng et al., 2001). However, investigation of alphavirus RNA dissemination and its expression 
abilities in vivo without any help of additional transport proteins was not performed. In Paper I we 
show how systemic i.p., i.v. versus direct i.t. routes impacted luciferase expression as an index of 
alphavirus RNA vector biodistribution in the whole animal. Significant recRNA-driven Luc 
expression was detected in all organs analyzed, indicating a broad dissemination and significant 
expression potency of self-replicating RNA vector. Moreover, we therein present for the first time 
recRNA as a promising vector for targeted gene delivery to the brain. Because administration of 
recSFV particles did not lead to predominant expression in the brain, we speculate that recRNA 
molecules may cross the hematoencephalic barrier more efficiently than viral vector. 
Relevant in this context, in later studies aiming target glioblastoma cells in the brain, multivalent 
naked RNA nanoparticles based on pRNA 3-way-junction from bacteriophage phi29 were 
generated. However, in this research the authors decided to increase the efficacy of the specific 
vector targeting by linkage of folate ligand. Thus, confirming our hypothesis, systemic inoculation 
of this vector successfully targeted and delivered siRNA into malignant brain cells of mice (Lee et 
al., 2015). 
Delivery of recombinant genes into the brain is becoming an increasingly important; this not only 
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for brain cancer therapy, but also as a strategy for answering questions about the molecular 
mechanisms underlying brain function. Thus we believe that further optimization of brain-targeted 
recRNA-based gene delivery is warranted. 
Despite having demonstrated broad dissemination and intensive expression of both recSFV and 
recRNA in mice, we would like emphasize the high level of biosafety of these vectors. No toxic 
side effects, inflammation or organs disfunction were observed in infected mice during our 
experiments. As a confirmation of alphavirus’s biosafety, thus far no patient has developed any 
serious side effects during clinical studies relevant there (for references see Review of the 
literature). According to these reports, alphavirus-based treatment was well tolerated by all patients.  
Although other viral vectors have been used with greater success in clinical trials (for the review 
see Kotterman et al., 2015), some clinical cases demonstrated that biosafety of gene delivery 
vectors require more attention and development. In 1999, in clinical trials aimed to treat ornithine 
transcarbamylase deficiency and following adenoviral vector administration, a young patient died 
due to systemic inflammation and multiorgan failure. Of note, this patient had a higher level of pre-
existing immunity to the vector. Based on this fact, this patient’s immune memory to the vector was 
put forward as one possible reason for this fatality. Another hypothesis focused on the possibility 
that certain proteins of the vector capsid inadvertently induced excessive release of inflammatory 
cytokines by antigen presenting cells (Wilson 2009). In this case, the absence of alphavirus pre-
immunity should be considered as a major advantage. Moreover, alphaviruses elicit only a low 
grade of specific immune responses against the vector itself.  
Another example underlining the requirement of applying only highly biosafe viral vectors was 
described in 2000. During the X-SCID trial, where the γ-retrovirus MLV was applied, 5 of 20 
patients developed clonal T-cell leukemia (Cavazzana-Calvo et al., 2000; Hacein-Bey-Abina et al., 
2003). This outcome was caused by the vector’s efficient integration into the host’s genome, 
preferentially near the transcriptional start site of genes and within hot spots enriched for proto-
oncogenes and genes controlling cell-growth (Cattaglio et al., 2007). In view of these issues, 
replication of RNA replicon–based vectors such as alphaviruses takes place in the cytoplasm and, as 
a consequence, integration into the host genome does not occur. Thus from our point of view, there 
is no current need to significantly improve clinical safety the case of alphaviruses. 
In summary, alphavirus vectors have been shown to display a strong safety profile and induce 
clinically relevant gene expression with subsequent protein activity. However, extremely efficient 
therapeutic outcomes were not yet achieved (see references in the Review of the literature). Main 
reasons underlying this lack of efficiency are thought to be poor characterization of these vectors 
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and the lack of innovative treatment strategies such as combined therapies. The latter are discussed 
below.  
4.2 Perspectives of cancer gene therapy based on combination of alphavirus 
vectors with other adjuvants in clinic 
By demonstrating numerous synergistic interactions that improve vector intratumoral spread and 
expression, thus far preclinical studies provide a strong basis for virotherapy (see review paper I in 
supplementary). In Paper II, enhanced intratumoral expression of replication-deficient SFV vectors 
upon direct and systemic inoculation was achieved by combination of the viral vector with 5-FU. 
Using a comparable approach, such combined therapy was applied for treatment of recurrent head 
and neck cancer patients in II phase of clinical trial. Administration of adenovirus vectors (ONYX-
015) together with cisplatin and 5-FU resulted in more than 50% reduction in tumor volume in 19 
out of 30 patients, including 8 complete responses and 11 partial responses (Khuri et al., 2000). In 
this case, adenovirus vectors were engineered to selectively replicate in p53-deficient cancer cells 
and subsequently lyse these cells. As alphaviruses naturally induce apoptosis in a p53-independet 
fashion, conducting similar trials are an intriguing proposition. Hence, we also believe that 
identification of additional drugs that positively interact with alphaviruses is of high priority. 
Investigating the reasons for high recSFV activity in mouse melanoma tumors in vivo compared to 
the same cells in vitro, we have concluded that alphaviruses likely benefit from or even require 
specific alterations to host cell pathways which are induced by tumor microenvironment. The 
identification of individual molecular markers determining a vector’s activity and specific antitumor 
properties may indeed significantly aid in predicting gene therapy outcomes. As shown in Paper 
III, high alphavirus infectivity was promoted by inhibition of IFN-alpha and down-regulation of 
IFN-regulated pathways (PI3K, p38 MAPK and JAK-STAT). These findings allow designating our 
vectors as interferon (IFN)-sensitive. One interesting strategy for cancer therapy in this context 
would be exploring the effects of alphavirus-based therapy with drugs specifically suppressing 
innate immune responses of virus infected cells. For example combination of alphaviruses and IFN 
inhibitors such as Ruxolitinib or histone deacetylase inhibitors (HDACi) could be explored. 
Advantageous in this respect if the fact that individually these drugs are already being evaluated for 
the treatment of cancer (Hurwitz et al., 2015; Kummar et al., 2007) and are known to prevent the 
transcriptional activation of antiviral genes after virus infection (Chang et al., 2004). However, 
additional preclinical studies to test the efficacy of these combinations are required as such 
intervention may in some cases interfere with the host’s own anti-tumor response. 
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Tumor cell respond to the tumor microenvironment on a molecular level that may have as a 
consequence alterations of the biomechanical properties of these cells and tissues. Understanding 
such processes may be instrumental in increasing our understanding of cellular behavior and 
cellular manifestations in cancer tissues. In Paper III, delineating the effects of alphaviruses in a 
mouse model of melanoma, we identified 26 genes, all associated with cytoskeleton organization, 
that were differently expressed depending on the method of culture (cells cultivated in vitro or in 
vivo during tumor development). Such alterations may not only affect virus traffic and secretion, 
but, by altering the physical features of cell membrane, also impact virus entry. During endocytosis, 
the cell membrane must deform and accommodate a high degree of curvature. In the case of HIV it 
was shown that elastic deformations of the cell membrane affect the required energy for HIV-host 
cell interaction (Sun et al., 2006). We would speculate that changes in cell membrane elasticity may 
also affect alphavirus infectivity. 
The possibility to measure elasticity in a cellular network has led to the development of drug 
molecules for cancer therapeutics attractive to the pharmaceutical industry (Pillet et al., 2013). One 
example is cytoskeleton-destabilizing agent (Cyt-B) that is able to attenuate the average elasticity of 
cells by disrupting actin filaments (Cai et al., 2010). It was shown that cisplatin-resistant ovarian 
cancer cells respond to a combination of cisplatin and Cyt-B treatment by reducing the elastic 
features of cell membranes (Sharma et al., 2012). Considering our results regarding membrane 
elasticity, it would be interesting to explore therapeutic efficacy of cytoskeleton-reorganization 
agents in combination with alphavirus vectors. 
4.3 Lessons from unexpected and negative results 
Twice during our studies in vitro experiments yielded results contrary towhen investigating the 
same question using in vivo model systems. First, in contrast to 4T1 allograft, combined treatment 
of 4T1 cells with recSFV and 5-FU in vitro did not cause synergic effects with respect to inhibition 
of cell proliferation and vector expression. In another experiment, whereas B16 mouse melanoma 
cells culturing in vitro ere insensitive to recSFV infection, the same cells were rendered susceptible 
to recSFV infection and triggered extremely high transgene expression after exposing them to in 
vivo conditions. These disparities have been incredibly informative and as described above in 
Paper II and III have fronted new concepts in the field. These include the need for a better 
understanding of the tumor microenvironment, challenges associated with a tumor tissue’s 
heterogeneity as well as drugs such as 5-FU in promotion modulating alphavirus vector activity. 
Based on our experience, we conclude that solely relying on results form in vitro experiments can 
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be misleading and must be validated further during the development phases of new cancer 
therapeutics. Correspondingly at the price of time and funds, results generated using in vivo model 
systems reflect complexities such as a tumor’s microenvironment what might be crucial under some 
circumstances while not in others. In this context, any approach and type of sample studied, form 
cell culture systems to animal models and clinical specimens, have their own sets of strength and 
weaknesses. Cross-validation and exploitation of different strategies to answer a specific objective 
are therefore key to provide a sound basis for proposing novel concepts for virus-based cancer 
therapy. We would like to emphasize the importance of investigation unexpected, incoherent and 
negative results, because they might hold the key to true understanding of mechanisms underlying 
infection quality and quantity as well as explain variability observed for host responses.  
By revealing alphaviruses as potent vectors for targeted gene delivery, this work contributes to 
providing novel and attractive options for designing innovative virus-based cancer therapy. 
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5 Conclusions 
1. Alphavirusescan infect a wide range of cancer cell lines in vitro. Despite recSFV and recSIN
being closely related viruses, the transduction ability and oncolytic properties of these
vectors differ significantly. In addition, infectivity and cytotoxic properties of the same
vector varies noticeably depending on cancer cells types.
2. Despite recSFV vectors having a broad dissemination in tumor-bearing mice upon systemic
vector administration, predominant tumor targeting could be attained via dose adaptation in
mouse models for mammary carcinoma and melanoma. However, the best results for
recSFV-mediated transgene expression were achieved when choosing the i.t. as the route of
administration.
3. Unpacked self-replicating recRNA can be used successfully as an alternative and safe
methodology for gene delivery. I.v. inoculation of recRNA provided primary brain targeting
in both tumor-free and mammary carcinoma bearing mice, whereas intratumoral inoculation
revealed localized high expression levels in tumors.
4. Although 5-FU inhibited SFV-mediated transgene expression in metastatic mammary
carcinoma (4T1) cells in vitro, delivery of 5-FU and recSFV as a combined treatment option
in vivo revealed synergic therapeutic effects. These include significant enhancement of
intratumoral transgene synthesis and tumor cleavage compared with mice only treated with
5-FU.
5. Comparative protein profiling of B16 mouse melanoma cells susceptible and non-
susceptible to alphavirus infection revealed differences in the expression of genes that
regulate antiviral responses and cytoskeletal organization processes. Indeed, inhibition of
IFN-alpha led to suppression of signaling cascades such as the PI3K, p38 MAPK and JAK-
STAT pathways and could represent a major key to modulate recSFV activity. The
alterations observed in proteins related with cytoskeleton organization in B16 cells when
isolated form tumors had as a consequence a significant modification of cell membrane’s
elasticity. Taken together these intracellular and physical alterations may promote
alphavirus entry and replication.
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6 Theses for defense 
1. Recombinant Semliki Forest virus is an efficient vector for targeted gene delivery to tumors
upon systemic administration.
2. Self-replicating alphavirus RNA may be used as alternative vector for efficient gene delivery
and expression.
3. The therapeutic efficacy of the recombinant Semliki Forest virus may be enhanced by
combination with chemotherapeutic drugs in cancer gene therapy.
4. A tumor’s microenvironment may affect recSFV infectivity. Alphavirus transduction and
replication thereby depends on changes in the host cell which are in turn triggered by the
tumor’s microenvironment.
5. In virology and when evaluating new approaches to cancer gene therapy, unexpected,
incoherent and conflicting results obtained via different methodologies and model systems are
common. Thus successful development of such therapies, depends on understanding the
strength and limitations of each approach and system.
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28.1  IntroductIon
28.1.1   Overview Of AlphAvirus 
replicAtiOn And Assembly
Alphaviruses represent a large class of arthropod borne 
viruses (Arboviruses) belonging to the Togaviridae family of 
viruses, which cause transient febrile illness or more severe 
diseases such as encephalitis. The most commonly used 
vectors were generated on the basis of three alphaviruses: 
Semliki Forest virus (SFV) (Liljestrom and Garoff 1991), 
Sindbis virus (SIN) (Xiong et  al. 1989), and Venezuelan 
equine encephalitis virus (VEE) (Davis et al. 1989).
The biology of these alphaviruses is similar. Their 
genome comprises a 5′ end capped and 3′ end polyadenylated
RNA molecule of approximately 12 kb in length. Since the 
RNA has a positive polarity, it is infectious, capable of initia-
tion of replication and translation when introduced into the 
cytoplasm of host cells. Functionally, the genome is divided 
into two parts coding for the nonstructural and structural 
proteins, respectively (Figure 28.1). Two-thirds of the 5′ end
of the RNA genome encodes a polyprotein that is processed 
into four viral nonstructural proteins responsible for the 
replication of the plus strand (42S) genome into full-length 
minus strands. These molecules then serve as templates for 
the production of new 42S genomic RNAs and subgenomic 
26S RNAs. The latter is an approximately 4000 nucleotide 
long subgenomic RNA and is collinear with the last third 
of the genome. Its synthesis is internally initiated at the 26S 
promoter on the 42S minus RNA strand.
The subgenomic RNA codes for the structural proteins of 
the virus, which are also synthesized as a polyprotein precur-
sor in the order C-E3-E2-6K-E1. Once the capsid (C) protein 
has been synthesized, it acts as an autoprotease, cleaving itself 
off the nascent chain (Hahn and Strauss 1990; Schlesinger and 
Schlesinger 2001). At the endoplasmic reticulum (ER) mem-
brane, the nascent chain is cotranslationally translocated and 
cleaved further by a signal peptidase to the three structural 
membrane proteins, p62 (precursor of E3-E2), 6K, and E1. 
After synthesis, the C protein complexes with genomic RNA 
into nucleocapsid structures in the cell cytoplasm. Usually, 
only the genomic RNA is packaged due to the presence of the 
encapsidation signal within the nsP1 and nsp2 genes for SIN 
and SFV, respectively (Frolova et al. 1997).
The membrane proteins undergo extensive posttransla-
tional modifications within the biosynthetic transport path-
way of the cell. The precursor protein p62 is proteolytically 
cleaved during the transport to the cell surface to form 
the mature envelope glycoprotein E2 (Lobigs and Garoff 
1990). The p62 forms a heterodimer with E1 in the ER 
(Barth et al. 1995). This dimer is transported to the plasma 
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membrane, where virus budding occurs via spike nucleocap-
sid interactions (for review, see Jose et al. 2009). At a very 
late (post-Golgi) stage of transport, the p62 protein is cleaved 
to E3 and E2 by host furin-like proteases. This cleavage acti-
vates the host cell-binding function of the virion as well as 
the membrane fusion potential of E1. In the absence of p62 
cleavage, virus particles are noninfectious. This feature was 
used for the construction of conditionally infectious particles 
(Salminen et al. 1992). In SFV, E3 remains part of the mature 
virion (Garoff et al. 1990), whereas it is shed from the spike 
in SIN (Welch and Sefton 1979).
Active alphaviral RNA replication triggers cell death in 
infected cells. The nonstructural region of the genome has 
been shown to be sufficient for the induction of apoptosis, 
while the structural region can be replaced by a gene of inter-
est (Urban et al. 2008). Although the precise mechanisms of 
cell death and virus persistence remain unclear, activation 
of double-stranded RNA-activated protein kinase R (PKR) 
has been proposed to contribute to blocking protein synthesis 
and induction of apoptosis in infected cells (Balachandran 
et al. 2000; Gorchakov et al. 2004; Venticinque and Meruelo 
2010). Other factors, such as caspase cleavage (Nava et  al. 
1998), reduction in intracellular superoxide levels (Lin et al. 
1999), bcl-2 downregulation (Scallan et al. 1997), and cyclin-
dependent kinase 2 (CDK2) activation (Hu et al. 2009), may 
participate in alphavirus-mediated induction of apoptosis, 
suggesting that several pathways are involved in this poten-
tially cell-specific process.
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FIgure 28.1  (a) Schematic structure of the alphaviral genome. The genome is a positive-strand RNA molecule that is capped and 
polyadenylated. It encodes two polyproteins indicated as nonstructural and structural parts of the genome. (b) Replication cycle of 
 alphaviruses. After virus particle penetration and uncoating, the viral genomic RNA is released into the cytoplasm. The replication is 
initiated by translation of the nonstructural proteins (nsP1–4) and formation of the replicase complex (1). The positive strand genomic 
RNA serves as a template for a full-length complementary negative strand (2). The negative strand in turn serves as a template for the 
synthesis of subgenomic RNA expressed from 26S subgenomic minus RNA promoter (3). The structural proteins are translated from 
the subgenomic RNA and are processed posttranslationally into the individual proteins (4). The positive RNA genome is encapsidated 
by the capsid protein (5). Virus budding occurs on the cytoplasmic membrane via spike proteins and nucleocapsid interactions (6). RER, 
rough endoplasmic reticulum; TGN, trans-Golgi network; NC, nucleocapsid.
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28.1.2  structure Of AlphAvirus vectOrs
The essential elements of the expression plasmids are 
shown in Figure 28.2. The expression system is based on 
the full-length cDNA clone of the corresponding alpha-
virus. The classical vectors were generated in such a way 
that the heterologous insert replaces the structural genes 
downstream of the 26S subgenomic promoter. Therefore, 
the vectors contain only the nonstructural coding region, 
which is required for the production of the nsP1–4  replicase 
 complex, the 26S subgenomic promoter, and a multiple clon-
ing site with several unique restriction sites for the foreign 
gene insertion. Because the RNA replication is dependent 
on short sequence elements located at the 5′- and 3′-ends of
the genomic RNA (Kuhn et al. 1990), these regions are also 
included in the vector construct.
To generate infectious particles, the genes encoding struc-
tural proteins can be provided in trans. This is a central 
part of the alphavirus expression technology representing 
the packaging of recombinant RNAs into infectious par-
ticles using a helper construct encoding the viral structural 
genes. In this procedure, in  vitro-made recombinant and 
helper RNAs are cotransfected into animal host cells (Figure 
28.3). The recombinant RNA codes for the RNA replicase 
needed for the amplification of both incoming RNA species 
(Bredenbeek et al. 1993)
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and the gene of interest, whereas the helper RNA encodes the 
structural proteins for the assembly of new virus particles. 
The helper vector is constructed by deleting a large portion 
of the nonstructural genes, retaining the 5′ and 3′ end sig-
nals needed for RNA replication. Since almost the complete 
nsP region of the helper is deleted, RNA produced from this 
 construct will not replicate in the cell, due to the lack of a 
functional replicase complex. When helper RNA is cotrans-
fected with recombinant RNA, the helper construct provides 
the structural proteins in trans to assemble new virus  particles, 
while the recombinant construct provides the nonstructural 
proteins for RNA replication of both recombinant and helper 
RNAs The goal for this trans-complementation process is 
selective packaging of only recombinant RNAs into virus 
particles, because the helper vector lacks RNA packaging 
sequence signals recognized by the capsid protein. This pack-
aging signal is located on the replicase-coding sequence. The 
produced recombinant virus stock, therefore, contains only 
recombinant genomes, and when such virus particles are used 
to infect animal host cells, no helper proteins are expressed, 
providing a one-step virus infection.
In order to reduce the chance of recombination and gen-
eration of replication-competent virus, a packaging system in 
which capsid and envelope genes are produced from  separate 
vectors has been developed (Smerdou and Liljeström 1999). 
Since the capsid gene contains a translational enhancer 
(Sjoberg et  al. 1994), this sequence was inserted in front of 
the spike sequence p62-6K-E1. On the other hand, to provide 
cotranslational removal of the enhancer sequence and normal 
biosynthesis of the spike complex, a sequence coding for the 
foot-and-mouth disease virus 2A autoprotease was inserted in 
frame between the capsid translational enhancer and the spike 
genes. Cotransfection of cells with both helper RNAs (SFV-
helper-C and SFV-helper-S) and the SFV vector replicon carry-
ing a foreign gene led to the production of recombinant particles 
with high titers (up to 8 × 108 particles per 106 cells). An empiri-
cal frequency of recombination and replication-competent 
virus appearance in this system would be very low (10−13), 
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FIgure 28.3  Recombinant alphavirus production. Two types of in vitro synthesized RNAs (recombinant RNA and helper RNA) are 
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emphasizing the high biosafety of the system based on two-
helper RNAs. A similar strategy of the two-helper RNA sys-
tem was developed on the basis of the Sindbis virus replicon 
(Frolov et al. 1997). In this system, the Sindbis spike genes were 
fused to the capsid gene of Ross River virus containing dele-
tions in the RNA-binding domain, which maintained both the 
translation-enhancing and the self-cleaving activities. The same 
bipartite helper packaging system has also been described for 
VEE (Pushko et al. 1997), but in this case, the spike proteins 
were expressed without the capsid translation enhancer, which 
apparently is not needed in the VEE context.
In contrast to replication-deficient particles providing 
one round of infection, production of replication-competent 
virus can be achieved by cell transfection with a single con-
struct (Hahn et  al. 1992; Vaha-Koskela et  al. 2003). These 
vectors may contain two 26S promoters, leading to the syn-
thesis of two subgenomic mRNAs: one is responsible for 
the expression of the heterologous product, and the other 
for the synthesis of virus structural proteins (Figure 28.2, 
replication-competent vectors). Alternatively, the gene of 
interest can be inserted into nonstructural polyprotein genes 
and expressed as a fusion protein (Atasheva et al. 2007), or 
it can be expressed as a cleavable part of a structural or non-
structural polyprotein (Thomas et  al. 2003; Tamberg et  al. 
2007). These vectors are self-replicating, produce infectious 
virus particles, and can spread from cell to cell in a manner 
similar to that of the parental virus. The obvious advantage 
of replication-competent vectors is the increased efficacy of 
in vivo gene delivery, which should allow for spreading in 
infected tissue and, therefore, enhancing the therapeutic effi-
cacy. However, the disadvantage is the safety concern related 
to potential uncontrolled spread of infectious particles.
Another type of alphaviral vectors commonly used in vac-
cine development is based on DNA vectors. To allow direct 
application of plasmid DNA, the SP6 RNA polymerase pro-
moter has been replaced by a DNA promoter (e.g., CMV IE, 
RSV LTR). In this case, transient transfection of plasmid 
DNA will result in expression of the gene of interest. DNA 
vectors could also contain a selection marker for stable trans-
fection. Moreover, it is possible to cotransfect the DNA vector 
with a DNA-based helper vector, and to obtain recombinant 
particles or to use helper-producing cell lines. However, 
the virus titer has generally been significantly lower in this 
system than in the case of RNA-based particle production 
(Diciommo and Bremner 1998).
28.1.3  Gene delivery by AlphAvirus vectOrs
Among recombinant viruses, alphaviral vectors are good 
candidates for cancer gene therapy due to their ability to 
mediate strong cytotoxic effects through the induction of 
p53-independent apoptosis, their ability to efficiently over-
come immunological tolerance by the activation of innate 
antiviral pathways, and the subsequent triggering of cyto-
toxic T-lymphocyte responses against tumors (Lundstrom 
2009; Quetglas et al. 2010; Osada et al. 2012). The advan-
tages of alphaviral vectors also include a low specific immune 
response against the vector itself and the absence of vector 
preimmunity in the major part of the population.
Alphaviruses have been widely accepted to display a 
broad tissue tropism and can efficiently infect and induce 
apoptosis in many types of cancer cells (Wahlfors et al. 2000; 
Rheme et al. 2005). In practice, the infectivity and cytotoxic 
properties of alphaviruses can vary significantly between 
 different types of cancer cells. A low level of IFN-β produc-
tion in some tumor cells has been shown to determine the 
susceptibility and oncolysis of tumors to SIN virus (Huang 
et al. 2012). Whether this correlation exists for other alpha-
viruses remains unknown. Although SFV, SIN, and VEE 
are closely related, substantial differences may exist in their 
tissue  tropism, vector infectivity, and cytotoxicity (Wahlfors 
et al. 2000).
The mechanism of virus infection and possible regulation of 
entry, which is important for tumor targeting, is  currently con-
troversial. Different proteins have been proposed as candidate 
receptors for alphavirus infection (for review, see Kononchik 
et al. 2011; Leung et al. 2011). However, because alphaviruses 
infect genetically divergent cells, they probably utilize multiple 
proteins as receptors or alternative entry  pathways in different 
cells. Thus far, only SIN has been considered to be capable of 
targeting tumors upon systemic injection into mouse models 
(Meruelo 2004; Tseng et al. 2004b, 2010; Unno et al. 2005). 
The mediastinal lymph nodes (MLNs) were shown as a site of 
early transient heterologous protein expression after intraperi-
toneal injection of SIN vectors, providing the generation of 
effector and memory CD8+ T cells against expressed tumor-
associated antigen (Granot et al. 2014). In contrast, SFV vec-
tors have been applied in most studies through intratumoral 
administration (Murphy et  al. 2000; Maatta et  al. 2007; 
Rodriguez-Madoz et al. 2007; Quetglas et al. 2012b). We have 
recently observed that SFV can target tumors upon systemic 
injection at a reduced viral dose, demonstrating that tumor-
targeted delivery of the vector may be possible under certain 
conditions (Vasilevska et al. 2012).
Despite rapid induction of apoptosis in infected cells, 
treatment with natural oncolytic alphaviral vectors did not 
result in complete tumor regression (Chikkanna-Gowda et al. 
2005; Smyth et  al. 2005). The administration of immuno-
modulator genes, such as cytokines or growth factors, was 
more efficient and led to successful tumor inhibition or com-
plete regression in animal models (Asselin-Paturel et  al. 
1999; Rodriguez-Madoz et al. 2005; Lyons et al. 2007). The 
use of replication-competent viruses is limited by safety 
restrictions, and most studies in recent years have focused 
on the use of suicidal replicons in the form of recombinant 
particles and DNA- or RNA-based vectors.
A promising new approach in vaccine development has 
been the use of plasmid DNA for immunization. In difference 
to conventional plasmid DNA, protein expression directed 
by alphaviral DNA vectors has a suicidal effect due to their 
strong cytopathic effect. Therefore, the use of these vectors 
eliminates the undesirable consequences of DNA integra-
tion into the host genome. Taking into consideration that the 
SFV replicon  vector is based on in vitro transcribed RNA, the 
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corresponding RNA (naked or encapsulated into transfection 
vesicles) can also be used as an alternative vector for cancer 
therapy. Self-replicating RNA can provide the same efficient 
cytoplasmic transgene expression and induction of apoptosis 
in host cells. It is safe for in vivo applications and does not 
induce antivector immunity (Cheng et al. 2001; Vignuzzi et al. 
2001; Saxena et al. 2009). Intramuscular injection of as little as 
1 µg of naked SFV RNA provided complete tumor protection
and extended the survival of treated mice when tumor cells 
were injected 2 days before immunization (Ying et al. 1999).
The issue of transgene distribution and persistence in vivo is of 
special importance when applications in gene and cancer therapy 
are considered. Therefore, in order to evaluate persistence and 
distribution of recombinant SFV particles, SFV-replicon-based 
DNA plasmid and conventional DNA plasmid were compared 
after intramuscular injection mouse and chicken model (Morris-
Downes et al. 2001). The presence of transgene was detected by 
RT-PCR. Recombinant SFV particles persisted for 7 days at the 
injection site, while SFV  replicon-based plasmid and conven-
tional DNA plasmid could be detected up to 93 and 246 days, 
respectively, at the injection site. In chickens, transgene could 
be detected up to 1 day at the injection site in case of recombi-
nant SFV particles and up to 17 days for the SFV-based plasmid 
and 25 days for the conventional DNA plasmid. In mice lymph 
nodes, the recombinant SFV particles were detectable for 1 day, 
and both plasmids for 3  months. Similarly, the two plasmids 
were present up to 3 months in tissues distal from the site of 
injection, indicating dissemination.
Localization and persistence of replicon RNA is also depen-
dent on the route of administration (Colmenero et  al. 2001). 
Intravenous administration resulted in a systemic distribution, 
and the reporter gene was detectable in spleen and lymph nodes 
as well as in nonlymphoid tissues. Subcutaneous injection leads 
to a local distribution in the draining lymph nodes and skin sur-
rounding the injection site, while intramuscular injection resulted 
in expression in local lymph nodes and at the injection site. This 
study confirmed the transient nature of SFV particles in vivo, 
since the reporter gene was almost undetectable by day 6 after 
injection by all examined administration routes. Intratumoral 
injection of SFV leads to localization of SFV-RNA in tumor 
cells and draining lymph node only (Colmenero et al. 2002). 
The short persistence renders the recombinant  replicon particles 
as a safe vaccine tool, but not relevant for applications where 
prolonged gene expression in vivo is desired.
28.2   eFFIcacy oF therapeutIc and 
prophylactIc antIcancer VaccInes 
Based on alphaVIrus Vectors
Mainly SFV, SIN, and VEE vectors have been tested for can-
cer treatment in animal models. Here we provide a detailed 
overview on different strategies of cancer treatment using 
immunogene delivery as naked RNA, plasmid DNA, and 
virus particles by replication-deficient vectors. Moreover, the 
possibility to employ oncolytic replication-competent alpha-
viruses is discussed.
28.2.1  melAnOmA
Melanoma is one of the most aggressive forms of skin can-
cer. Melanoma tumors arise from melanocytes and contain 
specific tumor-associated antigens (TAAs), which can be 
categorized as differentiation antigens such as Pmel17/gp100, 
p75/tyrosinase-related protein TRP-1, MART-1/Melan-A and 
the retained intron in tyrosinase-related protein (TRP-2-INT2) 
as well as TAAs like MAGE or melanoma cell adhesion mol-
ecule (MUC18) (Pleshkan et al. 2011). These antigens act as 
ideal targets for melanoma immunotherapy because of their 
preferential expression in melanocytes and melanoma cells. 
Alphavirus vectors have demonstrated advances in targeted 
prophylactic and therapeutic immunotherapy of melanoma in 
several preclinical studies.
Tyrosinase is an essential enzyme involved in the initial 
stages of melanin biosynthesis in melanocytes and melanoma 
cells (Kumar et al. 2011). The ability to stimulate or augment an 
immune response against melanoma by alphaviral  antitumor 
vaccines expressing either murine or human tyrosinase-related 
protein 1 (TRP-1) has been shown in two different studies. The 
efficacy of DNA-based SIN tumor vaccines pSIN-mTRP-1 and 
SIN-hTRP-1 was evaluated in a B16 mouse melanoma model 
(Leitner et al. 2003). It was one of the first demonstrations of 
prophylactic immunization with an alphavirus DNA vector 
where intramuscular injection was able to break immunologi-
cal tolerance and provide immunity against melanoma, when 
inoculated 5  days prior to cancer cells challenge. Similarly, 
the high prophylactic potential of alphavirus-based vaccines 
was confirmed by demonstrating the ability of VEE virus-like 
particle (VLP) vectors encoding murine or human TRP-1 to 
induce strong immune responses and to provide a significant 
tumor growth delay in immunocompetent melanoma tumor–
bearing mice (Goldberg et al. 2005).
In another study, the transmembrane melanosomal glyco-
protein TRP-2 was applied as a therapeutic gene in  controlling 
of melanoma growth (Avogadri et al. 2010). It has been shown 
that VEE-TRP-2 VLPs induced time-dependent tumor pro-
tection when vaccination was started as late as 5 days after 
tumor inoculation. Importantly, vaccination with VEE-
TRP-2 was more effective than combination of VEE-gp100 
with VEE-tyrosinase vectors. Moreover, the efficacy of the 
combination of all three VEE vectors was not significantly 
better than VEE-TRP-2 alone.
The SIN DNA vector (SINCp) was used to express the 
murine melanoma cell adhesion molecule (MCAM/MUC18) 
for vaccination against murine melanoma (Leslie et al. 2007). 
MUC18 is expressed in late primary and metastatic mela-
noma, but hardly at all in healthy melanocytes. Immunization 
with this vector showed no antitumor effect against parental 
B16F10 cells, probably because of extremely low expression 
of murine MUC18 in those melanoma cells. To increase this 
antigen expression in tumor cells, new B16F10 cells trans-
duced with MUC18 were obtained. Vaccination against 
MUC18 resulted in the induction of humoral and CD8+ T-cell 
immune responses against melanoma. In order to investigate 
the efficacy of recombinant alphavirus-based vaccines for the 
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stimulation of human immune responses, SFV VLPs encod-
ing MAGE-3 were administered in humanized BALB/c mice 
(Trimera murine model) (Ni et al. 2005). The results showed 
that the SFV vector elicited human MAGE–specific antibody 
and CTL responses in Trimera mice.
Several studies in melanoma therapy development have 
shown that expression of cytokine genes in tumor cells gener-
ally resulted in dramatic alteration of tumor cell growth and 
induction of tumor specific immunity. For instance, a single 
intratumoral injection of recombinant SFV particles express-
ing IL-12 caused significant inhibition of melanoma growth in 
tumor-bearing mice (Asselin-Paturel et al. 1999). Intratumoral 
administration of SFV-IL12 led to dramatic tumor necrosis in 
all treated mice, resulting in 70%–90% tumor growth inhibi-
tion. However, complete tumor regression was not achieved in 
this study. To improve the efficacy of antimelanoma therapy, 
a combined strategy including administration of SFV-IL-12 
VLPs and systemic costimulation with agonist anti-CD137 
monoclonal antibodies has been explored (Quetglas et  al. 
2012a), showing the powerful synergistic effects. Briefly, 
immune system stimulation with agonist agents acting on 
CD137 expressed on primed T cells resulted in the enhance-
ment of tumor-eradicating cytotoxic T-cell responses (Melero 
et al. 1997). In contrast to suboptimal therapeutic effect pro-
vided by intratumoral injection of SFV-IL-12 VLPs alone, 
combined administration of both SFV-IL-12 and CD137 mAb 
dramatically increased the therapeutic efficacy, inducing 50% 
and 75% of complete tumor remission, respectively.
The oncolytic potential of a replication-competent alphavi-
rus vector was also investigated for the treatment of  melanoma. 
In this context, the avirulent SFV strain A7 expressing EGFP 
was applied intravenously, intraperitoneally, and intratumor-
ally as a therapeutic vaccine in human melanoma-bearing 
SCID xenografts (Vaha-Koskela et al. 2006). A single inocula-
tion of the VA7 vector resulted in significant tumor regression, 
irrespective of the route of administration. The neurotropism 
of SFV did not restrict its ability to target tumors, as within 3 
weeks, VA7 had caused regression of tumors to far below the 
starting volume. Despite the positive treatment dynamic, small 
isolated groups of dividing tumor cells were detected within 
strands of connective tissue, indicating the potential tumor 
remission in the future.
28.2.2  breAst cAncer
Worldwide, breast cancer is the most common cancer among 
women. The HER2/neu is a member of the tyrosine kinase 
receptor family overexpressed in 30%–40% of breast can-
cers, correlating with increased metastasis and poor prog-
nosis, due to increase of mitotic activity, mutation of the 
p53 gene, negative estrogen receptor status, and absence of 
bcl-2 (Banin Hirata et al. 2014). The HER2/neu has a high 
potential as tumor antigen in breast cancer therapy. A DNA-
based SIN vector ELVIS-neu expressing the neu gene was 
used for intramuscular vaccination 14 days before injection 
of cancer cells overexpressing neu (Lachman et  al. 2001). 
The results showed a strong protection of mice against tumor 
development. Vaccination led to reduction of the incidence 
of lung metastasis from mammary fat pad tumors and also 
reduced the number of lung metastases resulting from intra-
venous injection of neu-overexpressing cells. Interestingly, 
intradermal vaccination also provided protection and required 
80% less plasmid for a similar level of protection. The ben-
eficial results of cancer vaccines based on the SIN neu vector 
to treat pre-existing tumors were also confirmed (Wang et al. 
2005). It was shown that therapeutic efficacy of the pSINCP/
neu vaccine depended on the order of vector and cancer cell 
injection, indicating that the prophylactic vaccine was effec-
tive only when administered before tumor challenge.
The therapeutic potential of immunotherapy with the 
pSINCP/neu DNA vaccine and the VEE/neu VLPs was 
enhanced by combination with the chemical anticancer agents 
doxorubicin and paclitaxel (Eralp et al. 2004). Administration 
of 5 mg/kg doxorubicin prior to pSINCP/neu DNA and VEE/
neu VLPs vaccination led to a significant delay in tumor pro-
gression. Despite doxorubicin being established as a standard 
adjuvant therapy for breast cancer, mice receiving chemo-
therapy alone did not demonstrate reduced tumor growth. 
Interestingly, but in contrast to the previous results, combined 
treatment with paclitaxel (25 mg/kg) increased the effective-
ness of only the VEE/neu VLP vaccine.
In another study, 36% of rat breast tumors were eliminated 
when a VEE-neu VLP vaccine was subcutaneously adminis-
tered to animals with aggressive preexisting mammary tumors 
(Laust et al. 2007). When DC-based cancer immunotherapy 
was combined with VEE-neu VLP administration, induction of 
both cellular and humoral immunity against neu was observed 
in transgenic human breast tumor– bearing mice (Moran et al. 
2007). Furthermore, the combination treatment led to signifi-
cant inhibition of tumor growth. Not only tumor antigens have 
been used for immune system stimulation. Cytokines such as 
IL-12 have potential as cancer therapy agents because of their 
antitumor and antimetastatic activities. For instance, enhanced 
IL-12 expression has been established from SFV10-E VLPs 
as a potential treatment for breast cancer (Chikkanna-Gowda 
et al. 2005). The enhanced SFV10-E vector has shown up to 10 
times higher expression levels of foreign genes as compared to 
the original SFV10 vector. Intratumoral administration of high 
titer SFV-E-IL-12 VLPs caused complete tumor regression in 
four out of six mice and noticeably reduced the amount of lung 
metastases.
The vascular endothelial growth factor receptor-2 (VEGFR-2) 
serves also as an attractive therapeutic target, because it is 
required for neovascularization within tumors and has been 
shown to be important for tumor growth, invasion, and metas-
tasis. The requirements for therapeutic efficacy of VEGFR-
2-expressing vectors are associated with the induction of an 
antibody response against VEGFR-2. It was demonstrated 
that both tumor growth and pulmonary metastatic spread 
were significantly inhibited in mice with preexisting tumors 
when subjected to five immunizations with SFV10-E VLP 
expressing VEGFR-2 (Lyons et al. 2007). Moreover, a signifi-
cant tumor regression was observed after coimmunization of 
mice with SFV particles encoding VEGFR-2 and IL-4.
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28.2.3  lunG cAncer
Lung cancer is the leading cause of cancer death in the 
industrialized world. The majority of patients are diag-
nosed at a locally advanced or metastatic stage, making 
systemic therapies the mainstay for treatment (Blanchon 
et al. 2006). In case of lung cancer, promising results were 
obtained only using direct intratumoral alphaviral vector 
administration. The first preclinical study using alphaviral 
vectors in lung cancer treatment was performed by direct 
intratumoral injections of SFV VLPs expressing EGFP into 
human non–small lung cancer xenografts (Murphy et  al. 
2000). The outcome was tumor growth inhibition, and in 
some cases, complete tumor regression was achieved. The 
effect was mediated by p53-independent apoptosis and 
necrosis, but required repeated intratumoral administra-
tion (three to six injections) and very high doses of the vec-
tor (1 × 1010 IU/mL).
In another lung tumor study, the synergistic effect of com-
bined therapy with SFV-IL-12 VLP and anti-CD137 monoclo-
nal antibodies was demonstrated (Quetglas et al. 2012a). Similar 
to B16 mouse melanoma, syngeneic TC-1 lung carcinoma 
was inhibited by a clinically feasible therapeutic combination 
involving intratumoral treatment with SFV-IL-12 and systemic 
costimulation with anti-CD137 monoclonal antibodies.
Oncolytic virotherapy with the attenuated replication-
competent SFV vector VA7-EGFP showed a good safety 
profile and resulted in almost complete inhibition of tumor 
growth in human lung adenocarcinoma NMRI nu/nu mouse 
models upon intratumoral administration (Maatta et  al. 
2007). In contrast, systemic administration resulted in only 
delayed tumor growth (intravenous injection) or total absence 
of response (intraperitoneal injection).
28.2.4  cOlOn cAncer
Colon cancer is the second most common cancer in the 
European Union, and at least 50% of patients develop recur-
rences or metastases during their illness due to aggressive 
behavior of this cancer type (Kuipers et  al. 2013). Several 
preclinical studies have demonstrated high potential of 
alphavirus vectors in the development of colorectal cancer 
therapy. For instance, an alphaviral DNA vector encoding 
LacZ (pSIN1.5-β-gal) was compared to a conventional CMV
promoter-based β-gal plasmid in CT26.CL25 tumors (Leitner
et al. 2000). It was shown that intramuscular immunization 
with plasmid DNA replicons of mice with preexisting tumors 
elicited immune responses at doses 100–1000-fold lower than 
when performed with conventional DNA plasmids. Mice 
bearing experimental tumors expressing the β-gal reporter
antigen were effectively treated and resulted in significant 
prolongation of survival rates.
Several alphavirus vectors have been engineered to 
express different cytokines to enhance antitumoral immune 
responses against colon cancer. A single intratumoral injec-
tion of 107 and 108 VLP of SFV-IL-12 resulted in a com-
plete tumor regression in 36% and 80%, respectively, in a 
mouse colon adenocarcinoma model (Rodriguez-Madoz 
et al. 2005). Moreover, application of the modified SFV vec-
tors with a natural capsid translation enhancer significantly 
increased IL-12 expression and tumor regression in treated 
mice. Six doses of high titer SFV10-E VLPs expressing 
IL-12 induced complete regression in all colon carcinoma 
tumor–bearing mice (CT26 model). During the treatment 
stage, tumor swelling occurred in relation to intratumoral 
necrosis and inflammation (Chikkanna-Gowda et al. 2005). 
In a similar study, colon carcinoma tumor–bearing mice 
were treated with six inoculations of high titer SFV10-E 
VLP expressing the murine IL-18 gene along with an 
Ig-kappa leader sequence (Chikkanna-Gowda et al. 2006). 
Although the growth of treated tumors was delayed, com-
plete tumor regression was achieved only in 33% of treated 
mice, where the induction of avascular and suppurative 
necrosis was observed.
In order to investigate the potential of angiogenesis inhi-
bition in primary colon carcinoma, mice were immunized 
with SFV10-E VLP expressing VEGFR-2 10  days prior 
to tumor cell injection (Lyons et al. 2007). Similar to 4T1 
mouse breast carcinoma, the growth of CT26 colon carci-
noma was inhibited in vaccinated mice. Microvessel den-
sity analysis showed that immunization with SFV-VEGFR-2 
VLPs led to a significant inhibition of tumor angiogenesis. 
Moreover, coimmunization of mice with SFV VLPs encod-
ing VEGFR-2 and IL-4 led to enhancement of mice survival 
and production of high titers of anti-VEGFR-2 antibodies in 
contrast to coimmunization with VEGFR-2 and IL-12, or 
VEGFR-2 alone.
The therapeutic potential of alphaviruses as oncolytic 
agents has also been studied. The virulent SFV4 strain and 
its derivative recombinant SFV-p62-6k vector, containing 
deletions of the capsid and E1 genes, were used to stimulate 
immunity in a CT26 model (Smyth et al. 2005). Direct intra-
tumoral injection of replication-deficient VLPs or virulent 
SFV4 resulted in an immediate and intense inflammatory 
reaction and significant effect on survival. No differences 
were observed in inhibition of tumor growth between VLP- 
and SFV4-treated animals. However, the antitumor effect 
could be enhanced by preimmunization of animals with the 
VLP vector.
28.2.5  OvAriAn cAncer
Ovarian cancer is the sixth most common malignancy 
in women. In advanced ovarian cancers, tumors spread 
throughout the peritoneal cavity and induce the production 
of ascites. Therefore, the high potential of systemic tumor 
targeting by SIN vectors is an important factor in  treatment 
of this type of cancer. Efficacy of SIN vector application in 
ovarian cancer treatment has been evaluated using several 
strategies, such as immunotherapy, oncolytic virotherapy, 
and combined therapy with chemical agents. It has been 
shown that SIN VLP vectors have the ability to  systemically 
and specifically target metastasized tumors within the peri-
toneal cavity, leading to significant suppression of tumor 
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growth in ovarian tumor–bearing xenograft models (Tseng 
et al. 2004b). However, incorporation of antitumor cytokine 
genes such as IL-12 and IL-15 genes significantly enhanced 
the efficacy of the vector (Tseng et al. 2004a; Granot et al. 
2011). Additionally, using C.B-17-SCID beige mice with 
selective impairment of natural killer (NK) cell functions, 
and C.B-17-SCID ovarian tumor–bearing mice, it was dem-
onstrated that anticancer efficacy of SIN vectors is largely 
NK cell dependent and depletion of these cells caused a sig-
nificant decrease in the therapeutic potential (Granot et al. 
2011; Granot and Meruelo 2012). Because of low efficacy 
of penetration in tumor vascular structures, the SIN vec-
tors were not able to reach and kill all tumor cells to ensure 
complete tumor regression. To solve this problem, a che-
motherapeutic drug was used. Due to the ability of pacli-
taxel to inhibit tumor angiogenesis at low concentration and 
increase blood vessel permeability, the combined treatment 
with paclitaxel (taxol) at a concentration of 16 mg/kg and 
intraperitoneally inoculated SIN-LacZ VLPs dramatically 
enhanced therapeutic effects (Tseng et al. 2010).
SFV replicon vectors were also utilized for ovarian cancer 
immunotherapy with granulocyte-macrophage colony-stimu-
lating factor (GM-CSF), which is an important hematopoietic 
growth factor and immune modulator (Klimp et  al. 2001). 
It was shown that intraperitoneal injection of SFV-GM-CSF 
VLPs in murine ovarian tumor models provided rise in the 
number of macrophages and neutrophils. It resulted in a 
modest tumor growth inhibition, but with no survival benefit.
The potential of the oncolytic SIN AR339 strain was 
evaluated for ovarian cancer treatment (Unno et al. 2005). 
Although the SIN AR339 is a replication-competent vec-
tor, this strain has not been reported to cause any serious 
human disease. Intraperitoneal vector administration in the 
human ovarian xenograft mouse model provided significant 
 suppression of ascite formation, an important therapeu-
tic outcome in the treatment of ovarian cancer. In another 
study, mouse ovarian carcinoma xenografts were treated 
with an  oncolytic SFV vector, using a readministration strat-
egy with the same or another (vaccinia) viral vector (Zhang 
et al. 2010). In  contrast to reinoculations of the same virus, 
the heterologous vector administration led to remarkably 
increased  oncolysis and generation of antitumor immunity 
that significantly  prolonged the survival.
28.2.6  cervicAl cAncer
Human papilloma virus (HPV) E6 and E7 oncogenes are 
promising targets for cervical cancer vaccine development. 
SFV VLPs expressing the HPV16 E6 and E7 as separate pro-
teins were applied as prophylactic vaccines in a mouse model 
for cervical cancer based on TC-1 cells expressing HPV16 
E6E7 (Daemen et  al. 2000). Preimmunization with three 
injections of 104 pSFV-E6E7 VLPs induced HPV-specific 
CTL response in 50% of the mice, whereas three inoculation 
with an increased virus dose of 106 resulted in CTL response 
in all treated mice. Furthermore, immunization with the 
highest dose of 5 × 106 of SFV-E6E7 VLPs protected 40% of 
the mice from tumor challenges. To enhance oncogene pro-
duction and improve the cellular immune responses against 
E6 and E7, a new vector encoding a fusion protein of E6 
and E7 together with the SFV core translational enhancer 
(pSFV3enh-E6,7) was generated (Daemen et  al. 2002). 
Immunizations with 5 × 106 SFV3-enhE6,7 VLPs protected 
four out of five mice from tumor development, and a second 
tumor challenge in tumor-free animals revealed complete 
long-term protection against tumor occurrence. In a further 
study, authors confirmed the high potential of the proposed 
SFV-enhE6,7 VLP vaccine by intravenous and intramuscular 
administrations (Daemen et al. 2004).
In addition to the promising prophylactic properties of 
the SFV3-enhE6,7 VLP vector, its therapeutic potential in 
tumor-bearing mice was also investigated (Daemen et  al. 
2003). Subcutaneous injections of the vector at the 2nd, 
7th, and 14th day after TC-1 cell challenge resulted in rapid 
CTL response induction and efficient protection against fast-
growing tumors (90%–100% of treated mice were protected 
even after a second tumor challenge). Importantly, the effi-
cacy of using adenovirus Ad-E6,7 VLPs was dramatically 
lower (20%–40% of treated mice were protected) (Riezebos-
Brilman et  al. 2007). To improve the therapeutic efficacy, 
coadministration of SFV3-enhE6,7 VLPs and different 
doses of SFV-IL-12 VLPs was examined (Riezebos-Brilman 
et  al. 2009). The results of coinoculation of both vectors 
depended significantly on the viral dose and injection sched-
ule. Synergistic antitumor activity was observed only at a low 
dose of SFV-IL12. Furthermore, heterologous prime-boost 
immunization strategy was shown to provide advantages 
over single immunization (Walczak et al. 2011). Heterologous 
prime boost with SFV3-enhE6,7 VLPs and virosomes con-
taining the E7 protein resulted in higher numbers of antigen-
specific CTL in mice than applying homologous protocols. 
Nevertheless, the high number of CTL initially primed by 
the heterologous protocols did not correlate with enhanced 
antitumor responses in vivo.
SIN self-replicating RNA vectors were developed to 
induce E7-specific immunity in a TC-1 mice model (Cheng 
et  al. 2001). Intramuscular inoculation of RNA, encod-
ing HPV E7 oncogene alone (SINrep5-E7), induced poor 
humoral and cellular immune responses and provided no pro-
tection against tumor challenge. However, another construct 
expressing E7 as a fusion with secretory Sig protein and 
lysosome-associated membrane protein-1 (LAMP-1) in the 
SINrep5-Sig/E7/LAMP-1 vector demonstrated E7-specific 
CD4+ helper T cells and CD8+ cytotoxic T cell activity and 
increased in vivo antitumor effect. Addition of the LAMP-1 
endosomal/lysosomal sorting signal to the E7 protein signifi-
cantly enhanced the oncogene processing and presentation 
in vivo in the case of uptake of apoptotic cells by APCs at 
sites of vector RNA inoculation.
The efficacy of prophylactic and therapeutic vaccines 
based on SIN VLPs expressing both E7 and  calreticulin 
(CRT), an ER Ca2+-binding transporter participating in 
 antigen processing and presentation with major histocompat-
ibility complex (MHC) class I, was tested (Cheng et al. 2006). 
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The developed SINrep5-CRT/E7 VLP vector was able to 
generate antigen-specific immune responses, antiangiogenic 
effect, and a strong antitumor activity. Intramuscular vac-
cination with SINrep5-CRT/E7 VLPs 1 week prior to the 
challenge with TC-1 cells provided excellent protection of 
all treated animals. To determine the therapeutic potential 
of the vector in established tumors, both  immunocompetent 
and nude mice were intramuscularly inoculated with 
SINrep5-CRT/E7 VLPs 2  days after tumor cell injection. 
Although this strategy did not provide complete tumor 
 elimination as a prophylactic approach, it resulted in a sig-
nificantly lower number of pulmonary tumor nodules in 
both mice groups.
Similar to other alphaviral vectors, VEE VLP-based vec-
tors expressing E7 provided satisfactory results when used 
as a prophylactic vaccine. It was shown that two subcutane-
ous preimmunizations with VEE-E7 VLPs 2 weeks prior 
to cancer cell injection prevented tumor formation in mice 
(Velders et  al. 2001). Moreover, mice challenged 3 months 
after immunization with cancer cells did not develop tumors, 
indicating induction of long-term memory responses by the 
vector. In contrast, the therapeutic approach was efficient 
only in 67% of treated tumor-bearing mice. In other studies, 
the efficacy of the VEE vector was increased by expression of 
both E6 and E7 oncogenes from the same vector (Eiben et al. 
2002; Cassetti et al. 2004). To test the HLA-restricted capa-
bilities of the vaccine, an HPV tumor model was established 
on the basis of HLA-A*0201 transgenic mice. In this case, 
preimmunization with VEE-E6E7 VLPs protected 100% 
of immune-competent and HLA-A*0201 transgenic mice 
from tumor development and induced specific T cell immune 
response against HLA-A*0201-restricted HPV16 epitopes. 
As a therapeutic vaccine, VEE VLPs were inoculated after 
a tumor challenge. Although the therapy did not completely 
eradicate tumors, approximately 90% of immune competent 
and transgenic mice demonstrated elimination of established 
tumors.
The anticancer potential of the oncolytic replication-
competent SIN virus AR339 strain was also explored using 
different human cervical cancer xenografts in mice (C33A) 
(Unno et  al. 2005). Therapeutic treatment by intratumoral 
or intravenous injection of the vector resulted in remarkable 
regression of tumor growth through induction of necrosis.
28.2.7  prOstAte cAncer
Alphavirus-based gene therapy represents an attractive 
strategy for noninvasive treatment of prostate cancer, where 
current clinical interventions show limited efficacy. The 
first promising results in preclinical trials were obtained 
using apoptosis-resistant tumor models. Immunodeficient 
mouse models with established rat prostate tumors, over-
expressing the Bcl-2 oncogene, were treated by intratu-
moral injections of SFV VLPs encoding the proapoptotic 
gene Bax, which plays a key role in programmed cell death 
(Murphy et  al. 2001). Expression of the Bax gene by the 
SFV1 vector enhanced its cytopathic potential and led to 
a remarkable 47% reduction in tumor volume compared to 
the control. However, complete regression was not achieved 
in this study.
One alternative strategy for prostate cancer treatment is 
immune system stimulation against specific prostate can-
cer antigens, like the prostate-specific membrane antigen 
(PSMA), the six transmembrane epithelial antigen of the 
prostate (STEAP), and the prostate stem cell antigen (PSCA) 
(Naz and Shiley 2012). PSMA is a highly restricted pros-
tate cell surface antigen. The VEE VLP vector, producing 
human PSMA, has demonstrated strong cellular and humoral 
immunities in mice upon subcutaneous inoculation (Durso 
et  al. 2007). Although additional preclinical studies were 
not conducted, due to the absence of relevant PSMA tumor 
 challenge models, the efficacy of VEE-PSMA VLP was stud-
ied in clinical trials (see Section 28.3).
The STEAP antigen is also an attractive target for immu-
notherapy, because it is predominantly expressed in prostate 
tissue, and is found to be upregulated in multiple cancer 
cell lines (Gomes et al. 2012). The potential of VEE VLPs 
expressing mouse STEAP was assessed in the context of 
prophylactic and therapeutic approaches (Garcia-Hernandez 
et  al. 2007). Mice preimmunized with VEE-STEAP VLPs 
showed a specific induced immune response and signifi-
cantly prolonged overall survival of TRAMPC-2 prostate 
tumor–bearing mice. The therapeutic effect of the VEE vec-
tor was tested by coadministration with the STEAP plasmid 
DNA vaccine, demonstrating short, but statistically signifi-
cant delay in tumor growth. More beneficial results were 
obtained using a PSCA as a target, which is upregulated in 
a large proportion of localized and metastatic prostate can-
cers. Prophylactic vaccination of transgenic (TRAMP) mice 
with the PSCA-cDNA plasmid followed by VEE-PSCA VLP 
inoculation generated a specific immune response and anti-
tumor protection in 90% of TRAMP mice.
28.2.8  brAin cAncer
In preclinical studies, intracranial injection of B16 mouse 
melanoma cells was applied to generate a mouse brain 
tumor model. This model was used to investigate the thera-
peutic potential of an SFV VLP vaccine–encoding mouse 
endostatin—a protein, possessing antiangiogenic properties 
(Yamanaka et al. 2001a). A significant reduction of intratu-
moral vascularization was observed in tumor sections after 
intratumoral injection of SFV-endostatin VLPs.
Another strategy of brain tumor therapy includes the 
immunization of mice with DCs isolated from bone mar-
row and transduced with SFV VLPs expressing cytokines or 
specific cDNAs from melanoma or glioma cells (Yamanaka 
et  al. 2001b). It was shown that prevaccination with DCs 
transduced by the same type of cDNA as the tumor (SFV-
mediated B16 complementary cDNA or SFV-mediated 
203 glioma cDNA vectors for B16 and 203 glioma tumors, 
respectively) provided protection from tumor challenge. 
Moreover, therapeutic vaccination of brain tumor–bearing 
mice prolonged the overall survival.
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Therapeutic immunization with DCs that have been 
pulsed with SFV IL-12 also significantly prolonged survival 
of B16 brain tumor–bearing mice (Yamanaka et  al. 2002). 
A similar survival rate has been detected after stimulation 
of the immune system with DCs transduced with SFV-IL-12 
VLPs in combination with systemically administrated IL-18 
(Yamanaka et  al. 2003). Interestingly, that combination of 
DCs pulsed with SFV-IL-12 and systemic inoculation of 
IL-18 has increased the survival rate.
Human melanoma–associated antigen gp100 is a mela-
nocyte differentiation antigen, which has been also detected 
in multiple glioma cancer cell lines (Liu et al. 2004). It was 
shown that vaccination with a plasmid DNA-based SIN 
vector expressing human gp100 and murine IL-18 induced 
specific antitumor CTL immune responses and provided 
antitumor protection (Yamanaka and Xanthopoulos 2005). 
Three prophylactic immunizations with both pSIN-hgp100 
and pSIN-IL-18 DNA resulted in prevention of the forma-
tion of B16-hgp100-transfected tumors. Therapeutic vacci-
nation of mice with established B16-hgp100 tumors showed 
significant survival prolongation (90 days) with both vectors, 
where median mice survival treated with either pSIN-hgp100 
or pSIN-IL-18 DNA was 24–28 days.
The antitumor capacity of the oncolytic replication- 
competent SFV VA7 vector was investigated in immunocom-
petent rat glioma-tumor models (Maatta et al. 2007). Neither 
intravenous nor intraperitoneal administration provided any 
positive therapeutic efficacy in glioma-bearing rats. In contrast, 
direct intratumoral injections of SFV VA7 led to a  significant 
reduction of tumor growth. However, these beneficial results 
were followed by accelerated increase in tumor mass, leading 
to eventual death of the animals. Despite the promising results 
of oncolytic virotherapy in other cancer types described ear-
lier, the SFV VA7 vector demonstrated insufficient efficacy 
in brain tumors in immunocompetent mice. Nevertheless, 
systemic inoculation of the SFV VA7 vector in nude mice 
caused complete subcutaneous brain tumor eradication while 
leaving healthy brain tissue unharmed (Heikkila et al. 2010). 
Furthermore, improved long-term survival was observed in 16 
of a total of 17 animals.
28.2.9  hepAtOcellulAr cArcinOmA
Hepatocellular carcinoma (HCC) is a liver cancer that has 
limited therapeutic options. In preclinical studies, wood-
chucks chronically infected with woodchuck hepatitis virus 
serve as a model for liver cancer therapy development. The 
therapeutic potential of SFV-E-IL12 VLPs was evaluated in 
woodchucks with hepatic tumors (Rodriguez-Madoz et  al. 
2009). The results indicated that a single intratumoral injec-
tion of vector provided partial, dose-dependent tumor regres-
sion in 58% of treated animals, leading to reduction in tumor 
volume of up to 70% 4 weeks after treatment. The promising 
therapeutic results were associated with a general activation 
of cellular immune responses against HCC. Nevertheless, 
tumor growth was restored thereafter. In a recent study, an 
L-PK/c-myc transgenic mice model was applied, providing 
spontaneous appearance of hepatic tumors with latency, his-
topathology, and genetic characteristics similar to human 
HCCs (Rodriguez-Madoz et  al. 2014). Intratumoral inocu-
lation of SFV-IL-12 induced growth arrest in most tumors, 
providing 100% survival rate.
28.2.10  OsteOsArcOmA
Osteosarcoma is the most common primary malignant bone 
tumor, which typically metastasizes into bones, lungs, and 
other soft tissues. The oncolytic SFV vector VA7 was tested 
as a virotherapy candidate against unresectable osteo-
sarcoma. Subcutaneous human osteosarcoma nude mice 
xenografts were treated by three intratumoral injections of 
SFV VA7-EGFP (Ketola et  al. 2008). Treatment with the 
oncolytic SFV was highly efficient, showing significant 
reduction of tumor size in comparison with the oncolytic 
adenoviral Ad5Δ24 vector. Additionally, a highly aggres-
sive orthotopic osteosarcoma nude mouse model charac-
terized by invasion to surrounding tissues, and emergence 
of hematogenous pulmonary metastases, was treated with 
VA7-EGFP. Intratumoral inoculations of oncolytic SFV 
significantly enhanced the survival rate in the orthotopic 
osteosarcoma model. However, none of the mice were even-
tually cured.
28.3  clInIcal trIals
Following beneficial results of cancer treatment in preclini-
cal trials, some therapeutic strategies have been evaluated 
in humans. The first phase I/II clinical study was performed 
using the SFV vector expressing the human IL-12 gene and 
encapsulated in cationic liposomes (LSFV–IL12) (Ren 
et  al. 2003). To assess the biosafety and optimal dosage 
of the vector, LSFV–IL12 was intravenously administrated 
in cancer patients with stage III or IV metastasizing mela-
noma or renal cell carcinoma every third day for 4 weeks 
in two different concentrations. The therapy demonstrated 
no toxicity or any significant changes in the  function of 
internal organs. However, therapeutic potential was indi-
cated by a 10-fold increase in IL-12 concentration in the 
peripheral blood of treated patients. In another phase I/II 
study, repeated inoculations of VEE VLPs expressing the 
carcinoembryonic antigen (CEA) induced clinically rele-
vant CEA-specific T cell and antibody responses due to the 
ability of alphaviruses to infect DCs (Morse et  al. 2010). 
The study which included patients with advanced or meta-
static cases of lung, colon, breast, appendix, or pancreatic 
cancers were pretreated with multiple courses of chemo-
therapy and received up to four injections of VEE-CEA 
VLPs. The majority of patients showed a dramatically low 
rate of clinical responses after the therapy. Regression 
of liver metastasis in one patient with pancreatic cancer 
was  detected. Moreover, two patients with no evidence 
of disease remained in remission and two patients were 
able to maintain stable disease. One of the most recent 
 alphavirus-based clinical trials targeted prostate cancer 
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taBle 28.1
prophylactic anticancer Vaccines Based on recombinant alphavirus Vectors
Vector 
expressed 
transgene  tumor Model 
Vaccination and Vector 
administration types  Vaccination efficacy  references 
SIN DNA/RNA layered vectors
SIN DNA TRP-1 Mouse melanoma B16 Prophylactic (i.m.) Immunity
Tumor prevention (60%–70%)
Leitner et al. (2003)
SIN DNA MUC18 Mouse melanoma B16 Prophylactic (s.c.) Ineffective MC Leslie et al. (2007)
Mouse melanoma B16 transduced 
with MUC18
Prophylactic (s.c.) Immunity
Tumor prevention (50%)
SIN DNA HER/neu Mouse breast cancer A2L2 Prophylactic (i.m.), (i.d.) Tumor prevention (80%) Lachman et al. (2001)
Reduction of metastasis
Increase of survival
SIN DNA HER/neu Mouse breast cancer A2L2 Prophylactic (i.m.) Tumor prevention (50%) Wang et al. (2005)
Partial tumor reduction
Reduction of metastasis
SIN DNA LacZ Mouse colon cancer CT26.CL25, 
β-gal-expressing clone
Prophylactic (i.m.) Complete tumor prevention (100%) Leitner  et al. (2000)
SIN DNA + 
SIN DNA
Gp100 Mouse brain cancer model B16 Prophylactic (i.m.) Tumor prevention (40%) Yamanaka et al. (2005)
IL-18 Increase of survival
SIN DNA P1A Mouse mastocytoma P815 Prophylactic (i.m.) Tumor prevention (60%–70%) Ni et al. (2004)
SIN RNA Sig/E7/
LAMP-1
Mouse cervical cancer model TC1 Prophylactic (i.m.) Immunity
Reduction of metastasis
Cheng et al. (2001)
SIN viral particles vectors
SIN VLP CRT/E7 Mouse cervical cancer model TC1 Prophylactic (i.m.) Complete tumor prevention (100%)
Immunity
Cheng et al. (2006)
SIN VLP P1A Mouse mastocytoma P815 Prophylactic (i.p.) Tumor prevention (80%) Ni et al. (2004)
SFV and SFV-E viral particles vectors
SFV VLP HPV16 E6, E7 Mouse cervical cancer model TC1 Prophylactic (s.c.), (i.p.) Tumor prevention (40%) Daemen et al. (2000)
SFV-E VLP HPV16 E6, E7 Mouse cervical cancer model TC1 Prophylactic (s.c.), (i.p.) Complete tumor prevention (100%) Daemen et al. (2002)
SFV10-E 
VLP
VEGFR-2 Mouse breast cancer 4T1 Prophylactic (s.c.) Partial tumor reduction
Reduction of metastasis
Lyons et al. (2007)
SFV-E VLP VEGFR-2 Mouse colon cancer CT26 Prophylactic (s.c.) Partial tumor reduction
Increase of survival
Angiogenesis inhibition
Lyons et al. (2007)
SFV-E VLP 
+ IL-12
VEGFR-2 Mouse colon cancer CT26 Prophylactic (s.c.) Inefficient Lyons et al. (2007)
SFV-E VLP 
+ IL-4
VEGFR-2 Mouse colon cancer CT26 Prophylactic (s.c.) Immunity
Increase of survival
Lyons et al. (2007)
SFV-E VLP P1A Mouse mastocytoma P815 Prophylactic (i.v.) Immunity
Tumor prevention (90%)
Colmenero et al. 
(1999)
SFV VLP + 
Ad VLP
P1A Mouse mastocytoma P1.HTR3 Prophylactic (i.v.) Increase of survival Näslund et al. (2007)
VEE viral particles vectors
VEE VLP TRP-1 Mouse melanoma B16 Prophylactic (s.c.) Immunity
Partial tumor reduction
Goldberg et al. (2005)
VEE VLP Gp100 Mouse melanoma B16 Prophylactic (s.c.) Ineffective Avogadri, et al. (2010)
VEE VLP Tyr Mouse melanoma B16 Prophylactic (s.c.) Ineffective Avogadri et al. (2010)
VEE VLP TPR-2 Mouse melanoma B16 Prophylactic (s.c.) Partial tumor reduction Avogadri et al. (2010)
VEE VLP HER/neu Mouse breast cancer A2L2 Prophylactic (s.c.) Complete tumor prevention (100%)
Complete metastasis prevention (100%)
Wang et al. (2005)
(Continued )
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(Slovin et  al. 2013). The immunotherapeutic efficacy of 
VEE VLPs carrying PSMA was evaluated for patients with 
castration resistant metastatic prostate cancer. The patients 
received a maximum of five subcutaneous injections in the 
deltoid region at two different vector concentrations. The 
vaccination did not cause adverse systemic or local toxicity 
and was generally well tolerated. However, the therapeu-
tic effect of both immunization strategies was very low. 
No cellular immune response to PSMA was observed, and 
only a small number of patients demonstrated a humoral 
response to PSMA.
28.4  concludIng reMarks
The most interesting and promising applications of alpha-
viruses for cancer treatment are summarized in Tables 28.1 
through 28.3. Alphavirus-based delivery platforms have 
numerous advantages, which render them attractive tools for 
immunotherapeutic vaccine and cancer therapy.
Safety: When the suicidal replication-deficient alphavi-
rus particles are used, viral structural genes are not 
present and the infectious virus capable of infect-
ing new target cells cannot generate virus progeny 
in immunized host cells. Particularly, the use of the 
second-generation helper vector (Berglund et  al. 
1993) and the split helper system (Smerdou and 
Liljeström 1999) prevents homologous recombina-
tion events and generation of  replication-competent 
virus progeny. Moreover, RNA replicon–based vac-
cines are not prone to random integration into the 
host genome, thus avoiding the risk of cell trans-
formation and development of tolerance or anti-
DNA antibodies due to persistence, which present 
a limitation for the  conventional DNA vaccines. 
Furthermore, the viral RNA is degraded within 
5–7 days. Additionally, apoptosis induced by alpha-
viruses in transfected cells is another safety feature 
of vaccines based on suicidal alphavirus vectors.
No preexisting immunity: Alphaviruses generally pos-
sess no widespread immunity in the human and ani-
mal populations although some epidemics related 
to SFV, SIN, and VEE has been documented. 
This limitation observed for other viral expression 
 systems does not prevent the use of alphaviruses for 
in vivo expression of heterologous genes.
Repeated administration: The viral structural genes 
are not intracellularly expressed. Therefore, alpha-
virus replicons can be repeatedly administered, 
since the host immune response to the vector itself 
does not cause rejection when subjected to booster 
immunizations, which has presented some serious 
limitations for other vector systems.
Stimulation of immune responses: Due to induc-
tion of apoptosis, gene expression is transient and 
lytic. The induced apoptosis assists in the uptake 
of transfected cells by DCs and, subsequently, 
facilitates activation and stimulation of these cells. 
Additionally, the viral double-stranded RNA mol-
ecules generated during alphavirus RNA replication 
provide an immunostimulatory effect on DCs and 
on innate immunity.
Application of alphavirus replicon systems induces broad 
and robust humoral and cellular immune responses to 
a wide array of tumor antigens and confers protection 
against tumor challenges as has been demonstrated in 
numerous studies employing several animal models. The 
demonstrated ability of alphavirus-based vaccines to break 
 immunological tolerance to self-antigens is crucial for 
 cancer therapy. Indeed, these vaccines have been found 
effective in cancer therapy models both in prophylactic and 
therapeutic settings. Plethora of successful preclinical stud-
ies already performed and future vector developments and 
improvements in vector delivery and targeting will contrib-
ute to widening the range of alphavirus vector applications 
and potentially paving the way for extremely versatile tools 
for future immunotherapy and cancer gene therapy.
taBle 28.1 (Continued)
prophylactic anticancer Vaccines Based on recombinant alphavirus Vectors
Vector 
expressed 
transgene  tumor Model 
Vaccination and Vector 
administration types  Vaccination efficacy  references 
VEE VLP E7 Mouse cervical cancer C3 Prophylactic (s.c.) Complete tumor prevention (100%) Velders et al. (2001)
VEE VLP HPV16 E6, E7 Cervical cancer model HLF16 Prophylactic (s.c.) Complete tumor prevention (100%) Eiben et al. (2002)
VEE VLP HPV16 E6, E7 Mouse cervical cancer C3, TC1 Prophylactic (s.c.) Complete tumor prevention (100%) Cassetti et al. (2004)
VEE VLP STEAP Mouse prostate cancer 
TRAMPC-2
Prophylactic (s.c.) Immunity
Increase of survival
Garcia-Hernandez 
et al. (2007)
VEE VLP + 
cDNA 
PSCA
PSCA Mouse prostate cancer 
TRAMPC-2
Prophylactic (s.c.) Tumor prevention (76%) Garcia-Hernandez 
et al. (2008)
DCs + VEE 
VLP
HER/neu Human breast cancer NT2 Prophylactic (s.c.) Immunity
Partial tumor reduction
Moran et al. (2007)
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taBle 28.2
therapeutic anticancer Vaccines Based on recombinant alphaviral Vectors
Vector 
expressed 
transgene  tumor Model 
Vaccination and Vector 
administration types  Vaccination efficacy  references 
SIN DNA/RNA layered vectors
SIN DNA HER/neu Mouse breast cancer A2L2 Therapeutic (into the 
foot pad)
Ineffective Eralp et al. (2004)
SIN DNA + 
DOX
HER/neu Mouse breast cancer A2L2 Therapeutic (into the 
foot pad)
Partial tumor reduction Eralp et al. (2004)
SIN DNA + 
PTX
HER/neu Mouse breast cancer A2L2 Therapeutic (into the 
foot pad)
Ineffective Eralp et al. (2004)
SIN DNA HER/neu Mouse breast cancer A2L2 Therapeutic (i.m.) Ineffective Wang et al. (2005)
SIN DNA + 
Ad vector
HER/neu Mouse breast cancer A2L2 Therapeutic (i.m.) Increase of survival Wang et al. (2005)
SIN DNA LacZ Mouse colon cancer CT26 . CL25 Therapeutic (i.m.) Increase of survival Leitner  et al. (2000)
SIN DNA + 
SIN DNA
Gp100
IL-12
Mouse brain cancer model B16 Therapeutic (i.m.) Increase of survival Yamanaka et al. (2005)
SIN DNA P1A Mouse mastocytoma P815 Therapeutic (i.m.) Tumor prevention (40%) Ni et al. (2004)
SIN viral particles vectors
SIN VLP P1A Mouse mastocytoma P815 Therapeutic (i.p.) Tumor prevention (50%) Ni et al. (2004)
SIN VLP LacZ
IL-12
Human ovarian cancer ES-2 Therapeutic (i.p.) Partial tumor reduction Tseng et al. (2004)
SIN VLP IL-12
IL-15
Human ovarian cancer ES-2 Therapeutic (i.p.) Partial tumor reduction Tseng et al. (2004)
SIN VLP + 
paclitaxel
LacZ Human ovarian cancer ES-2 Therapeutic (i.p) Partial tumor reduction
Increase of survival
Tseng et al. (2010)
SIN VLP CRT/E7 Mouse cervical cancer model 
TC1
Therapeutic (i.m.) Reduction of pulmonary 
nodules
Cheng et al. (2006)
SFV and SFV-E viral particles vectors
SFV VLP IL-12 Mouse melanoma B16 Therapeutic (i.t.) Partial tumor reduction 
(70%–90%)
Asselin-Paturel et al. 
(1998)
SFV-VLP + 
CD137 mAb
IL-12 Mouse melanoma B16 Therapeutic (i.t.) Complete tumor 
reduction (50%, 75%)
Immunity
Quetglas et al. (2012)
SFV-IL-with 
CD137 mAb
IL-12 Mouse lung cancer TC1 Therapeutic (i.t.) Partial tumor reduction Quetglas et al. (2012)
SFV VLP EGFP Human lung cancer H358a Therapeutic (i.t.) Partial tumor reduction
Complete tumor 
reduction (40%)
Murphy et al. (2000)
SFV VLP GM-CSF Mouse ovarian cancer MOT Therapeutic (i.p.) Partial tumor reduction
Immunity
Klimp et al. (2001)
SFV VLP BAX Rat prostate
cancer AT3
Therapeutic (i.t.) Partial tumor reduction Murphy et al. (2001)
SFV VLP Endostatin Mouse brain cancer model B16 Therapeutic (i.t.) Partial tumor reduction
Increase of survival
Yamanaka et al. (2001)
SFV-E VLP IL-12 Woodchucks liver cancer 
WCH17
Therapeutic (i.t.) Partial tumor reduction Rodriguez-Madoz et al. 
(2009)
SFV-E VLP P1A Mouse mastocytoma P815 Therapeutic
(i.t.), (peritumoral)
Partial tumor reduction
Complete tumor 
reduction (46%)
Colmenero et al. (2002)
SFV VLP IL-12 Mouse mastocytoma P815 Therapeutic
(i.t.), (peritumoral)
Partial tumor reduction
Complete tumor 
reduction (53%)
Colmenero et al. (2002)
SFV VLP IL-12 Mouse colon cancer MC38 Therapeutic (i.t.) Complete tumor 
reduction (80%)
Rodriguez-Madoz et al. 
(2005)
SFV-E VLP IL-12 Mouse colon cancer MC38 Therapeutic (i.t.) Complete tumor 
reduction (92%)
Rodriguez-Madoz et al. 
(2005)
(Continued )
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taBle 28.2 (Continued)
therapeutic anticancer Vaccines Based on recombinant alphaviral Vectors
Vector 
expressed 
transgene  tumor Model 
Vaccination and Vector 
administration types  Vaccination efficacy  references 
SFV-E VLP IL-18 Mouse colon cancer CT26 Therapeutic (i.t.) Partial tumor reduction
Complete tumor 
reduction (33%)
Chikkanna-Gowda 
et al. (2006)
SFV10-E 
VLP
VEGFR-2 Mouse breast cancer 4T1 Therapeutic (i.t.) Partial tumor reduction
Reduction of metastasis
Lyons et al. (2007)
SFV-E VLP HPV16 E6, E7 Mouse cervical cancer model 
TC1
Therapeutic (s.c.) Complete tumor 
reduction (100%
Daemen et al. (2003)
SFV-E VLP + 
SFV VLP
HPV16 E6, E7 Mouse cervical cancer model 
TC1
Therapeutic (s.c.) Complete tumor 
reduction (28%)
Riezebos-Brilman et al. 
(2009)
IL-21
VEE viral particles vectors
VEE VLP TPR-2 Mouse melanoma B16 Therapeutic (s.c.) Immunity
Reduction of metastasis
Avogadri et al. (2010)
VEE VLP HER/neu Rat breast cancer 13762 
MAT B III
Therapeutic (s.c.), (i.m.) Immunity
Complete tumor 
reduction (50%)
Nelson et al. (2003)
VEE VLP HER/neu Rat breast cancer 13762 
MAT B III
Therapeutic (s.c.) Partial tumor reduction Laust et al. (2007)
VEE VLP E7 Mouse cervical cancer C3 Therapeutic (s.c.) Partial tumor reduction Velders et al. (2001)
VEE VLP HPV16 E6, E7 Cervical cancer model HLF16 Therapeutic (s.c.) Partial tumor reduction Eiben et al. (2002)
VEE VLP HPV16 E6, E7 Mouse cervical cancer
C3 cell line
Therapeutic (s.c.) Partial tumor reduction Cassetti et al. (2004)
HLF16 cell line Therapeutic (s.c.) Complete tumor 
reduction (90%–100%)
VEE VLP + 
STEAP 
cDNA
STEAP Mouse prostate cancer 
TRAMPC-2
Therapeutic (s.c.) Partial tumor reduction Garcia-Hernandez et al. 
(2007)
taBle 28.3
oncolytic anticancer Vaccines Based on replication-competent alphavirus
Vector 
expressed 
transgene  tumor Model 
Vaccination and Vector 
administration type  Vaccination efficacy  references 
Sindbis virus
SIN AR339 EGPF Human ovarian cancer OMC-3 Therapeutic (i.p.) Suppression of ascites formation Unno et al.  (2005)
SIN AR339 Nonspecified Human cervical cancer HeLaS3 
and C33A
Therapeutic (i.t.) Partial tumor reduction
Increase of survival
Unno (2005)
SIN AR339 Nonspecified Human cervical cancer C33A 
cell line
Therapeutic (i.v.) Partial tumor reduction Unno et al. (2005)
SFV virus
SFV VA7 EGFP Human melanoma  A2058 Therapeutic
(i.v.), (i.p.), (i.t.)
Partial tumor reduction Vähä-Koskela et al. 
(2006)
SFV VA7 EGFP Human lung cancer A549 Therapeutic (i.t.) Almost complete tumor reduction Määttä et al. (2008)
Therapeutic (i.v.) Partial tumor reduction
Therapeutic (i.p.) Ineffective
SFV VA7 EGFP Rat brain cancer BT4C Therapeutic (i.v.), (i.p.) Ineffective Maatta et al. (2007)
Therapeutic (i.t.) Partial tumor reduction
SFV VA7 EGFP Human brain cancer U87 Therapeutic (i.v.) Complete tumor reduction (95%) Heikkilä et al. (2010)
SFV VA7 EGFP Human osteosarcoma Saos2LM7 Therapeutic (i.t.) Partial tumor reduction Ketola et al. (2008)
SFV + VV Non-specified Mouse ovarian cancer MOSEC Therapeutic (i.p.) Increase of survival
Immunity
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